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VOORWOORD 
Hoewel een proefschrift op naarn van een onderzoeker 
pleegt te kornen, is het duidelijk dat rneerdere personen 
eraan hebben bijgedragen. zo ook in dit geval, waarvoor 
rnijn erkentelijkheid. 
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veelvuldige adviezen voor grate en kleine problernen heb ik 
gewaardeerd. 
Marcel Edixhoven wil ik bedanken voor de technische 
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meeste experimenten, die in dit proefschrift verrneld staan. 
Veel praktische rnoeilijkheden bleken door jou snel over-
wonnen te worden. Menige druppel bloed heb je voor het werk 
afgestaan. 
Inez Luyt-Houwen, ik wil jou danken voor de proeven 1 
die jij 1 voornamelijk tijdens je HBO-stage, hebt uitgevoerd. 
Gezond kritisch inzicht bleek je toen al te bezitten. 
Dr. J. de Gier en dr. A.M. Stadhouders ben ik erkente-
lijk voor het feit, dat ze het proefschrift wilden refereren, 
en voor de wijze waarop ze dat gedaan hebben. 
Professor Will em C. Hlilsmann 'i'Vil ik dankzeggen voor het 
doorlezen van de manuscripten en de vele uren, die hij als 
hoofd van het instituut besteed heeft aan werkbesprekingen. 
Dr. Herman F.M. Busch fungeerde veelvuldig als nuttige 
vraagbaak voor medische problemen en was zo vriendelijk het 
manuscript kritisch door te lezen. 
Dr. Hugo R. de Jonge ben ik dank verschuldigd voor Zl]n 
goede ideeen, die de studie zeker positief belnvloed hebben. 
Dr. Jos 1\'l.J. Lamers gaf me als "karnermaat" veel bruikbare 
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adviezen. Dr. Rob P. van Hoeven dank ik voor zijn intro-
ductie in de fluorescentie polarizatie en voor de gastvrij-
heid bij het Antoni van Leeuwenhoek-Huis te Amsterdam. Dr. 
Ad Montfoort en Wil Boere (inst. Pathologische Anatomie) 
hebben algemene steun gegeven bij problernen op het terrein 
van de lipiden. 
In de tweede plaats ben ik verscheidene personen zeer 
erkentelijk voor hun hulp bij het verkrijgen van bloed van 
patienten en controles. Zender hen zou maar weinig rnateriaal 
beschikbaar zijn geweest. Berniddeld hebben dr. H.F.M. Busch, 
rnw. drs. M.C.B. Loonen, drs. C.J. HOv.;eler, rnw. dr. A.N. 
Batenburg-Plenter, mej. N. Hudde, drs. Chr.E. Kamminga, 
ir. L.H.M. van Riel en rnw. R. Willernstein. Uiteraard wil ik 
de kinderen, die zelf bloed hebben afgestaan, in het bij-
zonder danken voor hun essentiele bijdrage aan het onderzoek. 
In de derde plaats wil ik bedanken al degenen, die rnij 
geholpen hebben tijdens rnijn werk van de laatste vier jaar, 
maar waarvan het resultaat niet direkt in dit proefschrift 
is te vinden. 
Joke Jonkers-van der Zwaag hielp een jaar bij het ont-
wikkelen van een enzyrnhistochemische methodiek. Stelling 7 
onderstreept het belang van dit werk. Dr. Maarten P. Mulder 
(inst. Celbiologie) was zo vriendelijk met raad en daad 
terzijde te staan bij het kweken van spier. Ook dr. Wirn F. 
Stevens (Medisch Biologisch Laboratorium TNO, Rijswijk) 
adviseerde daarbij. 
Cecile Hanson dank ik voor de nauwgezette uitvoering 
van het omslachtige typewerk voor het manuscript. 
Verder vdl ik iedereen binnen het insti tuut bedanken, 
die rnee heeft geholpen, op welke rnanier dan ook, het werk 
rnogelijk en plezierig te rnaken. Ook medewerkers van andere 
instituten 1 die incidenteel steun verleend hebben 1 wil ik 
hier dank betuigen. De service en outillage van de Medische 
Bibliotheek wil ik met name noemen. Ook niet vergeten wil 
ik rnijn beide paranimfen Aky Oerlemans en Marcel Edixhoven 1 
en degenen, die adviseerden bij het opstellen van de stel-
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lingen. 
Mijn vrouw Nellemieke dank ik voor de morele steun, 
maar ook voor de concrete assistentie bij verschillende 
onderdelen van het werk. Mijn ouders hebben al in een 
vroeger stadium een essentiele bijdrage geleverd tot het 
bereiken van deze rnijlpaal. 
Tenslotte zeg ik het Prinses Beatrix Fonds dank voor 
de financiele steun bij het nu afgeronde onderzoek en voor 
de geboden mogelijkheid het projekt over spierdystrofie 
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CHAPTER! 
INTRODUCTION 
1.1. Muscular dystrophies 
More than 250 different forms of human neuromuscular 
diseases are known. They differ in age of onset, severity 
of weakness, rate of progression, type of inheritance, 
groups of muscles affected, frequency of incidence. 
Sometimes the clinical symptoms are not restricted to 
nervous and/or muscular tissue. The muscular dystrophies 
form an extensive subdivision of the neuromuscular 
diseases. This group of disorders is inheritable and it 
is accompanied by progressive weakness and degeneration 
of skeletal muscle. The aetiology is not known. The most 
progressive type of the dystrophies is the Duchenne form, 
first described in detail by Duchenne de Boulogne in 
1868 (83) . Another representative, with several 
dissimilarities with the Duchenne type, is the myotonic 
dystrophy, also called dystrophia myotonica, myotonia 
atrophica or Steinert•s disease. This disorder shows, 
apart from dystrophic characteristics, myotonic symptoms, 
i.e. there exists a delay in relaxation of the affected 
muscles after contraction. The myotonic and Duchenne types 
are the most frequently occurring forms of human muscular 
dystrophy. These types of muscular dystrophy have been the 
subject of this thesis, and details of the disorders will 
be given first. 
1.2. Clinical aspects of Duchenne muscular dystrophy (18,131,224) 
The mode of inheritance of the Duchenne disorder is 
X-chromosomal and recessive and isolated cases have been 
described (see also 249,280,389). Thus, boys carrying the 
gene are affected, and girls carrying the gene are 
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asymptomatic, but transmit the disease. Some cases of girls 
with the clinical symptoms of Duchenne dystrophy have been 
reported (79,116,146,240). Estimations of the rate of 
incidence vary between 2 and 4 cases per 10,000 male births 
(see 38,66,145,349). 
The most clear sign in the first stage of the disease 
is the drastically increased activity of enzymes in the 
blood. Schapira and Schapira (299) first described a high 
aldolase activity and Ebashi et al. (85) a high creatine 
phosphokinase activity in Duchenne sera. These and other 
enzymes, originating from the cytosol of skeletal muscles, 
also have a high activity in serum (see 131) . 
At the end of the second year of life the muscles of 
the pelvic girdle and calves are weakened, resulting in 
difficulties in rising from the floor, climbing stairs, 
running and hopping. The patients frequently fall. They 
have a waddling gait and a pathological lordosis. Later, 
the proximal muscles of the arms become affected. 
Contractures and deformities of the extremities are often 
observed. The proximal skeletal muscles are affected in an 
earlier stage than the distal ones. The facial muscles 
remain intact during most stages except the final one of 
the disorder. Pseudohypertrophy of the calf muscles is seen 
in most patients, owing to abundant connective and adipose 
tissue in the wasting muscle. This can be clearly seen in 
microscopic preparations, in which also degenerating and 
regenerating fibres and macrophage infiltrations can be 
observed (37,205). The fibre size varies too much and 
central nuclei are present. Fibre type differentiation is 
not very pronounced, type I (oxidative) fibres may be 
predominant (80). Electron microscopic studies reveal many 
abnormalities of the intracellular organization. Different 
stages can be distinguished, also in a single biopsy (64) 
The Z-lines are often discontinuous, the volume of mito-
chondria is decreased, that of the cytoplasm increased. 
Later, the myofibrils are more disorganized and disappear 
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in some areas. Other areas contain overcontracted sarcomeres. 
The characteristic striations have disappeared or make 
uncommon curves. Undulation of the sarcolemma has been 
observed. An increase of glycogen granulae, lipid droplets 
and lysosomes takes place. Later stages show clumps of 
contracted material, which condense more and more. Fibres 
with structureless cytoplasm can be seen. The contractile 
apparatus is absent and mitochondria degenerate. The earliest 
detectable alteration is not well-defined. Mokri and Engel 
(221) reported focal lesions in Duchenne skeletal muscular 
plasma membranes in only mildly affected fibres, while 
Schotland et al. (312) reported less protein particles in 
these membranes. For detailed description of electron-
microscopic alterations, see Stern et aZ. (338) and 
Markesbery (205). Most of the morphological alterations are 
not very specific for one neuromuscular disease. 
Apart from the skeletal muscles, cardiac and smooth 
musculature may also be involved in Duchenne dystrophy 
(14,60,132,208,291). Mental retardation, already present 
in early stages of the disorders, has been described, but 
may be absent (102). The electromyographic pattern in 
Duchenne dystrophy is comparable with that in other 
myopathies. Involvement of the nervous system has been 
postulated by McComas and coworkers (200,326), but was 
rejected by others (15, see also 283). 
The progression of the disease is rapid. The use of a 
wheelchair at about 10 years is often necessary. Later 
follows irnrnobilisation in bed, and as no therapy exists 
for the muscular dystrophy hitherto (see 119) death 
usually occurs at the end of the second or beginning of 
the third decade. The cause of death is often pneumonia 
and/or heart failure. 
As a rule the female carriers of the Duchenne gene do 
not show clinical symptoms. Abnormalities have been found 
in electromyographic, histological and electron-microscopic 
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studies. Furthermore in 60-80% of the carriers high levels 
of muscle enzyme activity are found in the blood, but they 
are much lower than those of their affected sons (see 372) . 
1.3. Clinical aspects of myotonic muscular dystrophy (224,390) 
Myotonic dystrophy is inherited in an autosomal 
dominant trait. Several symptoms have been reported in 
this type of dystrophy. Muscles are affected in a 
characteristic pattern, being the facial, pharyngeal and 
neck muscles and the distal muscles of the extremities. 
Affected muscles become weak and atrophic, and also show 
myotonia. In addition to skeletal musculature 1 heart 
muscles and smooth muscles of the gastrointestinal tract 
may also be affected. In some cases the cardiac myofibres 
are degenerated; arrhythmia and electrocardiographic 
abnormalities are common (106). Involvement of eyes, scalp, 
bones, testes and brains is often observed. A low level of 
immunoglobulin G (269) and hyperinsulinism (see 225} have 
been reported (see 5.3.). Easily recognizable symptoms in 
this multi-systemic disease are facial paresis, open mouth, 
frontal baldness, cataracts, defective speech 1 difficult 
swallowing, infertility. As the expressivity of the mutant 
gene varies, the relative severity of these symptoms greatly 
varies from patient to patient and also between close 
relatives. 
Characteristic in the electromyographic pattern for 
myotonia are delayed discharges. Microscopic studies of 
affected muscles reveal variation in fibre size, atrophy and 
predominance of type I (oxidative) fibres, rounded fibres, 
too many central nuclei, desorientation of the fibres 
relative to each other. The amount of connective tissue and 
re-and degenerating fibres is lower than in Duchenne 
muscular dystrophy. 
Owing to the great variation in symptoms and age of 
onset, a reliable rate of incidence is not available. 
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Grimm (121) estimated it on 5.5 per 10,000 individuals. 
The progession of this disorder is much slower than in 
the Duchenne type, but varies greatly. Mean life span is 
shortened, due to heart failure and respiratory problems. 
The dystrophic process cannot be arrested, but myotonic 
symptoms can be relieved by drugs, which interact with 
membranes, for example diphenylhydantoin (120). 
Since about 1965 several infants and children have 
been reported with symptoms of myotonic dystrophy from 
the day of birth. Characteristics of the congenital variant 
of myotonic dystrophy are: severe hypotonia, affected 
facial muscles, deformities of joints, mental retardation, 
speech retardation and difficult swallowing (19,124,125, 
237,362). After some years the "classical" symptoms 
gradually appear. Strikingly, the congenital type is 
nearly always maternally inherited, possibly due to a 
special interaction between altered intra-uterine 
circumstances with the fetal mutant gene (126) 
1.4. The site of the lesion in muscular dystrophy 
For a long time the aetiology and pathogenesis of the 
human muscular dystrophies have been discussed. Three 
important theories have been postulated as to the site of 
the primary cause of the disorders: muscle, nerve and 
blood vessels. Most of the alterations in patients are 
found in the muscular tissue and that was the reason to 
believe that the primary cause was located in the muscle 
itself. But other workers ascribed the dystrophies to a 
primary defect in the nervous system. This concept was 
based upon some parameters of the electromyogram and upon 
the fact that the nerve fibres innervate the muscle fibres 
and determine the type of metabolism of them. The neural 
hypothesis is defended recently especially by McComas (90, 
199-202,326). Other studies on the innervation of the 
muscle fibres in Duchenne patients do not support the 
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neural hypothesis { 15,58, 59) . The vascular/biogenic amine 
theory was based upon the finding that a combination of 
inferior blood supply and serotonin induces in rat muscle 
a histological pattern, similar to that found in Duchenne 
patients {see 213) . Also serotonin plus imipramine 
injection caused the lesions {215). Later r.1unsat et al. 
{226) reported that the changes were different from those 
in Duchenne dystrophy. It has now been established that 
the blood supply is normal in Duchenne patients (35,154, 
177,178,235). The hypothesis is defended in spite of the 
normal blood supply, owing to alterations found in 
serotonin uptake by platelets from Duchenne patients {227) 
and to various influences of biogenic amines on cell 
membranes {91,92,233,234,365,366). None of the hypotheses 
can explain all aspects of the symptoms in muscular 
dystrophy. The various arguments pro and contra the 
concepts have been put forward repeatedly {9,34,73,99,153, 
242,244,273,348,353,354,372). Recently, a combination of a 
neural and myogenic factor has been proposed for myotonic 
dystrophy (232) . 
Recently, a new hypothesis has gained ground. The 
human dystrophies should be caused by a generalized 
membrane defect, present not only in muscle cells but in 
other cell types, too. Thomson et aZ. {355) suggested 
already in 1960 that an increase in membrane permeability 
was the cause of the dystrophies. High serum activities 
were found, also in early stages of the Duchenne disease, 
of enzymes originating from muscle (see 1.2.). Nhether 
the enzyme leakage can be explained by a simple hole-in-
membrane-theory is doubtful as for other compounds, like 
amino acids, a normal serum value has been found (16). 
Kleine (173) found evidence for the release of enzymes 
from different tissues in Duchenne dystrophy. Further 
evidence carne from abnormal features of erythrocyte 
membranes (10,39,136,186). Rowland (283) has surruuarized 
the arguments for the membrane concept in the Duchenne and 
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myotonic forms of muscular dystrophy, after Howland (136) 
and Attley (ll) had pointed again at this theory. The 
reason why most symptoms (in Duchenne disease) are 
restricted to muscle tissue may be that skeletal muscle 
is very vulnerable towards a membrane defect by its long 
tubular form and its motion. The reason why not all muscles 
are affected to the same degree remains unexplained. 
This thesis deals with studies in which the involve-
ment of cell membranes in human muscular dystrophy has been 
the subject. In section 1.5., the alterations of the muscle 
membrane in human dystrophy are summarized. Chapters 2 1 3 
and 4 contain details of biochemical and biophysical 
properties in erythrocyte membranes of patients and controls. 
In section 5.3., some data for other cell types are 
summarized. 
1.5. Muscle membrane alterations in human dystrophy 
1.5.1. Duchenne dystrophy 
Both biochemical and morphological changes have been 
described for muscle membranes in Duchenne dystrophy. 
Samaha and Gergely (290) reported a lowered capacity of 
sarcoplasmic reticular vesicles to accumulate ca2+-ions 
with a reduced s9eed of uptake and lowered ATPase actlvity. 
Takagi et aZ. (346) found less phosphat.idylcholine in 
these vesicles, and proposed that the cause of this and of 
2+ the low Ca -uptake could be contamination by adipose and 
connective tissue. A normal rate of ca2+-uptake by the 
microsomal fraction from Duchenne patients was reported by 
Radu et al. (257). Peter and Worsfold (245) measured a 
lower ca2+-affinity and normal ca2+-accurnulating capacity 
in less affected muscles. Indirect indication for an 
early manifesting impairment of sarcoplasmic reticulum 
came from measurements of tension generation {383) . 
Dhalla and coworkers (75) measured ATPase activities 
in Duchenne muscle sarcolemmal fractions. The Mg 2+ 
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stimulated 
components 
2+ . 2+ 
and the Ca -stlmulated, Mg -dependent 
were increased, while the (Na+ + K+)-stimulated 
component was decreased. Three studies have been published 
about the membrane-bound adenylate cyclase. Mawatari et 
al. (209) found a normal, Canal et al. (52) a lower basal 
activity. Both studies, and that of Susheela et al. (341) 
show decreased activity after stimulation by epinephrine, 
isoproterenol and fluoride. Kar and Pearson (162) 
described a proteinase, which is likely to be membrane-
bound and of increased activity in Duchenne muscle. 
Further support for the membrane concept came from a 
study on glucose metabolism (88). Increased glucose-
transport was suggested to explain the abnormalities. Mokri 
and Engel (221) reported morphologic lesions in the plasma 
membrane of non-necrotic fibres in Duchenne dystrophy, 
combined with hypercontraction of the adjacent myofibrils, 
as a proof of Ca 2+-influx. This lack of membrane barrier 
may form an early change of the Duchenne muscle cells. It 
may be that these holes cause the drastical ca2+-
accumulation, described by this group (27} . In a freeze 
fracture study Schotland et al. (312) detected less protein 
particles and a nonuniform distribution of them in plasma 
membrane. An irregular localization of binding sites for 
concanavalin A has recently been reported (30) , while 
cluster formation of patient's myoblasts in culture may 
also point to muscle membrane impairment (353). The fact 
that in Duchenne carriers serum enzym activities are often 
elevated, while their muscles are not weak, may also point 
to an early impairment of the membrane in this disease. 
An elevated sphingomyelin and lowered phosphatidyl-
choline content in Duchenne muscle homogenates have been 
reported (143,185). Takagi et al. (344) found in 
phosphatidylcholine an increase of oleic acid at the cost 
of linoleic acid. Kunze and coworkers (187) reported a 
similar fatty acid alteration in phosphatidylcholine. They 
reported metabolic studies in order to investigate the 
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possibility that a defect in the phosphatidylcholine 
metabolism is the primary cause of Duchenne muscle 
dystrophy (for reviews, see 183,184). 
1.5.2. Myotonic dystrophy 
Strong evidence for a muscular site of the lesion in 
myotonic dystrophy is the fact that myotonia can be evoked 
in patients by percussion, i.e. without involvement of the 
nervous system (see 120). Based on the reduced Cl 
conductance in myotonic animals, the chloride hypothesis 
was applied to all forms of myotonic disorders and thus 
considered as muscle membrane disorders (see 17). However, 
normal Cl conductance was found in myotonic dystrophy 
(195). There exist better indications for a muscle membrane 
defect in this disorder. Hofmann and DeNardo (134) 
suggested an enhanced Na+-permeability. In animals myotonia 
could be evoked by inhibition of the cholesterol synthesis 
{7). Samaha and Gergely (290) found a normal capacity for 
ca
2
+-accumulation and normal ATPase activity. Radu et al. 
(257), however, measured a 
A l ff . . f 2+ norma a 1n1ty or Ca 
2+ decreased rate of Ca -uptake. 
of the microsomes has been 
reported (246). The unstimulated activity of adenylate 
cyclase seems normal, but the fluoride- and epinephrine-
stimulated activity may be lowered {52,209). A lm,_rer degree 
of membrane protein phosphorylation by endogenous protein 
kinase under certain incubation conditions has been 
reported (274). In myotonic dystrophy hyperinsulinism has 
been established and it is likely that the muscles are less 
sensitive to this hormone (for a review, see 225). Whether 
the increased insulin secretion is the trigger for the 
insensitivity of the muscle receptor or the reverse, is not 
known (see also 350) . 
1.6. Objective of this study 
The aim of the present study is to gather information 
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about the biochemical features of human muscular dystrophy. 
On the one hand 1 insight into the primary lesion of the 
disease could be obtained 1 possibly resulting in a 
therapeutic tool. On the other hand, the study may lead to 
a diagnostic tool, to be used to determine the carrier 
state incontrovertibly in the case of X-chromosome linked 
dystrophy. As it appears that membranes of various cell 
types are disordered in the muscular dystrophies (see 1.4.) 
we have used the general membrane defect hypothesis as 
starting-point. This theory predicts membrane lesions in, 
among others 1 erythrocytes, and some alterations were 
already described when the study was started. Analysing 
muscle membranes has many disadvantages above erythrocyte 
membranes: 
a) Purification of muscle plasma membranes is rather 
difficult; contamination with reticular and tubular 
membranes easily occurs. 
b) Muscle hornogenates contain, in addition to muscle fibre 
components, adipose tissue, connective tissue and blood 
remnants; especially in severely affected muscles the 
contribution by connective and adipose tissue may be 
considerable. 
c) In muscle disorders often one of the fibre types is 
predominantly affected; in addition, regenerating and 
degenerating fibres may be present. 
d) The availability of muscle biopsy material is restricted. 
These points make it difficult to interprete biochemical 
data from muscle membrane fractions. Furthermore, much 
basic knowledge about the red cell membrane is present. 
The cells are relatively easy to obtain, while very pure 
membranes can be isolated. 
Therefore, we have used erythrocyte membranes from 
patient and control groups for this study in order to 
elucidate the cause of the red cell membrane abnormalities 
and after that extending the results to muscle. An 
interesting note may be that the first study on 
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erythrocytes in connection with dystrophy was already 
published in 1958 by Corsini and Cacciari (63) . 
We limited the experiments to two types of human 
muscular dystrophy. The Duchenne type is by far the most 
severe type. Myotonic dystrophy was chosen as the second 
object for analysis. The myotonias are considered as 
membrane diseases; myotonic dystrophy is the most frequent 
form of the myotonias. Restriction to the congenital type 
of myotonic dystrophy was made because its severity, to 
get a homogeneous group, and for age-matching reasons. 
Duchenne patients were aged from 3 till 18 years, the 
patients with congenital myotonic dystrophy between 6 and 
14 years (all males). Controls were boys without any neuro-
muscular or hematological disorder, aged between 4 and 20 
years. All blood donors, including controls, were fasted 
overnight before venapuncture, and did not use medicaments. 
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CHAPTER II 
THE LIPID COMPOSITION OF THE ERYTHROCYTE MEMBRANE IN HUMAN 
MUSCULAR DYSTROPHY 
2.1. Lipid cZasses 
In 1973 Kunze and coworkers published a report about 
the amounts of the various lipid classes in erythrocytes 
from patients suffering from different kinds of muscular 
dystrophy (186). They found a slightly elevated level of 
sphingomyelin for Duchenne patients. The levels of 
cholesterol, phosphatidylcholine and phosphatidylethanol-
amine plus -serine were normal. In 2 myotonic dystrophic 
patients all levels were unchanged. Since the publication 
of this study, several other groups have analysed the 
lipid composition of erythrocytes from dystrophic humans. 
The results of the studies are summarized in Table 2-I. 
These values are comparable with control values, gathered 
by Nelson (228). Only Kalofoutis et al. (160) reported 
significant differences. They found 8% increased sphingo-
myelin, 7% decreased phosphatidylcholine, 51% increased 
lysophosphatidylcholine (only covering a very small part 
of total phospholipid content) and 104% increased 
cardiolipin (which has only rarely been detected in 
erythrocytes) in Duchenne membranes. The other studies 
suggest that the lipid composition of erythrocytes from 
patients with myotonic muscular dystrophy and patients and 
carriers of Duchenne dystrophy is normal. This does not 
necessarily implicate that the lipid microenvironment of 
any enzyme, which may be very important for the enzyme 
kinetics (l66),is not altered (see Chapter 4). Such changes 
may be too small to detect in the bulk lipid fraction. 
Special interest has to be paid to cholesterol and 
its precursors in myotonic dystrophy. It has been reported 
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"' 
TABlE 2-I LIPID CCMPClSITICli! OF ERY'll-IKCYTES IN DOCHENNE AND M'iOirniC MUSCUU\R DYSTroPHY. 
Values are in ]lllOles/rnl cells, the phospholipid ratio in % of tot.?.l j:hospholipids. 
Between brackets: patient value as percentage of control value; n is the nurrber of 
patients. For significancy, see text. 
Duchenne muscular dystrophy Myotonic muscular dystrophy 
Lipid class Patients 
Kun:?.e et al. Kalofoutis Koski et al. Kobayashi 
et al, et al. 
1973 (n=l4) 1977 (n=ll) 1978 {n=S) 1978 (n=9) 
Cholesterol 3. 75 (116%} 1.92a (88%) l. 3d {85%) 
Triglycerides 0,27a,b(l29\\) 
Total phosrflolipids 4,00 (lll%) 4.Jla,c {93%) 3.41 (111%} 2.3c,d(89%} 
PhoSPholipid ratio {in %} 
Phospha tidy lcholine 36 (103%) 28 (93%) 30 (99%) 29 (97%) 
" ethanolamine 25 (95%) 28 {101%) 30 (95%) 27 {79%) 
" serine l2 (95%) ll (115%} }15 (100%) 
" inositol 3.6 (116%) 1.5 (99%} 
S!_±tingcrnyelin 37 (ll9%) 19 (108%) 28 (95%) 26 (98%) 
I,ysq:he>sphatidy !choline 2.3 {151%) l.O (159%) 
Cardiolipin l.l (204%} 
Sare figures were obtained by converting the original data by using: 
a l"ean corpuscular volurre = 94 x 10-lS 1/cell 
b Moan nulecular weight of triglycerides = 350 
c ~ nulecular weight of phosfbolipids = 725 
d Recovery of 4 lf8 rrerrbrane protein/ml cells 
Carriers 
Gcdin et al. Godin et al Kunze et al. 'lhomas and 
Harper 
1978 (n=lO} 1978 (n=6) 197) (IF2) 1978 {n=S} 
2.2d(ll2%) 2.4d (Ill%) 3. 05 {94%) 3.02 (102%) 
1.02 (109%} 
2.7d{l0l%) 2.8d (88%} 3. 77 {104%) 3.82 {99%) 
28 {97%) 30 (114%) 32 (107%) 30 (100%) 
40 (107%) 38 (BG%) l 35 30 (l02%) {104%) 
20 (99%} 
" 
(107%) f 13 (100%} 
7.8 (55%) 8. 5 (65%} 33 {90%) 28 (97%) 
that 20,25-diazacholesterol, an inhibitor of cholesterol 
synthesis from 24-dehydrocholesterol, induces myotonia 
(7,248). In the presence of this drug, desmosterol (24-
dehydrocholesterol) accumulates in plasma and red cell 
membranes, while plasma cholesterol decreases. This 
condition also leads to cataracts, another symptom often 
seen in myotonic dystrophy patients. It has been proposed 
to use the drug-induced disorder as model for human 
myotonic dystrophy (248). Analysis of plasma from 
myotonic dystrophy individuals indeed revealed a higher 
desmosterol level (368). But later in two studies 
unchanged levels in plasma and red blood cells were 
reported (8,352). Thus, at this moment no clear 
relationship between myotonic dystrophy and an impairment 
of the cholesterol metabolism has been established. 
2.2. Fatty acid composition 
Kunze et al. (186) determined the fatty acid 
composition of sphingomyelin, phosphatidylcb.oline and 
phosphatidylethanolamine in a mixed group of patients 
with progressive muscular dystrophy (X-chromosomal and 
autosomal type) . They reported increased stearic acid 
(from 13 to 27%) and decreased linoleic (from 13 to 5%) 
and nervonic acid (from 17 to 9%) in sphingomyelin. In the 
phosphatidylethanolamine (plus -serine) fraction the 
content of arachidonic acid was decreased (from 19 to 13%), 
while the dimethylacetals, originating from the 
plasmalogen form (1-alkenyl,2-acylphosphatidylethanolamine), 
were increased from 7 to 15%. However, direct measurement 
of the plasmalogen amount reveals no alteration. 
Incorporation experiments with labelled palmitic and 
linoleic acid did not result in an explanation for the 
abnormal fatty acid spectrum. 
It seemed useful to check and extend the data of Kunze 
et aZ. (186), since they were not satisfactory in some 
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details {patient's heterogeneity, aberrant fatty acid 
composition of control sphingomyelin; compare 228). 
Thereforef we have set up a series of experiments in order 
to characterize the fatty acids in the various lipid 
fractions of erythrocytes from patients with either 
Duchenne or congenital myotonic muscular dystrophy. The 
length of the fatty acid chains and the amount of un-
saturated carbon-carbon bonds are important for the 
fluidity of the lipid bilayer in the membrane. This 
parameter co-determines the mobility of the other membrane 
components like enzymes, ion-pumps,hormone receptors and 
structural proteins. Furthermore special phospholipid 
classes have their influence upon enzyme and transport 
systems {61,96). The results of our study can be found in 
appendix paper I (286). The main fatty acids in 
phosphatidylcholine, -ethanolamine, -serine, sphingomyelin 1 
phosphatidic acid, lysophosphatidylcholine, glycosphingo-
lipids and an unknown one have in both dystrophic groups 
normal levels. The major alteration in less occurring fatty 
acids was the decrease level of palmitoleic acid in 
diglycerides and triglycerides from 10% in controls to 2% 
in myotonic dystrophy. In Duchenne dystrophy the percentage 
of palmitoleic acid in diglycerides was reduced to 4%. The 
origin of these neutral lipid fractions may be not the 
erythrocyte membrane itself 1 but contaminating plasma (228) 
Reticulocytes form another sGurce. They are able to 
synthesize neutral lipids de novo (192) . Palmitoleic acid 
may come from dietary fats, especially animal fat (364) or 
as a product of palmitic acid desaturase (258). Children 
with essential fatty acid deficiency possess enhanced 
palmitoleic, oleic and eicosatrienoic acid levels in serum 
lipids, at the cost of linoleic and arachidonic acid (236) 
There are no indications for an-abnormal diet in the case 
of patients, and it seems doubtful whether it could bring 
about such a major deviation in palmitoleic acid content 
(97). So, it is difficult to correlate the declined 
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palmitoleic acid concentration with any disturbed 
metabolic process. 
Wakamatsu et al. (368) found decreased palmitoleic 
acid levels in various serum lipid fractions from patients 
with myotonic dystrophy or congenital myotonia. Howland 
and Iyer (137) reported a lowered content of palmitoleic 
acid in total lipid extracts from red blood cells of 
Duchenne patients and carriers. Yao et al. (387) detected 
abnormalities in the palmitoleic acid content in neutral 
lipids from serum of patients with various types of 
neuropathy. Apparently palmitoleic acid is involved in 
red cell metabolism of patients with neuromuscular 
disorders, but the mechanism is not known. 
Recently, Kobayashi et al. (176) published normal 
fatty acid patterns in Duchenne erythrocytes for 
phosphatidylcholine, -ethanolamine, -serine plus -inositol 
and sphingomyelin. 
From the normality of the fatty acid composition it 
cannot be concluded that the immature stages of the red 
blood cells also possess normal fatty acid levels. During 
the erythrocyte life span lipids are lost, are exchanged 
with blood lipids or are 1 after deacylation 1 reacylated 
( 359) . Phosphatidylcholine 1 lysophosphatidylcholine 1 
sphingomyelin 1 free fatty acids and cholesterol from the 
bloodstream are exchanged with their red cell membrane 
counterparts. Lysophosphatidylcholine and -ethanolamine 
are readily acylated to intact phospholipids. These 
processes are likely able to normalize the fatty acid 
pattern in erythroid cells. In order to elucidate a 
probable influence of blood phospholipids, the fatty acids 
in patient's serum phosphatidylcholine 1 -ethanolamine, 
sphingomyelin and lysophosphatidylcholine have been 
determined (appendix paper I; 286). Myristic acid levels of 
sphingomyelin and lysophosphatidylcholine were increased in 
plasma from myotonic dystrophy patients (from 3 to 5% and 
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from 4 to 9%, respectively). Stearic acid was diminished 
in sphingomyelin (from 19 to 13%) and eicosatrienoic acid 
in phosphatidylcholine was reduced (from 3 to 2%) in this 
group. In plasma phospholipids from Duchenne patients no 
alterations were found. It is clear that an abnormality of 
fatty acids in the early stages of the erythroid cells 
cannot be excluded definitely. It is noteworthy that 
reticulocyte counts in Duchenne blood have been reported 
to be normal (2,68). Reticulocytes have a fatty acid 
pattern different form mature red cells; especially the 
content of linoleic and arachidonic acid is dissimilar (360) 
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CHAPTER Ill 
THE PHYSICO-CHEMICAL PROPERTIES OF THE ERYTHROCYTE MEMBRANE IN 
HUMAN MUSCULAR DYSTROPHY 
An important stimulus to investigate physico-chemical 
characteristics of erythrocytes from dystrophic patients, 
was the altered morphology of Duchenne erythrocytes 
reported by Matheson and Howland (206) . The following 
parameters will be discussed: morphology, electrophoretic 
mobility, microviscosity, viscoelasticity and osmotic 
stability. 
3.1. Morphology of erythrocytes 
In 1974 Matheson and Howland published a scanning 
electron microscopic study (206), in which they reported 
an increased percentage of echinocytes in the blood of 
Duchenne patients and carriers. {Echinocytes are red cells 
with many crenations at the surface, a sea-urchin 
appearance, which can be reversibly formed in vitro from 
normal erythrocytes (discocytes) (22,74,373).) Hatheson and 
Howland ascribed the echinocyte formation to an 
abnormality of the membrane lipid, as fatty acids and lyse-
phospholipids are able to induce this cell shape. The 
deviation was confirmed by Lurnb and Emery (19ji) in a light-
microscopic study, although a smaller difference was found. 
Some papers followed, reporting no echinocytes in ouchenne 
blood (216,219). Matheson found, with other coworkers, that 
the way of preparation was important for the shape of the 
erythrocytes and could not reproduce the earlier finding 
(207). In contrast, Howells (135) reported significantly 
more echinocytes in blood samples from Duchenne patients, 
independent from the treatment. Korczyn et al. (181) 
reported abnormal morphology, but considered it as an 
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artifact that supported the membrane hypothesis (see 1.4.) 
In an extensive study Soltan (333) could not detect more 
echinocytes, while Grassi et al. (118) only found more 
abnormal erythrocytes in Duchenne patients when analysed 
immediately after blood withdrawal. The difference had 
disappeared after a storage period of 3 days. The amount 
of echinocytes in carrier blood was elevated in those 
cases, in which serum creatine phosphokinase level was also 
increased. 
Morphology of red cells from patients with myotonic 
muscular dystrophy has been scarcely described. Miller and 
coworkers (220) counted more stomatocytes in patient's 
blood samples. (Stomatocytes are cup-shaped cells with the 
central biconcave region not circular, but elongated (22) .) 
They found the same in Duchenne patients and carriers. 
Grassi et al. (118) reported an increased number of 
echinocytes in various types of muscular dystrophy, among 
others myotonic dystrophy. In neurogenic disorders no 
aberration was found. 
There exist no indications that patient's red cells 
are odd-shaped in vivo; their life span is normal (2,68) 
A possible explanation for the described results may be 
that the erythrocytes in Duchenne and myotonic muscular 
dystrophy have an increased sensitivity to an unknown in 
vitro condition, leading to controversial results. ca2+ 
may be considered to play this role. Weed and Chailley 
(373,374) reported that increasing ca 2+-1evels produce a 
higher oleate- or salicylate-induced echinocyte formation. 
Dise et al. (77) have demonstrated an enhanced sensitivity 
of Duchenne erythrocytes to intracellular ca2+. The 
crenations could have been formed after interaction of 
ca
2
+ with an irregularly stimulated or localized 
contractile apparatus. High intracellular ca2+ and/or low 
ATP concentrations may induce aggregate formation of 
dephosphospectrin molecules in the membrane. These 
aggregates may interact with actin, resulting in 
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"contraction 11 of the membrane and echinocyte transformation 
(190). However, hitherto there are too few indications in 
favour of this idea to exclude other mechanisms. 
3.2. Electrophoretic mobility of erythrocytes 
Bosmann and coworkers (33) measured the mobility of 
red cells, suspended in saline-sorbitol, under the influence 
of an electric field. The mean electrophoretic mobility of 
cells from myotonic and Duchenne dystrophy patients was 
elevated. However, 42% of the myotonic and even all the 
Duchenne values were within the normal range. The mobility 
is a measure for the average surface charge. In erythrocytes 
the negative charge is for a great part determined by the 
sialic acid moieties of glycoproteins and glycolipids (351) 
Neuraminidase treatment greatly reduces the electrophoretic 
mobility (375). Bosmann et aZ. (33) suggested that their 
results may be explained by an increase in negatively 
charged groups, e.g. sialic acid, in dystrophic erythrocyte 
samples. Godin e t aZ. ( 112) demonstrated recently that the 
total sialic acid content of red cells from Duchenne 
patients was only lightly elevated (not significantly) . The 
problem remains whether it can explain the small increase 
in electrophoretic mobility. An alternative explanation may 
be that the membrane charges are masked in a different way 
in patient and control red cells, for example by a more 
deep or superficial localization (see also 33,112). 
Szibor et aZ. (343) measured just a lower mobility for 
Duchenne erythrocytes. Ouabain reduced the mobility of 
control cells, but enhanced it in 5 of 7 cell samples of 
Duchenne patients. This effect may be related to the (by 
some groups found) ouabain stimulation of (Na+ + K+)-
ATPase of patient's membranes (see 4.2.). 
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3.3. Fluidity OP microviscosity of the erythrocyte membranes 
In addition to the investigations on the lipid and 
fatty acid composition of the red cell membrane in various 
types of muscle dystrophy (see Chapter 2) , some studies 
have been published on the fluidity of the membrane in 
these diseases. The fluidity is important for cell 
metabolism, as it has its influence on the activity of 
membrane-bound enzymes and transport processes (61,166) 
The techniques used are: electron spin resonance (ESR) and 
fluorescence polarization. 
3.3.1. Fluorescence polarization studies 
This method is based on the determination of the 
degree of polarization of an organic fluorescent molecule, 
embedded in a membrane. The degree of polarization of the 
fluorophore (also designated as probe) is a measure for 
its rotational mobility, which is defined by the fluidity 
of its local environment, also called microviscosity (323; 
for a review, see 324). The hydrophobic probe 1,6-diphenyl-
1,315-hexatriene (DPH) is frequently used to monitor the 
fluidity of lipids in natural and artificial membranes. 
we have measured the degree of polarization of the 
probe DPH introduced into red cell membranes from patients 
suffering from either Duchenne or congenital myotonic 
muscular dystrophy, and from control boys. One portion of 
the membranes (about 0.2 mg protein) 1 prepared according to 
the method described in appendix I (286) 1 was washed with 
5 mM EDTA, another portion with 5 rnM CaC1 21 and both in 
20 mM Tris-HC1 1 pH 7.4. The EDTA-mernbranes were incubated 
with 2 x 10- 6 M DPH in 130 mM NaCl, 2 mM EDTA, 20 mM 
Tris-HCl, pH 7.4. ca 2+-membranes were incubated in the same 
medium while EDTA was replaced by 5 mM CaC1 2 . The conditions 
for incubation and measurement have been published by 
Van Hoeven et al. (361). The results are shown in Table 3-I. 
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TABLE 3-I. DEGREE OF POLARIZATION OF DPH IN ERYTHROCYTE MEMBRANES FROM 
PATIENTS WITH DUCHENNE AND CONGENITAL MYOTONIC MUSCULAR 
DYSTROPHY IN THE PRESENCE OR ABSENCE OF 5 mM Ca2+, AT 25° 
AND 12°C (means ! SEM) 
25°C 12°C 
Preparation 
ca2+ EDTA ca2+ EDTA 
Control 0.333+0.001 0.336!0.002 0. 355!(1.004 0.363!0.004 
{n.,J) (n,3) {n""2) (n .. 2) 
Duchenne dystrophy 0.333,:t0.001 0.334+0.002 0.354.:t:_0.001 0.358:!::0.002 
{n=5) (noo5) {n"'2) (n"'2) 
Myotonic dystrophy 0.334,:t0.002 0.33l.:t:_0.007 0.357.:t:_0.005 0.364:!::0.002 
(n,4) {n,.4) (n,2l (n=2) 
Control values are in agreement with those found by 
Van Hoeven et al. (361) for human red cell membranes. No 
differences have been found between patients and controls 
d •t . . . 2+ d esp1 e var1at1on 1n Ca an temperature. As we assumed 
2+ l . l . h l . Ca p ay1ng a ro e 1n t e a terat1ons of the red cells 
of dystrophy patients, we measured the membrane fluidity 
in the absence and presence of ca2+. The same polarization 
values were obtained at both conditions at 25°c. Obviously, 
binding of ca2+ to membrane components like phosphatidyl-
serine and proteins has no effect on the fluidity of the 
hydrophobic core as measured by DPH polarization. These 
results are different from ESR-studies which showed that 
ca
2
+ increased the fatty acid chain mobility in erythrocyte 
2+ 
membranes (1). A Ca -effect is also observed, when the 
ionophore A 23187 is applied as fluorophore in red cell 
membranes (376). A temperature decrease from 25° to 12°C 
gives rise to increase in polarization and, therefore, 
decrease in fluidity, with the same change in the three 
groups. From these results it may be concluded that the 
flm.-7 activation energy in patient's membranes is normal. 
Although not significantly, ca2+ seems to have a little 
decreasing effect on the fluidity at 12°C. 
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The degree of polarization of the probe depends on 
several factors: the length of the fatty acid chain and 
number of unsaturated carbon-carbon bonds in it, the 
cholesterol concentration {or better the cholesterol/ 
phospholipid ratio) and sphingomyelin content {62,222) 
Erythrocyte membranes and liposomes, prepared from the 
erythrocyte lipids, show about the same degree of 
fluorescence polarization or microviscosity, indicating a 
low to negligible effect of the proteins of the (mature) 
red cell membrane to the lipid fluidity {6,222,285). The 
lack of protein influence may be caused by: 
a) Proteins do not influence the structure of the lipid 
bilayer and have no effect on the microviscosity. 
This seems in contrast to studies applying other 
techniques for fluidity determination and is in dis-
agreement with today's conceptions of membrane 
architecture {1,20,36,65,282,317,321,330,371,391) 
b) The probe is embedded in the more apolar lipid regions 
of the membrane, where the lipid-pr0tein interactions 
are not strong. The reason for the localization of the 
probe could be the lack of a polar group in the probe 
molecule. 
c) The probe is localized in both apolar and polar regions 
of the membrane, while the contribution of the latter to 
the fluorescence polarization is negligible. This 
possibility seems not satisfactory, as more than half of 
the amount of phospholipids is in direct contact with 
proteins {65), containing for a great part polar moieties. 
Some contribution of DPH in the polar domains, and 
therefore influence of proteins, should be expected to be 
detectable. 
The second possibility seems the most attractive one. The 
conclusion from the normal values for the degree of 
fluorescence polarization has to be that the average fluidity 
of the relative hydrophobic parts of the red cell membrane in 
Duchenne and myotonic dystrophy is unchanged. This points to 
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normal lipid, especially cholesterol, levels and fatty 
acid composition. The measurements described in Chapter 2 
are thus supported by physical findings. 
3.3.2. Electron spin resonance studies 
In these studies probes are introduced into the 
membrane, from which the tumbling motion of the label spin 
reflects the motion of the probe. The probe motion is 
defined by the environment to which it is bound. Two 
important labels are: the nitroxide derivatives of stearic 
acid and the nitroxide derivative of N-ethylmaleimide. 
These probes, often applied in erythrocyte studies, give 
insight into the fluidity of the lipid and protein(-SH-
moieties) of the membrane, respectively. The structure of 
the stearic derivative is given below. The m and n of the 
probe I(m,n) can be chosen, which makes it possible to vary 
the distance between the nitroxide spin and the carboxyl 
group, which is anchored in the polar layers of the 
membrane. 
I (m,n) 
By this method the various 11 depths" of the membrane can be 
monitored (21,44,138,164,313). 
Butterfield e"t aZ.. (46) concluded from ESR experiments, 
using I(l2,3), that the fluidity of the lipids rather near 
the membrane surface was elevated in erythrocytes from 
patients with myotonic dystrophy. The lipid fluidity in 
these cells becomes more and more normal deeper in the 
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membrane, as tested with I(5,10) and I(1,14). The same 
group reported that phenytoin decreases the fluidity in 
myotonic cells to a normal value (277) . This drug is 
applied for the stabilization of epileptic and myotonic 
syndromes (120). Tetany and other clinical symptoms of 
hypocalcemia are improved by phenytoin {298). It is bound 
to nervous tissue, probably to both proteins and lipids 
(115). It inhibits the ca2+-transport in brain (250) and 
synaptosomes 
C 2+ b" d" a - ln lng 
(332) and has a stimulating 
to phospholipids (114). The 
effect on 
membrane fluidity 
may be lowered by phenytoin in the same manner as 
cholesterol does (36,62) 1 namely intercalating its apolar 
(phenyl) moieties between the fatty acid chains and the 
polar {hydantoin) group in the area of phospholipid bases. 
So, it may be that the packing of the myotonic erythrocyte 
membrane directly beneath the hydrophilic region is less 
condense. It is not clear whether the cholesterol-
desmosterol hypothesis for myotonia (see 2.1.) may be 
applied here. It is obvious that desmosterol interacts in 
a similar way with the lipid bilayer as cholesterol does, 
but the interaction with the proteins may be different 
(43 1 70). The proteins in their turn may influence the 
fluidity of the lipid domains. 
Another explanation for the higher fluidity may be a 
protein aberration. Butterfield and coworkers applied the 
nitroxide derivative of N-ethylmaleimide to erythrocytes 
from· myotonic dystrophy patients (48). This probe reveals 
the presence of two types of SH-moieties, a strongly and 
a weakly bound group (329). The amount of strongly bound 
SH-groups is reduced in red cells in myotonic dystrophy, 
the arnoqnt of weakly bound groups is unaltered (48). The 
weakly bound SH-groups are located superficial, the 
strongly bound ones both superficial and deeper into the 
membrane layer. The exact reasoning for these changes is 
obscure. 
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ESR studies have also been performed on red cells 
from Duchenne patients. Spin labelling of the fatty acid 
chains with I(l2,3) reveals no abnormality (47). The ratio 
of weakly bound to strongly bound SH-moieties is increased 
(45). Butterfield (44,45) concluded that dystrophy is 
accompanied with altered membrane protein features, and 
myotonia with abnormal lipid fluidity. Sato et al. (297) 
found with the I(l2,3) probe also normal fluidity values 
for the lipids in Duchenne red cells. Using I(l,l4), they 
indicated a decreased fluidity near the centre of the 
hydrophobic core. The fluidity of that region also 
possessed altered pH and temperature dependency. The 
authors suggested that the cause may be a more tight 
protein-lipid interaction in Duchenne cells. Wilkerson 
et al. (378) applied I(l2,3) combined with the saturation 
transfer ESR technique, which detects slow motions of the 
label (107). They found abnormal intensities both after 
short and long labelling times. They concluded that those 
results were due to the spin exchange effect and concluded 
that in Duchenne erythrocytes the label was primarily 
bound to specific sites at a high concentration, followed 
by a delayed distribution to other sites. This idea may be 
in agreement with a stronger protein-lipid interaction, as 
suggested by Sato et al. (297). It is not excluded that the 
altered SH-groups (45) are involved in this interaction, 
too. 
3.3.3. Conclusions from the fluidity measurements 
From the foregoing studies it is clear that in some 
cases fluorescence polarization measurements give normal 
fluidity values, while with ESR studies abnormal values 
are found. Fluidity, measured by ESR, is influenced, as 
is the case with fluorescence polarization, by cholesterol, 
fatty acid chain length and -saturation degree and the 
nature of the polar headgroup of the phospholipids (98, 
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167,322). The reason for the discrepancies in the two 
techniques may be ascribed to the fact that the mobility 
of the ESR fatty acid probes is influenced by proteins (1,20, 
282,317,321,371) ,while erythrocyte proteins do not affect 
the lipid fluidity as detected in fluorescence studies 
with DPH (see 3.3.1.). ESR offers the possibility to 
distinguish between fluidity of the lipid bilayer and the 
lipids, bound very tightly to proteins (5,23,157). The 
nitroxide label has a much more polar character than the 
acyl chains and may be more embedded in the polar lipid 
domains. Possibly the degree of DPH polarization reflects 
the fluidity of the bulk lipids, comparable with the 
chemically determined composition 1 and ESR probes 
predominantly monitor the fluidity of those lipids, which 
are in close contact with proteins. A second reason for the 
discrepancies between the two techniques may be a difference 
in sensitivity to certain membrane compounds. 
Both types of microviscosity measurements make use 
of probes which may perturb the native state of the 
membrane to a certain extent. Some studies have revealed 
label-induced deviations, 'i'Thile other ones showed no 
changes (23,49,50,139,161; for a review, see 164). It is 
hardly possible to say to what extent the original 
fluidity has been influenced by the various probes. 
With these notions in mind it can be concluded that: 
a) there exist no changes in the composition of the bulk 
of the lipids in red blood cells of Duchenne and 
myotonic muscular dystrophy patients. 
b) in both patient groups ESR studies have shown some 
alterations in lipid fluidity and protein architecture; 
the origin of the alterations may be a change in some 
protein property 1 although a primary lipid change cannot 
be excluded. 
c) in Duchenne red cell membranes there exists a less 
uniform distribution of membrane proteins and lipids. 
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d) the nature of the membrane alterations is different in 
the two muscular dystrophies. 
3.4. Viscoelasticity of the erythrocyte membrane 
When an erythrocyte is forced to pass through a micro-
pipette with an orifice diameter of 3 ~m, it can do so only 
after deformation~ as the erythrocyte diameter is about 
8.3 ~m (377). The underpressurer necessary to aspirate the 
red cell into the pipette is a measure for the deformability 
or viscoelasticity of the cell. The lower the elasticity 
the higher the aspirating force necessitated. 
Percy and Miller (243) performed the described technique 
on red cells from Duchenne patients and carriers. They found 
for both groups that less cells could be aspirated by 
pressures under 100 rnrn Hg. The conclusion can be that these 
cells possess a larger volumer an altered geometry, an 
increased rigidity or a combination of these factors. In the 
case of patientsr no indication for a larger volume exists 
(2). A (tendency to) geometric alterations has been discussed 
in section 3.1. The study of Kohn et al. (180) seems to 
support the possibility of an increased rigidity in Duchenne 
erythrocytes. They calculated a significantly increased 
elastic shear modulus from experiments, in which not the 
whole cell but only a part of it was sucked into a micro-
pipette. The same deviation, although to a minor extent, was 
found in myotonic muscular dystrophy. Cells from patients 
suffering from neurological, non-dystrophic diseases, showed 
normal viscoelastic parameter values. 
The elastic shear modulus of the cell, a measure for 
the extension of the cell rr.embrane per pressure unit, is 
mainly defined by the membrane protein-protein interactions 
(94,130,375). Some of these interactions are, in their turn, 
influenced by lipids. Heusinkveld and coworkers (130) 
reported that crosslinking of the membrane proteins (by 
glutaraldehyde) drastically increased the elastic shear 
43 
modulus. Reduction of the spectrin content lowered the 
modulus value, while sulfhydryl reagents and glycophorin 
only had little influence. Spectrin 1 an extrinsic protein 
at the cytoplasmic side of the membrane,can form aggregates 
or polymers with other membrane proteins at increased ca2+ 
concentrations (53 1 87,328). ATP is able to prevent the 
ca
2
+-induced aggregation (53,198). Low ATP and high ca2 + 
concentrations are well-known circumstances related to 
reduced deformability (130,194,198,375). Thus, this type of 
spectrin-involved crosslinking may be responsible for the 
increased rigidity in Duchenne erythrocytes 1 and perhaps 
also for red cells in myotonic muscular dystrophy. 
One may wonder whether the reduced deformability after 
ATP-depletion may be directly linked to the ca2+-induced 
aggregation. For, the former process is reversible (375), 
the latter being irreversible (53 1 328). It may be that the 
spectrin conformation is changed by a moderately increased 
2+ Ca and/or moderately decreased ATP concentration, leading 
to a rather small reduction of deformability, while more 
extreme circumstances induce (via spectrin) protein 
polymerization. The reversible condition may be compared 
with the discocyte-echinocyte transformation and the 
irreversible one to the glutaraldehyde-treated cells, with 
an almost normal and drastically increased elastic shear 
modulus 1 respectively (190). The deformability, however, of 
echinocytes is significantly decreased (194). ca2+-levels 
above 0.5 mM may stand for such extreme conditions. These 
concentrations induce the mentioned protein aggregation 
(53,168,328), while rigidity increased already at 
concentrations 10 times lower (375). Palek et al. (231) 
described two different crosslinking reactions: one being 
reversible and occurring at an intracellular ca 2+ 
concentration of 0.1 mM and the other being irreversible. 
This polymerization takes place at ca2+ concentrations above 
0.5 mM and may be catalyzed by a ca2+-stimulated, ATP-
dependent transglutaminase (328). The influence of ca 2+ 
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upon membrane proteins is visible in the electrophoretic 
pattern (168). At 0.1 mM ca 2+ more hemoglobin is 
attached to the red cell membrane than at 10 mM or without 
Ca 2+. The hemoglobin binding may be concerned to the 
mildly increased rigidity of the membrane (375). So, an 
increased elastic shear modulus may be caused by an extra-
polation of conditions 1 inducing reduced deformability. 
The condition in Duchenne and myotonic dystrophy 
erythrocytes may be rather disordered, as revealed by the 
increased elastic shear modulus. 
3.5. Osmotic stability of erythrocytes 
The osmotic stability is the capacity of the cell to 
resist pressures, exercised by the increasing volume of 
the cell content. It is determined by several factors, 
including the viscoelasticity (190): 
a) the surface/enclosed volume-ratio 
b) the viscoelasticity (or rigidity) (see 3.4.) 
c) the yield shear, the elastic limit of the membrane 
d) the shear viscosity at irreversible (plastic) extension. 
The osmotic stability of erythrocytes from Duchenne 
patients has been reported to be reduced in 5 studies (101, 
112,196,289 (appendix II) ,334). Adornato et aL (2) 
reported normal stability. Godin et al. (112) and Lloyd and 
Nunn (196) found normal cell stability in Duchenne carriers. 
Patients with congenital myotonic muscular dystrophy have 
red cells which are less stable than control and Duchenne 
cells (289; appendix II). A serum factor, which eventually 
persists in causing fragility during hemolysis was excluded 
in our study by applying the NaCl-phosphate buffered 
solutions to washed cells instead of whole blood, which was 
taken in the other studies. 
In order to obtain information about the cause of the 
fragility, we have incubated red cells in the presence of 
various phospholipases A. The phospholipase from bee venom 
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is able to hydrolyse erythrocyte phospholipids, while 
phospholipase from pancreas and Crotalus snake venom 
cannot (392). This difference may be due to the fact that 
the latter two enzymes are unable to phospholipid break-
down at surface pressures above 23 dynes/em (71). Thus, 
the study may give insight into the surface architecture 
of patient's erythrocytes (289; appendix II). Only the bee 
venom phospholipase-treated cells of Duchennes, myotonics 
and controls were hemolysed to a greater degree when 
compared with untreated cells, after being brought into 
the same NaCl-phosphate solutions. The same order of 
stability was found in the three groups of cells, 
independently from the type of phospholipase A applied. 
A surprising effect of the treatment of cells from 
Duchenne patients and controls v.1as, that more cells lysed 
at isotonic NaCl-phosphate solutions than at about 0.50% 
(wjv) solutions. This holds for all types of phospholipases 
tested. Erythrocytes from myotonic dystrophy patients 
hardly demonstrate this phenomenon. Omission of phospho-
lipase from the pretreatment medium results in 10% lysis of 
erythrocytes from control men in isotonic medium. The 
addition of phospholipase causes 11, 36 and 78% extra lysis 
of these cells in isotonic medium, for pancreatic, snake 
venom and bee venom enzyme, resT,)ectively. When the ca 2+ 
concentration of the pretreatment medium was lowered from 
14 to 6 mM, lysis was hardly detectable both with and 
without phospholipase-treatment. It turned out that 
omission of phosphate (present in the lysis medium, not 
during pretreatment) made lysis disappear, and that 
+ 
replacement of Na by other monovalent cations drastically 
reduced hemolysis. Furthermore, addition of 10 rnM ribose, 
glucose or sucrose decreased the rate of lysis to less 
than half the amount, as did ouabain. These effects 
cannot simply be explained by an energy sparing effect, 
as sucrose is not metabolized by red cells (218). Moreover, 
we were unable to detect lowered amounts of ATP or 
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2,3-diphosphoglycerate (the most im9ortant high-energy 
compounds in erythrocytes) in the cells remaining after a 
high degree of lysis had taken place. The same lack of 
correlation was found between the Ca 2+content and rate of 
hemolysis. La 3+-ions and mersalyl, which suppress the ca 2+-
efflux and enhance passive ca2+-influx (308,342), greatly 
enhanced the lysis process. A high extracellular ca2+ 
concentration (about 25 mM) and no phosphate after pre-
treatment results in less lysis. Therefore, a high intra-
cellular ca2+-level alone cannot explain the lytic 
process. The Na+-transport inhibitor tetrodotoxin (222a), 
the serine protease inhibitor phenylmethylsulfonyl 
fluoride (168, this drug did not inhibit a postulated 
membrane-bound protease in red cells) and the cholinergic 
agent carbamyl choline {142) all reduce lysis by 60-70%. 
2+ + It is clear, that the Ca -, Na -, and phosphate-
dependent process (es) 7 causing the high degree of lysis in 
control red cells, and which is induced or stimulated by 
exogenous phospholipase, is less or not active in myotonic 
dystrophy cells. The results of this study can be 
compared with the findings of Huestis (142), who treated 
erythrocytes with liposomes and found an increase in Na+-
permeability and in lysis, which processes were 
diminished by tetrodotoxin. Treatment of the extracted 
cells with liposomes, which were loaded with proteins, 
previously extracted from the same cells, also redu~es 
lysis and Na+-permeability. The rate of hemolysis was 
reduced by sucrose. In another publication Huestis (141) 
reported that incubation of erythrocytes with carbamyl 
choline resulted in decreased lipid fluidity if external 
ca
2
+ was present. The effect was absent when tetro"dotoxin 
and ca 2+-chelator were added. An acetylcholine receptor 
was isolated in this study. These studies suggest that, 
when the acetylcholine receptor is stimulated 1 aNa+-
specific ion channel is opened and hemolysis is induced. 
Ca 2+ should be required for this process. Comparison of 
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these data with the phospholipase-treated cells in our 
study may suggest that the described liposome-treated 
cells have (partly) the same characteristics as the 
phospholipase-treated cells from controls. During pre-
treatment one or more proteins, which are involved in the 
Na+-channel (perhaps coupled to the acetylcholine receptor), 
may have been removed. The inhibition of the hemolysis by 
sucrose and EGTA and partly inhibition by tetrodotoxin are 
2+ + in agreement with this idea. Apart from Ca - and Na -
ions, phosphate plays also a role in the high degree of 
lysis in our experiments. This effect may be comparable 
v1ith the somewhat enhanced phosphate uptake by the liposome-
treated red cells (142) . The abnormality of the red cells 
from patients with congenital myotonic muscular dystrophy 
may be caused by the unaccessibility of the Na+-channel/ 
acetylcholine receptor-complex to phospholipase attack. 
Whether this is due to an abnormal superficial structure, 
or to an alteration in the channel-receptor 1.vi th its 
direct environment, is not to conclude. Obviously this 
concept cannot explain all results enumerated in appendix 
II. But it may reflect one of the processes that results in 
a high rate of lysis in control cells, or may be the 
process that triggers other pathvmys causing hemolysis. 
3.6. Discussion 
This chapter contains data obtained by techniques 
based on different principles. In spite of it, some 
aspects are repeatedly prominent. From measurements of 
the lipid fluidity (see 3.3.) and the viscoelasticity (see 
3.4.) it is clear that the protein-proteiD or protein-
lipid interactions may be altered in both myotonic and 
Duchenne dystrophy. The suggested tightened interactions 
(297) may be accompanied with ~ high rigidity of the 
2+ 
membranes. Ca and ATP play important roles in membrane-
protein interaction. Both cytoplasmic and membrane-bound 
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2+ proteins are involved inCa -dependent processes (see 3.4.) 
A role for ca2+ has been proposed from the hemolysis (see 
3.5.) and ESR data (see 3.3.2.), while the abnormal shape 
of erythrocytes, sometimes found (see 3.1.), also may point 
to a ca 2+-involvernent in red cells from dystrophic patients. 
Thus, many of the deviations can be explained by an 
elevated ca 2+-level or a diminished ATP content. These two 
conditions often coincide (130,357,375). The consequences 
are reduced deformability, high elastic shear modulus and 
aggregation of membrane proteins (see 3.4.). One can 
imagine that these conditions are linked with altered 
membrane sulfhydryl group properties, as demonstrated by 
ESR studies (see 3.3.2.). The osmotic stability of red 
cells also depends on the ca 2+ concentration, but not in a 
simple way. Lake et al. (191) described that intracellular 
2+ Ca -levels up to about 1 mN increased the stability, while 
extremely high ca2+ concentrations lowered the stability. 
From these data it can also be seen that changes in osmotic 
stability are not negatively correlated with rigidity 
changes. For,the rigidity of red cells is increased at 
2+ 0.05 mM and more Ca (170), while the osmotic stability is 
2+ 
optimal in the presence of 1 mM Ca (191). ATP prevents 
excessive binding of ca2+ to the membrane via complexation 
of ca2+ or via hemoglobin-ATP interaction {55,271). Maybe 
ATP has a direct effect upon the membrane organization, 
which changes the phospholipid environment at the outside of 
the membrane (325). ATP may be required to maintain spectrin 
in its phosphorylated, monomeric form (24,169,188). The 
ratio of phosphorylated-dephosphorylated spectrin molecules 
is controlled by a protein kinase and protein phosphatase 
(24). Evidently, ATP has an important function as energy 
source for different anabolic pathways, like the renev1al of 
membrane components. 
There are no indications for a low ATP-level {32,67, 
295) or a high Ca 2+-level (77) in Duchenne erythrocytes. It 
is conceivable that patient red cells are more sensitive 
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towards ca2+ owing to, for example, an enhanced affinity of 
spectrin for ca2+. Dise et al. {77) reported that Duchenne 
erythrocytes, loaded with ca2+ to the same level as control 
cells, reveal an enhanced response as to hemolysis and K+-
efflux. 
Apart from ATP, 2,3-diphosphoglycerate can lower the 
free ca2+-levels. This compound can maintain a high degree 
of deformability of red cells (189). Bosia et al. (32) 
reported in red cells from Duchenne patients a normal level, 
but Sarpel et al. (295) found half the normal level of 
2,3-diphosphoglycerate. 
The physico-chemical properties of erythrocytes can 
also be changed by the binding of prostaglandins and 
catecholamines. Prostaglandin E 2 and epinephrine induce a 
lowering of lipid fluidity as measured by ESR (188). Cyclic 
AMP or cyclic GMP can induce this change in intact 
erythrocytes. The authors suggested that the fluidity 
change takes place via a phosphorylation-dephosphorylation 
mechanism of spectrin. Prostaglandin E 2 and epinephrine 
increased the viscoelasticity of the red cells (4). These 
hormones also cause a higher rate of hemolysis, an effect 
which can be induced by exogenous cyclic AJ~ in intact 
cells (260). The hormones, however, do not increase the 
(intra- or extracellular) cyclic AMP-levels. Prostaglandin 
E 2 diminishes the size of a rapidly exchangeable, oscillating 
calcium pool and reduces the amplitude of the concentration 
2+ 
oscillations (260) . The changes in the Ca -pool may trigger 
the rigidity and osmotic stability of the cells. Ji and 
Nicholson (155) demonstrated a transmembrane effect by a 
lectin upon red cell protein crosslinking. One of these 
receptor-mediated mechanisms may be impaired in red cells 
from Duchenne (and perhaps myotonic) muscular dystrophy. In 
this context it is of interest that Wakayama et al-. (370) 
recently published a freeze fracture study, showing a lower 
amount of intramembranous protein particles in both layers 
of the membranes. Furthermore, the particles were not 
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distributed uniformly, supporting the explanation of 
Wilkerson et al. (378) for their ESR data (see 3.3.2.) As 
the protein-lipid ratio (112,176,182) and the electro-
phoretic pattern (see 4.1.) are normal for Duchenne red 
cells, it can be concluded from these studies that protein 
aggregation has taken place. The pattern of protein 
distribution is comparable with the picture seen after a 
moderate degree of protein aggregation (stage 1, 
see 86) . 
It has to be stated that the above described 
suggestions especially refer to the Duchenne type of 
muscular dystrophy. For myotonic dystrophy much less data 
are available. For instance, the ca2+-level in erythrocytes 
in this disorder is unknown and the ESR and rigidity studies 
are more limited. Similarities with the Duchenne red cells 
are the normal lip~d fluidity as measured by fluoresCence 
polarization, the altered sulfhydryl group conformation, the 
increased elastic shear modulus and the reduced osmotic 
stability. Dissimilarities are the elevated lipid fluidity 
as measured by ESR and the behaviour of phospholipase-
treated cells (see 3.5.). Furthermore, a higher ATP-level 
has been reported in erythrocytes in myotonic dystrophy 
(67), while no abnormality was found in freeze fracture 
pictures (369). Therefore, it may be that the trigger for 
the abnormalities in myotonic dystrophy cells has a nature 
different from that in Duchenne dystrophy, but that the 
consequences are partly similar. 
Finally, based on the decreased osmotic stability and 
deformability, one should expect a decreased survival of 
the red cells in both types of dystrophy. However, Adornato 
et al. (2), taking into account reticulocyte counts (see 
also 68) , hemoglobin measurements and decay of 51cr-labelled 
cells, concluded that Duchenne red cells have a normal time 
of survival. Additional support for this view can be found 
in the study of Campbell et al. (51) . 
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CHAPTER IV 
THE PROTEINS OF THE ERYTHROCYTE MEMBRANE IN HUMAN MUSCULAR 
DYSTROPHY 
Activities of various membrane-bound enzymes have been 
determined in erythrocytes from patients suffering from 
muscular dystrophy. The determinations give insight into 
several aspects of cell metabolism. An altered enzyme 
property may be the clue to the primary cause of the 
disorders. It may point to an adaptation of the cell to 
changed conditions caused by a metabolic perturbation. It 
may be the consequence of an abnormal membrane structure. 
Especially the lipid environment of the enzymes is able to 
induce changes in enzyme properties. Some enzymes are 
surrounded by a lipid layer with a composition strongly 
different from the total membrane lipid composition. 
Destruction of that layer drastically affects the enzyme 
activity and other kinetic parameters. The effect of more 
moderate influences can be seen in diet and hormonal 
studies, which change the fluidity of the membrane lipids 
(for reviews, see 61,96,166). 
This chapter deals with the red cell membrane protein 
composition and phosphorylation in the myopathies. Studies 
on activities and other kinetic parameters of membrane-
bound enzymes in red cells will be summarized. 
4.1. Membrane proteins and their phosphorylation 
The protein pattern, as seen after SDS-polyacrylamide-
gel electrophoresis, of membrane ghosts from Duchenne 
patients (278) and patients with myotonic muscular 
dystrophy (275) is quite normal. Godin et al. (112) 
reported normal values for the amount of sialic acid, and 
for superficial and total amino groups in Duchenne 
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erythrocytes. The same study showed that these properties 
were also normal in Duchenne carriers. Normal protein 
spectra and glycoprotein bands were reported by 
Kobayashi et al. (176). 
Another way to study possible alterations in 
erythrocyte proteins is to separate them after 
phosphorylation with labelled ATP. The group of Roses and 
Appel has analysed the phosphorylation of the proteins of 
erythrocyte ghosts from dystrophic patients by endogenous, 
membrane-bound protein kinases. They measured a 50% 
decrease in phosphorylation of one component of band III 
in myotonia dystrophica (275; for enumeration of the 
electrophoretic pattern, see 336). They also reported 
enhanced phosphorylation of band II (spectrin) and band 
III in Duchenne erythrocyte membranes (276). The results 
of both studies can be explained by an altered substrate 
or ratio of protein kinase-protein phosphatase activities. 
Further purification of the band II reveals that some 
polypeptides in Duchenne membranes are phosphorylated to a 
higher degree, while other ones are not (279). Treatment 
of band II with trypsin yields fragments, of which the 
phosphorylation is abnormal in a pedigree-specific manner 
(281) • 
More detailed studies are required for determination 
of the exact alterations in the muscular disorders. Helpful 
may be the addition of stimulators (cAMP) or inhibitors 
(ca 2+ or Na+) of the phosphorylation of band III in control 
membranes (95,123). Then band III kinase can be distinguished 
from the spectrin band II kinase, which is stimulated by 
C 2+ M 2+ a , g and monovalent cations and hardly stimulated by 
cyclic AMP (13,284). In this way it may be elucidated 
whether the altered phosphorylation is due to a structural 
change of the kinase or substrate, or to a reduced or 
enhanced phosphorylation degree of the substrate. That lack 
of details does not justify far-reaching conclusions from 
these experiments, is supported by Iyer et al. (150). 
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These investigators did not find increased and decreased 
protein phosphorylation in Duchenne and myotonic dystrophy, 
respectively. They just reported an enhanced band III 
phosphorylation in myotonic dystrophy and a normal 
phosphorylation pattern in Duchenne dystrophy. 
4.2. (Na+ + K+)-ATPase and K+-PNPPase; the ouabain effect 
The most widely studied enzyme in erythrocytes from 
Duchenne patients is the (Na+ + K+)-stimulated, Mg2+-
dependent ATPase. This activity, which correlates with the 
ATP-driven Na+-extrusion and K+-uptake of the cell, can be 
inhibited by the glycoside ouabain (see 31). Since Brown 
et al. in 1967 reported that ouabain stimulated (Na+ + K+)-
ATPase of Duchenne erythrocytes (39), several studies have 
been published with controversial results. Table 4-I 
summarizes the data hitherto published. The results vary to 
a great extent, especially as to the ouabain effect. 
Several groups (including ours, see 287i appendix III) have 
assayed the enzyme in two different media, namely at optimal 
and sub-optimal cation concentrations, but the medium does 
not alter the ouabain effect. Of more importance could be 
the purification procedure of the membranes. Dystrophic 
serum has been reported to lower the ouabain inhibition of 
control membranes (247,327). In the study of Mawatari et al. 
(210) epinephrine normalized the ouabain sensitivity (cyclic 
AMP did not). The outside of the cells may be altered by a 
factor in the Duchenne plasma. The use of other ATPase or 
cation transport inhibitors does not result in a clear 
explanation of the underlying mechanism (238) . 
The differences of the ouabain effect either in control 
and patient membranes may be partly due to the orientation 
of the vesicles. Ouabain, which binds to the outside of the 
red cell membrane, is not able to reach its binding site in 
inside-out vesicles. Latency phenomena were not present in 
our study as a detergent was applied and a freeze-thawed 
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preparation was used (287; appendix III). 
The influence of ouabain was also determined in other 
kinds of studies. Bosia et aZ. (32) incubated intact red 
cells in the presence of ouabain and glucose. In cells 
from Duchenne patients ouabain did not increase the levels 
of fructose-1,6-diphosphate and dihydroxyacetonphosphate 
as it did in control cells. Ouabain had also an abnormal 
effect upon the ATP level. At 5 mM K+, ouabain reduced the 
ATP-level, while ouabain had no effect at 40 mM K+. In 
control cells ATP was enhanced at both K+-concentrations. 
These results point to an altered influence of ouabain 
upon the Na+-K+-pump of the membrane, resulting in changes 
in some of the glycolytic steps. The link between the pump 
and glycolysis is likely the phosphoglycerate kinase/ 
phosphoglycerate mutase-complex, which can bind to the 
mb d h . d h + + . h (104 me rane an t us prov1 e t e Na -K -pump w1t ATP , 
105,318). The binding of this complex with the membrane 
can be suppressed by ouabain. 
An altered ouabain effect should also be demonstrable 
in the K+-stimulated p-nitrophenylphosphatase (K+-PNPPase) 
activity. It correlates with the second, rate-limiting 
step of (Na+ + K+)-ATPase, at which the ATPase molecules 
are dephosphorylated (31,109). We have analysed the ouabain 
effect on K+-PNPPase in erythrocyte membranes from patients 
with Duchenne and congenital myotonic dystrophy (287; 
appendix III). This study reveals normal ouabain sensitivity 
of K+-PNPPase, as well as of (Na+ + K+)-ATPase in patients. 
In no case we found stimulation by ouabain. It would be of 
interest to determine the ouabain effect upon the easily 
measurable K+ -PNPPase in those preparations tt1hich sho1:1 
ouabain stimulation of the (Na+ + K+)-ATPase activity. 
Ouabain influences the Na+-and K+-flux through the 
erythrocyte membrane. Probstfield et al. (254) showed 
normal uptake in Duchenne cells of a rubidium isotope, and 
thus of K+-influx (31) in the presence and absence of 
ouabain either in washed cells and in cells plus plasma. 
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Lloyd et aL. (197) reported for Duchennes a normal 
erythrocyte/plasma ratio for this isotope, indicating a 
normal K+--permeability. Sha'afi et al. (319) found an 
unchanged ouabain-sensitive Na+-efflux and a somewhat 
higher K+-influx in red cells from Duchenne patients and 
carriers. A decreased Na+-efflux was also reported (335) 
Hull and Roses (144) measured a lower ouabain-sensitive 
Na+-efflux and normal K+-influx in red cells from 
myotonic dystrophy patients. Thus, the results of the 
studies on ouabain influence on cation transport are as 
controversial as those found in (Na+ + K+)-ATPase studies. 
A clear explanation for the abnormal ouabain effect, 
found by some investigators, is not available. 
4.3. Ca 2+-ATPase and Ca 2+-PNPPase 
2+ As has been discussed in section 3.6., Ca may be 
involved in various abnormalities reported in erythrocytes 
of Duchenne and myotonic muscular dystrophy. An enhanced 
sensitivity of Duchenne red cells towards ca 2+ has been 
described (77). Therefore, we have determined the kinetic 
properties of two membrane-bound enzyme activities, which 
are stimulated by ca2+-ions, viz. ca2+-stimulated, Mg2+-
dependent ATPase (Ca 2+-ATPase) and ca2+-stimulated 
p-nitrophenylphosphatase (Ca 2+-PNNPase). For a correct 
interpretation of the results, firstly a kinetic model of 
ca
2
+-ATPase will be presented. 
4.3.1. Kinetic model for ca2+-ATPase activity and ca2+-
transport 
2+ The Ca -ATPase activity is related to the pump, 
extruding ca 2+-ions out of the red cells. This pump is 
capable to maintain the total calcium 
less than about 15 ~moles/liter cells 
concentration at 
2+ 
and the free Ca -
level at less than 1 ~M (304,367). The reaction mechanism 
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for ca2+-ATPase is less well established than for (Na+ + K+)-
ATPase (331). However, recently many kinetic data about Ca2+-
ATPase have been published. The following scheme (Fig. 4-I) 
has been proposed to explain these data (see also 304, 306) . 
R-C 1 and R-c 2 are two different conformations of the enzyme, 
R being a regulatory subunit, C a catalytic subunit. The 
R-c 1 complex can be phosphorylated in the presence of ca
2+ 
(step II; 163,174,261 1 306). The complex may be 
VI 
ATP 
I C-R 
2 \ 
Mg 
v 
Fig. 4-I. Kinetic model for ca2+-ATPase and ca 2+-transport in human erythrocytes. 
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dephosphorylated in the absence of Mg 2+ to a very low 
degree, but Mg 2+ greatly stimulates the Ca 2+-ATPase 
activity and tWe dephosphorylation of the enzyme (step V; 
261,267,305). In the kinetic model Mg 2+ is bound toR of 
the phosphorylated complex together with ATP (step III). 
This scheme thus accounts for 2 types of ATP binding sites 
(267). Binding of Mg 2+ and ATP induces a conformational 
change from R-c 1 to R-c 2 , resulting 1n a diminished 
2 2+ affinity for Ca +. The complex looses Ca at the outside 
of the cell (step IV) and is dephosphorylated (step V). 
2+ Thereafter Mg and ATP leave R-C 21 which is then 
converted into R-C 1 {step VI) . 
Originally, MgATP was supposed to be the substrate 
2+ for Ca -ATPase, but recently more data appear, in favour 
of free ATP (see 261,294,300,305,381). Richards et al. 
(267) suggested that R has a low affinity for ATP, which 
could only bind in the presence of Mg 2+ His study infers 
that binding of ATP to R is not strictly required, but 
that the ATPase activity is enhanced by ATP binding, as is 
the dephosphorylation (163). 
It is likely that the scheme of Fig. 4-I demonstrates 
only a simplified model of the enzyme kinetics. Wolf et al. 
(382) d . "f" d 2+ . h reporte 1n a purl 1e Ca -ATPase preparat1on t ree 
different subunits, one of which could be phosphorylated. 
Allosteric effects of ca 2+ and ATP may point to an enzyme 
complex with several catalytic and/or regulatory subunits. 
Furthermore, some reaction steps are reversible (306). One 
important question is the stoichiometry of the pump. Some 
authors have reported a Ca 2+-ATP ratio of 1:1 (193,303), 
while others found a 2:1 ratio (256,293). In spite of these 
restrictions, the scheme may be useful in understanding the 
following experiments. 
4.3.2. Ca 2+-PNPPase 
2+ . l d d l f h Ca -st1mu ate hy ro ysis o p-nitrop enylphosphate 
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(Ca 2+-PNPPase) has been described previously in erythrocyte 
2+ 2+ 2+ 
membranes (110,253,262). Ca -PNPPase needs Ca , Mg and 
ATP. The substrate p-nitrophenylphosphate inhibits the 
active ca 2+-efflux (262). Analogous to K+-PNPPase (see 4.2.), 
2+ 
one could suppose that Ca -PNPPase represents the 
dephosphorylation of ca2+-ATPase (step IV-V in Fig. 4-I; 266) 
But the dephosphorylation is not stimulated by ca 2+ (261), 
while ca2+-PNPPase is. The only ca 2+-stimulated step in the 
scheme is step II. It is unlikely, that p-nitrophenyl-
phosphate can replace ATP in forming the high energetic 
phosphorylated enzyme. Richard et al. (266) concluded from 
the results of phospholipase C-treated membranes that the 
R-C 1-ATP complex is required for ca
2
+-PNPPase activity. This 
complex, without forming the phospho-enzyme, could hydrolyse 
- 2+ 
p-nitrophenylphosphate in the presence of Mg under the 
influence of ca2+. The exact relationship between ca2+-
stimulated ATPase and PNPPase has yet to be established. The 
PNPPase has the advantage of being easily determinable. 
We have estimated the ca2+-PNPPase activity in 
erythrocyte membranes from patients with either the congenital 
myotonic type or Duchenne type of muscular dystrophy (287; 
appendix III) . In ouchenne dystrophy the specific activity 
at 10 rnM substrate was increased twofold, the maximal 
velocity being about 3 times higher than in controls. The 
pH optimum, concentration with half-maximal velocity of 
and the Hill-coefficient for p-nitrophenylphosphate, and the 
half-maximal activation by ca2+ were unchanged. It seems 
that the enzyme molecules may have normal properties, but 
that the amount is increased in Duchenne membranes. The 
velocity of the enzyme in myotonic dystrophy was not 
significantly increased. 
2+ 4.3.3. Ca -ATPase 
h . d 2+ . . . h T e 1ncrease Ca -PNPPase act1v1ty 1n Due enne 
dystrophy (see 4.3.2.) may be linked with the increased 
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2+ 
activity of Ca -ATPase, reported by Hodson and Pleasure 
(133). Therefore, we have also analysed the kinetic 
parameters of ca2+-ATPase (287; appendix III). The 
activities at 0.18 and 0.97 rnM and at infinite MgATP 
concentration are about two times increased in both groups 
of patients, as compared with control erythrocytes. The 
apparent affinity of the enzyme for MgATP is normal in 
Duchenne preparations. The Duchenne enzyme reacts with 
ca
2+ and ca2+-dependent stimulator protein in a normal 
manner. This protein which is present in the soluble 
fraction of human erythrocytes (28,151) likely enhances 
2+ 2+ the affinity of Ca -ATPase for Ca (117 1 302). Perhaps 
it binds to the catalytic subunit C (see Fig. 4-I), thereby 
regulating the ca2+-ATPase activity (302). It stimulates 
the ca2+-extrusion out of the red cell (203). It has been 
demonstrated to stimulate cyclic AMP phoshodiesterase and 
adenylate cyclase activities in other cell types (for a 
review, see 56;151). The stimulator interacts normally with 
ca
2+-ATPase in Duchenne membranes. The ratio of protein 
stimulated to unstimulated activity is similar in Duchenne 
2+ 
and control membranes (1.8 at 500 ~M Ca and 7.8 at 50 ~M 
ca
2+). The enhanced ca 2+-ATPase activity in the Duchenne 
membranes can therefore not be ascribed to the presence of 
more stimulator protein. The cause of the high activity 
2+ 
seems, as was concluded for Ca -PNPPase, an increased 
amount of normal enzyme molecules. This is not in agreement 
with the finding of Hodson and Pleasure {133), who reported 
a decreased Km of MgATP for the Duchenne enzyme. But for 
controls they reported a Km which was more than 10 times 
higher than the literature (304) and our values. 
The ca 2+-ATPase activities have been determined in the 
presence of Na+: 140 mM in the study of Hodson and Pleasure 
(133) and 70 mM in our study (287; appendix III). K+ and Na+ 
2+ 
each stimulate an ATPase activity in the presence of Ca 
(29,307). The authors of the latter study suggested that 
the stimulation by the monovalent cations was due to an 
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uncoupling of (Na+ + K+)-stimulated ATPase by ca2+ Recent 
studies, however, indicate that the (Ca 2+ + Na+/K+)-
stimulated ATPase shows parallelism with ca 2+-ATPase after 
different treatments of red cell membranes (265,266). Na+ 
and K+ stimulate the ca2+-transport in membrane vesicles 
(294). These and other studies (301) suggest that Na+ and 
+ 2+ + + K can influence Ca -ATPase per se. Na and K may 
stimulate both the phosphorylation and dephosphorylation 
of the enzyme molecule (263). Scharff (301) concluded 
from kinetic studies on stimulator associated and 
dissociated ca2+-ATPase, that monovalent cations interact 
with the ca 2 + binding sites. 
In appendix III is reported that ca2+-ATPase in 
+ 
control membranes is activated by Na according to the 
Michaelis-Menten kinetics with a half-maximal activating 
concentration of 26 rnM, which is in agreement with the 
study of Scharff (301). The Duchenne enzyme shows a 
biphasic interaction with Na+, resulting in half-maximal 
activating concentrations of 4 and 58 rnM Na+. The point of 
intersection in a reciprocal plot of the activity against 
the Na+ concentration lies at 34 rnM Na+. Preliminary 
experiments demonstrate a comparable behaviour of ca 2+-
ATPase from membranes of Duchenne carriers (Scholte and 
Houwen, personal communication). Thus in the membranes 
of Duchenne patients and carriers an extra ATPase 
activity can be measured at low Na+ concentrations. As 
the physiological Na+ concentration is about 10 mM (241), 
this enzyme activity may have a role in vivo. At 1 mM 
2+ 2+ MgATP and 0.5 mM Ca , theCa -ATPase activity in controls 
is 2.2, and in Duchennes 4.2 nmoles/rng protein/min, both at 
+ 2+ 10 mM Na . This means that under these conditions the Ca -
ATPase activity in Duchenne membranes is elevated by 90%. 
Table 4-II summarizes the results of the Na+ stimulation 
of ca2+-ATPase in myotonic muscular dystrophy. The first two 
membrane preparations interact in a monophasic manner with 
+ Na , the other three in a biphasic manner. The first two 
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TABLE 4-II. Na+-DEPENDENCY OF ca2 +-ATPase IN ERYTHROCYTE MEMBRANES IN 
MYOTONIC MUSCULAR DYSTROPHY (CONGENITAL TYPE) . Ka is the 
apparent concentration of Na+, which stimulates half-
maximal (for assay, see appendix III). 
Point of Ka (low Ka (high 
Patient intersection Na+-affinity site) Na+-affinity site) 
I absent 21.9 mM absent 
II absent 12.6 mM absent 
III 55.5 mM 38.3 mN 1.6 mM 
IV 40.0 mM 30.5 mM 2. 0 mM 
v 34.5 mM 45.7 mM 0 mM 
membranes have a Ka within the control range. The second 
three ones have K -values which are dissimilar 
a 
with that 
of Duchenne values. Especially the + Ka' s of the high Na 
affinity site are lowered in these three myotonic 
patients. 
Some experiments were performed in order to 
+ the origin of the abnormal influence of Na upon 
elucidate 
ca2+-
+ + ATPase in Duchenne erythrocytes. Replacement of Na by K 
gives essentially similar results. This fact supports the 
idea that in our study we measure indeed the monovalent 
cation-stimulated ca 2+-ATPase. Addition of 0.2 mN La 3+, 
inhibitor of ca2+-ATPase {193,256,342), results in 
an 
inhibition of the Duchenne enzyme, maintaining the biphasic 
behaviour to Na+. The half-maximal activation constants for 
Na+ remain unchanged, suggesting that the extra enzymatic 
activity in Duchenne membranes is related to the ca2+-
stimulated, Mg 2+-dependent ATPase. Thus, the involvement of 
ca
2
+-stimulated ATPase {not Mg 2+-dependent) present in 
spectrin preparations (171) in these studies can be excluded. 
Other arguments are the low activity of this ATPase under 
the conditions applied, and the fact that contractile 
proteins are largely removed at low ionic strength and in 
2+ the presence of Ca -chelators (12,171,272). 
Table 4-III shows the effect of the stimulator protein, 
+ 2+ 
ethanol and epinephrine upon the Na -dependency of Ca -
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ATPase in Duchenne and control membranes. 
TABLE 4-III. INFLUENCE OF Na+ UPON Ca 2+-ATPase ACTIVITY IN DUCHENNE AND 
CONTROL ERYTHROCYTE MEMBRANES IN THE PRESENCE OF SOME COMPOUNDS 
Type of 
membrane 
Duchenne {n"'4) 
Duchenne {n=2) 
Duchenne {n"'3) 
Control {n=4) 
Control {n=3) 
Control {n=3) 
Control {n"'4) 
(for assay, see appendix III). Ka is the apparent concentration 
of Na+ in mM, resulting in half-maximal stimulation (means~ SEM) 
Addition Point of Ka for low Ka for high 
intersection Na+-affinity Na+-affinity 
( [Na +] in mM) site site 
- 34+2 58+9 4~1 
stimulator protein 28; 35 32;66 3. 6; 6. 7 
0. 5 M ethanol 45+6 56+18 9~2 
- absent 26~9 absent 
stimulator protein absent 16+6 absent 
0. 5 M ethanol 38~3 42+8 5~2 
10-6 M epinephrine 23+1 40+12 see text 
The stimulator protein has no influence upon the activation 
coefficients in both types of membranes. In one experiment 
control membrane was assayed in the presence of 
as this drug stabilizes the membrane likely via 
phenytoin, 
2+ 
a Ca -
effect (see 3.3.2.). A biphasic curve in a reciprocal plot 
of the activity against Na+ concentration was the result, 
comparable with the curve of Duchenne membranes without 
phenytoin. The effect, however, was caused by the solvent 
of the drug: ethanol. As can be seen in Table 4-III, 0.5 M 
ethanol has hardly any effect upon the Duchenne ATPase, 
while the control enzyme is drastically influenced. We 
wondered whether the ethanol effect on control membranes 
was mediated by a receptor, as the effect was also found 
at l mM ethanol. As shown in Fig. 4-II,l ~M epinephrine 
induces a biphasic behaviour of control Ca2+-ATPase towards 
Na+. The affinity at Na+ concentrations above 23 mM is 
similar to that of the Duchenne enzyme without epinephrine, 
and also similar to that of the control enzyme, measured in 
the presence of 0.5 Methanol (see Table 4-III). At lower 
+ Na concentrations a stimulating effect of epinephrine was 
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+ •plnephrjne 
+ethanol 
Fig. 4-II. Influence of epinephrine (10- 6 M) and ethanol (0.5 Ml on the Na+-
dependency of ca2+-ATPase in control red cell membranes. 
found, which was increasing at decreasing Na+ concentrations. 
Thus it seems that ethanol and epinephrine unmask a binding 
+ 2+ 
site for Na at the Ca -ATPase molecule, which cannot be 
occupied under standard assay conditions. This binding site 
is always accessable on the Duchenne enzyme. The difference 
between the curve for control ATPase plus epinephrine and 
the curve for Duchenne enzyme is not clear. It may be that 
the epinephrine effect is concentration-dependent. 
It has to be mentioned that the erythrocyte membranes 
are washed several times. Therefore, it is likely that 
epinephrine or epinephrine-like substances have been 
removed from them. This suggests that the 
membrane properties are changed either during synthesis or 
later by an irreversible alteration in dystrophic blood. 
4.4. Adenylate cyclase 
Recently, a low activity of adenylate cyclase has 
been established in human red cell membranes (159,270). 
The activity is slightly stimulated by adrenergic agents 
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and prostaglandins, while F -ions stimulate to a higher 
degree. ca 2+ at a concentration above 10 ~M is inhibitory 
(260,270). 
Mawatari and coworkers (210) reported that in membranes 
from Duchenne patients and carriers adenylate cyclase was 
somewhat more active than in control preparations. F--ions 
stimulated the cyclase to control values. In the presence 
of epinephrine the activity in Duchennes was lower than in 
controls. Thus, the hormone sensitivity of the enzyme is 
diminished. The cause may be rather a membrane defect than a 
high in vivo stimulation by catecholamines. These compounds 
are excreted in the urine of patients to a normal level 
(214). 
In myotonic dystrophy a normal basal activity and F -
stimulation was found, with a reduced epinephrine response 
(but higher than in Duchenne membranes) (210). 
4.5. Acetylcholinesterase 
Acetylcholinesterase activity in human erythrocytes 
is localized on the outer surface of the cell membrane (165) 
Its function is still obscure. It is likely that an acetyl-
choline receptor is also present in human erythrocytes (141) 
and it may be coupled to the Na + channel (142). 
Das (69) reported that acetylcholinesterase in 
erythrocytes from Duchenne patients and carriers react 
abnormally to various inhibitors of the enzyme. He claimed 
that the inhibition rate of nialamide and eserine was a 
good tool for carrier detection. In another study a 
lowered activity was found in Duchenne dystrophy (113) 
However, in an extensive kinetic study, Scholte and 
Houwen (311) found a quite normal acetylcholinesterase 
activity and behaviour in erythrocyte membranes from 
Duchenne patients and carriers and from patients with 
congenital myotonic muscular dystrophy. The study included 
the interaction of various inhibitors with the enzyme, the 
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activation energy and heat stability measurements. Normal 
Hill-coefficients for F and imipramine inhibition likely 
point to an unchanged lipid fluidity in the vicinity of the 
enzyme (see 26,96). 
4.6. Phospholipase 
Iyer et al. (149) reported that in red cell membranes 
from Duchenne and myotonic muscular dystrophic patients the 
phospholipase A activity was increased by 60 and 240% 1 
respectively. In spite of the low activity (3-9 nU/mg 
protein) , the increment may point to an increased breakdown 
of the membrane. Phenytoin normalized the hydrolytic 
activity, probably via a ca 2+-mernbrane interaction (see 
3. 3. 2.) . 
4.7. Long chain acyl-CoA synthetase and carnitine 
palmitoyltrans[erase 
Acyl-CoA synthetase produces acyl-CoA esters, the 
substrates for the incorporation of fatty acids into the 
membrane. This enzyme may determine the relative 
availability of the activated fatty acids for the renewal 
of the membrane. Furthermore 1 its activity may give 
insight into the (ab-)normality of the microenvironment 
of the enzyme. 
we have tested the activation of palmitic, palmitoleic 
and linoleic acid in patient and control membranes (288; 
appendix IV) . Red cell membranes from patients with 
congenital myotonic dystrophy reveal a twofold increase in 
acyl-CoA synthetase activity. Membranes of Duchenne patients 
were normally active. The activity was independent from the 
fatty acid in all groups of membranes. It is evident that 
these findings cannot explain the diminished palmitoleic 
acid content of the membrane neutral lipid fractions in 
Duchenne and myotonic dystrophy (286; appendix I). The 
increased fatty acid activation may, combined with the 
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enhanced phospholipase activity (see 4.6.) point to a more 
rapid turnover of the phospholipids in myotonic muscular 
dystrophy. 
Leucocyte homogenates from patients with congenital 
myotonic dystrophy possess a normal acyl-CoA synthetase 
activity. This activity is higher with palmitate than with 
palmitoleate or linoleate, independently from the 
investigated group. The differences in properties of acyl-
CoA synthetase in leucocyte homogenates and erythrocyte 
membrane may be due to a different subcellular localization, 
accompanied with a different microenvironment. 
The presence of carnitine palmitoyltransferase in 
human erythrocyte membranes was first demonstrated by 
Wittels and Hochstein (380). The function of this enzyme 
is not known. It may be concerned in transport or storage 
of acylcarnitine (see also appendix IV). 
We have tested the carnitine palmitoyltransferase I 
activity at 1.6 and 8.0 ~M palmitoyl-CoA in patient's red 
cell membranes (288; appendix IV). No alterations were 
found, indicating a normal activity and normal affinity of 
the enzyme in erythrocytes in human muscular dystrophy. 
4.8. Discussion 
This chapter summarizes the features of the proteins 
of the red cell membranes in human muscular dystrophy. The 
enhanced phosphorylation rate of spectrin in Duchenne 
membranes (see 4.1.) may support the involvement of this 
structural protein as discussed in section 3.6. The 
abnormalities found for ca2+-ATPase, adenylate cyclase, 
phospholipase and acyl-CoA synthetase in one or both types 
of dystrophy can hardly be explained by a change in a 
single definite phospholipid, interfering with the micro-
environrnen ts of the various enzymes. ,Neither can they 
easily be understood by an adaptation to one metabolic 
alteration. In section 4.3.3. the fact has been mentioned 
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that ethanol and epinephrine are able to uncover a high-
affinity site for Na+ in Ca 2+-ATPase of control membranes 1 
which is comparable with Duchenne membranes. As pointed 
out in section 3.6. 1 epinephrine exercises a radical 
influence upon red cell membranes. It seems reasonable to 
suppose that enzyme activities undergo changes under that 
condition. This may form the origin of the various 
deviations 1 described in this chapter. A possible role of 
epinephrine or related compounds and the consequences of 
it will be further discussed in chapter 5. 
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CHAPTER V 
THE EPINEPHRINE-Cal+ HYPOTHESIS; THE POSSIBLE INVOLVEMENT OF OTHER 
CELLS; FINAL REMARKS AND PERSPECTIVES 
It may be clear from the foregoing chapters, that 
erythrocyte membranes from patients with myotonic and 
Duchenne muscular dystrophy are altered in several 
respects. Whether the alterations are caused by a change 
of one or more membrane characteristics is not clear, 
2+ but it is likely that Ca plays a role. The fact, that 
some alterations are different and other ones similar in 
both diseases may point to a different origin, causing 
several secondary, including common, effects. In the 
next two sections the possible origin of the modifications 
will be discussed separately for the two disorders. 
5.1. Erythrocytes in Duchenne muscular dystrophy; the 
evinevhrine-Ca 2+ hypothesis 
Several times an involvement of hormones (see 
sections 3. 4. 1 3. 6. 1 4. 2. 1 4. 3. 3., 4. 4. and 4. 8.) or Ca 2+ 
(see sections 3.1., 3.3.2. 1 3.4. 1 3.5., 3.6., 4.3.2., 
4. 3. 3., 4. 6. and 4. 8.) is proposed to explain the 
abnormalities of Duchenne erythrocytes. Most of the 
observed changes can be explained by the following 
epinephrine-ca 2+ hypothesis. 
1) In red cells of Duchenne patients the B-adrenergic 
receptor has a conformational state, which simulates 
a receptor, loaded with its effector epinephrine. 
2) This state causes enhanced basal adenylate cyclase 
activity, reduced epinephrine stimulation, and normal 
F--stirnulation of adenylate cyclase. This situation 
has been described in Duchenne erythrocytes (see 
4. 4. I . 
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3) The state is accompanied with increased phosphorylation 
of specific membrane components, e.g. of band III (see 
4.1.), and with enhanced affinity of certain membrane 
2+ . 2+ 
moieties for Ca (see 260). The change 1n the Ca -
membrane interaction may be responsible for the high 
sensitivity of Duchenne erythrocytes towards ca2+ (77) 
4) The B-adrenergic stimulated state leads to unmasking of 
a high affinity activating site for Na+ at ca2+-ATPase. 
The site is overt in Duchenne membranes (see 4.3.3.). 
5) The epinephrine stimulated state explains the enhanced 
rigidity (4,188,260) and the reduced osmotic stability 
(260), which have been found in Duchenne cells (see 
3.4. and 3.5.). These effects are the consequences of 
the intensified ca 2+-membrane interaction (170,375) 
Another consequence of this interaction may be an 
augmented echinocyte formation (see 3.1.; 320,373) 
6) The high ca2+ affinity of certain membrane groups leads 
to increased Na+ levels and K+ permeability, effects 
described for control cells loaded with ca 2+ (84,170, 
292). These changes in cation concentration and 
permeability have been observed in untreated Duchenne 
cells (78,136). 
7) Probably the phosphorylation change causes the non-
uniform distribution of proteins (370), the delayed 
energy transfer in saturating transfer ESR studies 
(378) and the alteration in protein SH-groups (45), 
reported in Duchenne membranes (see 3.3.2. and 3.3.3.) 
Whether cyclic AMP plays a role in the phosphorylation 
and/or other changed properties of the Duchenne erythrocyte 
is uncertain. Although Rasmussen et al. (260) could not 
detect epinephrine-stimulated cyclic AMP synthesis, they 
were able to mimic the hormone effect with exogenous 
cyclic AMP. Maybe epinephrine alters the affinity of the 
nucleotide binding site of the membrane-bound, cyclic ~MP­
dependent protein kinase as they were detected by 
Fairbanks and Avruch (95) and Clari et a!. (57). It is 
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hypothetical that cyclic AMP is involved in the rapid-
2+ 
exchangeable, oscillating Ca -pool of red cells, as 
described by Rasmussen et al-. (259,260). 
It would be useful to check the hypothesis at various 
points. E.g. the normal fluidity observed by Butterfield 
et aZ. (47) does not support this hypothesis, since 
epinephrine induces an enhancement of the microviscosity 
(188). The pedigree-specific enhanced phosphorylation of 
some spectrin bands (281) is not explained by the concept. 
Measurements of the rapid-exchangeable ca2+-pool (260) in 
Duchenne erythrocytes may give useful information, as do 
studies on the affinity and capacity of membrane 
fractions to bind ca2+ (see 103,223 ,,296) . 
The primary cause of the hormone-stimulated state of 
the red cell in Duchenne dystrophy is not known. It is not 
likely, that it is caused by an increased level of 
catecholamines, as Mendell e t al. ( 214) reported normal 
urine levels of these compounds and metabolic products in 
patients. Moreover, the hormone should be washed out from 
the cells during membrane isolation. This argument also 
holds for the various possible effectors v1hich are present 
in the blood after muscle damage. The cause may rather be 
a true membrane defect. In this context it would be of 
interest to check the metabolism of phosphatidylinositol. 
This lipid plays a role in hormone-receptor interactions 
and ion transport (128,217). In these processes ca2+ and 
cyclic AMP may also be involved. It is meaningful to 
mention here that erythrocyte membranes with a high content 
of polyphosphatidylinositide can bind more ca2+ and reveal 
high Ca 2+-ATPase and normal (Na+ + K+)-ATPase activity (41). 
The phosphorylation of phosphatidylinositol, located at 
the inner side of the membrane (111}, is drastically 
inhibited at elevated endogenous levels of ca2+ (41} The 
breakdown of polyphosphatidylinositide may also be 
regulated by the intracellular ca 2+ level (3). There is no 
evidence suggesting that the reduced level of palmitoleic 
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ac~d in diglycerides of Duchenne red cells (286; a?pendix 
I) is involved in these metabolic pathways. 
Further insight into the origin of the alterations may 
be obtained by treatment of the membranes with pronase and/ 
or diethylether 1 which results in perturbation of well 
defined membrane portions (65). The treatment may elucidate 
whether and which type of lipids are important for the 
receptor conformation change. The importance of spectrin 
can be determined in cytochalasin-treated membranes; this 
drug interferes with the contractile apparatus (93,141) 
Prostaglandin E2 influences the rigidity, lysis, 
lipid fluidity and rnernbrane-ca 2+ interaction of red cells 
in a similar manner as does epinephrine (188,260). But 
there also exist differences between effects of these 
hormones. The fact, that prostaglandin E2 increases the 
2,3-diphosphoglycerate level/ while catecholamines do not 
(156) is in favour of a role for the epinephrine receptor. 
5.2. Erythrocytes in myotonic muscular dystrophy 
Research data about red cells in myotonic dystrophy 
are scarce. As pointed out already, some deviations are 
identical with those found in Duchenne dystrophy. However, 
the increased lipid fluidity (see 3.3.2.) and the 
aberrant behaviour after phospholipase-treatment (see 3.5.) 
cannot be explained by the hypothesis outlined above for 
Duchenne dystrophy. In section 3.5. the osmotic behaviour 
of the myotonic red cells has been suggested to be due to 
an acetylcholine receptor, which is masked or less active 
than in control cells. Little is known about the effect of 
cholinergic stimulation on erythrocyte metabolism. At the 
present, it cannot be concluded that the other abnormalities, 
like increased viscoelasticity and hemolysis (see 3.4. and 
3.5.) can also be explained by a reduced influence of 
cholinergic compounds upon myotonic cells. 
Indicative for an acetylcholine receptor impairment in 
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myotonia may be the finding that (drug-induced) myotonic 
rats show myotonic discharges which could be evoked by 
stimulators of the cholinergic receptor and silenced by 
tetrodotoxin, a Na+-transport inhibitor (40). A coupling 
between the cholinergic receptor and Na+-ion channel is 
widely spread in nature (140) and maybe also in 
erythrocytes ( 141) • 
Abnormal high fatty acid activation rates were found 
in this disorder (see 4.7.). A stimulation of fatty acid 
2+ incorporation in normal erythrocytes by Ca has been 
reported (76). This, combined with the elevated ca2+-
ATPase activity (see 4.3.3.), the increased ca2+ 
permeability (251), and the fact, that phenytoin normalizes 
the phospholipase activity and the microviscosity (as 
measured by ESR) (see 3. 3. 2. and 4. 6.) point to an involvement 
of calcium in the red cell of myotonic muscular dystrophy 
patients. Whether acetylcholine receptor and calcium 
functional impairments are interrelated, and whether they 
are the real origin(s) of the alterations, remain to be 
established. Studies, in which various stimulatory and 
inhibitory effects upon normal and myotonic red cells are 
compared, may be useful in elucidating these problems. 
5.3. Non-erythroid aeZZs in human muscular dystrophy 
After considering the red cells, the problem arises, 
whether the alterations are specific for this cell type. 
Apart from studies on muscular tissue only few data have 
been published about non-erythroid cells. 
5.3.1. White blood cells, platelets, fibroblasts. 
Pickard et al. (249) reported diminished cap 
formation in lymphocytes of Duchenne patients and of most 
carriers. An alteration of the membrane fluidity was 
suggested, probably combined with a defect of the 
contractile proteins or ca2+-metabolism. Normal cap 
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formation was observed in myotonic dystrophy. Abnormal 
chemotaxic activity and chemiluminescence have been 
described in polymorphonuclear leucocytes in myotonic 
dystrophy (316). A discrepancy exists about the number of 
insulin binding sites in monocytes in this disorder (100, 
175). Normal fatty acid activation has been described in 
leucocytes from both Duchenne and congenital myotonic 
dystrophy patients (288; appendix IV). Normal ratio of 
active and inactive phosphorylase in leucocytes from 
Duchenne and myotonic patients has been found (310), 
suggesting normal cyclic AMP levels. The platelets seem 
also affected in muscular dystrophy. An increased 
aggregation of them by epinephrine, owing to abnormal 
a-receptors was found (54) in myotonic dystrophy. In 
Duchenne platelets a diminished serotonin uptake (227) 
and an augmented oxidation of epinephrine and dihydroxy-
phenylalanin (72) was reported. The isoenzyme pattern of 
this oxidase is normal (230). 
A few studies have been published, in which the 
characteristics of cultivated fibroblasts from dystrophic 
patients have been analysed. Kohlschlitter et al. (179) 
found normal phospholipid and fatty acid composition. Pena 
et al. (239) found no abnormalities in the major protein 
fractions. However, Ionasescu et al. (147) reported 
differences in collagen and non-collagen protein synthesis. 
Characteristic inclusion bodies were described (386). 
Normal growth and acetate incorporation in various lipid 
classes were found in fibroblasts from patients with 
myotonic muscular dystrophy. 
These results with white blood cells, platelets and 
fibroblasts do not clash with the suggested hypothesis 
proposed for patient's erythrocytes (see 5.1. and 5.2.) 
but on the other hand also do not support it. 
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5.3.2. Skeletal muscle cells 
The epinephrine effect on skeletal muscle is rather 
2+ 
complicated and fibre type dependent. The Ca -pump of the 
sarcoplasmic reticulum may be enhanced by a cyclic AMP 
mediated stimulation of protein phosphorylation. ca2+-
accumulation may be increased, and relaxation and tension 
parameters are changed {340). A higher ca2+-ATPase activity 
has indeed been found in Duchenne muscle (75) . 
In skeletal muscle of Duchenne and myotonic muscular 
dystrophy patients the stimulation of adenylate cyclase by 
epinephrine is reduced (see 1.5.1.), like in Duchenne red 
cells. However 1 in contrast to the red cell enzyme 1 the 
basal and fluoride-stimulated activities are normal and 
reduced, respectively. Thus 1 it is not allowed to conclude 
merely that in Duchenne muscle cells the epinephrine-like 
state is present (see 5 .1. ). But it is striking that a higher 
basal activity and a reduced stimulated activity of 
adenylate cyclase has been found in cultured myotubes from 
Duchenne tissue (211). Some evidence for a catecholamine 
involvement may be the enhanced fluorescence 1 possibly owing 
to catecholamine accumulation, which seems specific for 
Duchenne fibres (309,384). Takamori (347) reported a super-
sensitivity of muscles from Duchenne carriers to epinephrine 
as to contraction-relaxation parameters. He considered this 
deviation to be a property of the dystrophic muscle. 
. l d h h . h . c 2+ Summarizlng, we may cone u e t at t e eplnep rlne- a 
hypothesis may hold for muscle tissue in Duchenne patients, 
too 1 but the support for it is scarce. It looks reasonable 
to suspect an improvement by insulin, if the muscle cells 
of Duchenne patients are epinephrine-stimulated, as 
insulin often inhibits catecholamine-induced stimulations 
(264) . In 1950, Mayerhofer already reported clinical improve-
ment by insulin (212) but no other cases have since been 
reported. The fasting insulin level and secretion seems to 
be normal (129), while the glucose tolerance is normal 
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(345) or decreased (129). It may be that during glucose-
insulin-infusion the leakage of muscle compounds into the 
bloodstream is diminished (25) . After infusion serum enzyme 
activities return to the original levels (see also 268). 
Glycogen, the synthesis and breakdown of which is influenced 
by insulin and catecholamines, has a normal or somewhat 
lower concentration in skeletal muscle of Duchenne patients 
(131,337). Thus, these data also do not give a definite 
answer to the problem of the epinephrine receptor state in 
Duchenne muscular dystrophy. 
Some aspects of red cells in myotonic dystrophy could 
be explained by an altered acetylcholine receptor structure 
or structural change in its environment (see 5.2.). Although 
the influence of cholinergic agents on skeletal muscle has 
been described (see 255), other available data for myotonic 
dystrophy do not allow to conclude whether the receptor plays 
a role of importance. It has to be established whether the 
hyperinsulinism, described in myotonic dystrophy (see 225), 
is important in the explanation of the ~athogenesis of the 
disease. Its effect upon erythrocytes will be low, since 
glucose transport in red cells is insensitive to insulin 
( 158) . 
Like in erythrocytes, ca2+ may play a central role in 
Duchenne muscle tissue. The increased ca 2+-ATPase and 
decreased capacity for accumulating ca2+ are examples. The 
drastical accumulation of ca 2+ in Duchenne fibres (27) may 
2+ lead to cell necrosis in later stages. The role of Ca in 
fibre necrosis has been discussed in the literature (91,348, 
385,388). 
The most promising strategy at this moment seems to 
elucidate first the primary cause of the red cell 
abnormalities. The same factor may be responsible in the 
diseased skeletal muscle. From the available data it is not 
possible to conclude that the aberrations are primarily 
caused by a membrane factor. The membrane is involved, but 
it cannot be excluded that a serum factor has induced the 
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membrane changes. The possible importance of a serum 
factor has been proposed by W.K. Engel and coworkers (see 
1.4.), who obtained evidence predominantly from animal 
models. In few studies an influence of dystrophic serum 
has been reported. Sugita and Tyler (339) observed that 
serum from Duchenne patients induces leakage of enzymes 
from rat muscle in vitro. This finding has not been 
confirmed. Peter et al. (247) found an abnormal ouabain 
inhibition of (Na+ + K+)-ATPase in control red cells 1 
incubated in Duchenne serum. Dubowi tz e t a l. ( 81) 
observed abnormal growth of Duchenne muscle in culture 
only in the presence of dystrophic serum. An inhibitor 
of fibroblast outgrowth was found in urine of Duchenne 
patients (122). All these effects may be due to some 
compounds leaked from the affected muscle cells. 
Another explanation is 1 that it is the factor which 
attacks the various cell membranes, with the fatal 
consequence for the muscles. 
5.4. Treatment and prenatal diagnosis of patients; carrier 
detection 
Returning to the purpose of this study (see 1.6.) it 
is clear that with the present knowledge of the origin of 
Duchenne muscular dystrophy it is impossible to prevent 
the dystrophic process by some drug or other treatment. 
Further research with the catecholamine metabolism in the 
centre may be fruitful for basic knowledge and patient 
care. The same, yet gloomy, perspective has to be given 
for myotonic muscular dystrophy. A few starting-points for 
further research in this disorder have been mentioned (see 
5. 2.) . 
The only expedient of prenatal diagnosis in Duchenne 
dystrophy hitherto is the determination of the sex of the 
fetus. In cultivated fibroblasts our group is trying to 
find reliable alterations which may be used in cultivated 
79 
amniotic cells with a prospecting value for the condition 
of the fetus. Also determinations of the most promising 
features, found in our erythrocyte studies (see appendix 
III) will be performed in order to check their 
applicability in amniotic fluid cells and erythrocytes from 
fetal blood. Whether fetal blood also offers the possibility 
in distingu~shing affected and healthy fetuses in the case 
of Duchenne dystrophy by determination of creatine phospho-
kinase activity is open to question (82,89,148,204). 
Muscle abnormalities in fetuses at risk for Duchenne 
dystrophy have been described (358,363,379). 
Prenatal diagnosis in myotonic muscular dystrophy 
is feasible in special cases. The test is based on the 
determination of blood group substances in the amniotic 
fluid. These compounds are only found in the case of a 
secretor-positive fetus. The secretor locus is closely 
linked to the locus coding for myotonic dystrophy (314, 
315) 
The early detection of heterozygotes with the gene for 
myotonic dystrophy has been described (42 1 252). The 
possibilities of detecting Duchenne carriers have recently 
been reviewed (127). An extensive research publication has 
appeared (356). However, at this moment it is still hard to 
detect the carrier state with a security of more than about 
75%. A screening program has been proposed for male 
children at the age of 18 months for detecting Duchenne 
dystrophy at an early time (108). We have now planned a 
study in which the applicability of the ca 2+-ATPase 
deviations (see 4.3.3.) for Duchenne carriers will be 
checked. 
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SUMMARY 
The subject of this study is to characteristic bio-
chemical changes in persons carrying the gene of Duchenne 
muscular dystrophy or myotonic dystrophy. Probably the 
findings ultimately will contribute to understanding the 
primary cause of human muscular dystrophy. 
Recently, data became available, supporting the hypo-
thesis that muscular dystrophy is caused by a generalized 
membrane defect. Thus, not only muscular membranes are 
impaired, but also the membranes of other cell types. We 
performed research on the erythrocyte membrane of patients 
suffering from Duchenne dystrophy or congenital myotonic 
muscular dystrophy. 
Lipids (Chapter II) 
The major fatty acids have normal levels in each of 
eight phospholipid classes in erythrocyte membranes from 
dystrophy patients. Other investigators found unchanged 
concentrations of the different phospholipids in isolated 
erythrocyte membranes of patients. From these facts v.Je 
conclude that there are no alterations in the major li?ids 
of red cells from patients with muscular dystrophy of both 
types. The normal lipid fluidity 1 as measured by 
fluorescence polarization (see 3.3.1.) is in agreement with 
this conclusion. 
We did find alterations in minor lipid components of 
the isolated membranes. Palmitoleic acid in neutral lipid 
fractions of patients is decreased. In Duchenne patients 
the level in diglycerides is reduced by 66% and in myotonic 
patients by 86%. In the latter group of patients triglyceride 
palmitoleic acid is reduced by 75%. This does not 
necessarily points to an abnormality of the membrane. 
The fatty acid composition of phospholipids in blood 
plasma is normal in muscular dystrophy. 
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Osmotic stabil-ity (Chapter III) 
washed red cells of dystrophic patients have a 
diminished osmotic stability. An abnormal feature of red 
cells in myotonic dystrophic patients was observed after 
phospholipase treatment. These cells, like untreated ones, 
are more stable in isotonic than in hypotonic solutions. 
On the contrary, phospholipase-treated red cells from 
controls and Duchenne patients lyse to a greater extent 
in isotonic than in 0.5% phosphate-buffered NaCl solutions. 
2+ This phospholipase-induced process is stimualted by Ca 
Na+ and phosphate. The nature of the normal osmotic 
behaviour of myotonic cells may be, that the acetylcholine 
receptor and/or the Na+-ion channel in these cells is not 
destructed by phospholipase, in contrast to control cells. 
Membrane-bound enzymes (Chapter IV) 
Other indications for a membrane defect may be changes 
in kinetic properties of membrane-bound enzymes. 
Long chain fatty acid activation in red cell membranes 
is increased in congenital myotonic dystrophy only. The 
activation in leucocytes is not changed. Erythrocyte fatty 
acid activation has the same activity with palmitate, 
palmitoleate and linoleate. Leucocytes activate palmitate 
with a higher velocity than the other two fatty acids. 
Carnitine palmitoyltransferase in myotonic red cell 
membranes is not much increased. Its affinity for palmitoyl-
CoA is the same in patients and controls. 
The activities of (Na+ + K+)-ATPase and K+-stimulated 
+ + p-nitrophenylphosphatase, both related to the Na -K -pump, 
are not changed in dystrophy. Also the ouabain sensitivity 
is unaltered. 
The activities of ca2+-ATPase and ca 2+-stimulated 
p-nitrophenylphosphatase are twofold increased in both 
2+ types of human muscular dystrophy. The interaction of Ca -
2+ ATPase from Duchenne membranes with MgATP and Ca is the 
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same as in controls, but the Ca 2+-ATPase activation by Na+ 
is different. ca 2+-ATPase from Duchenne red cells has two 
activating sites for Na+, while control cells have only 
one, low affinity, site. The high affinity site is 
responsible for an extra enzyme activity below 34 mM Na+ in 
Duchenne red cells. At a physiological intracellular Na+-
2+ 
concentration of 10 mM, the activity of Ca -ATPase is 
nearly doubled. In control membranes, a second Na+-
activation site is uncovered by ethanol or epinephrin~. 
The Na+-activation of control membranes in the presence of 
ethanol is the same as in Duchenne membranes without 
ethanol. Epinephrine stimulates control activity even more 
at decreasing Na+-concentrations than ethanol. 
Hypothesis 
Other investigators reported an increased basal 
activity of adenylate cyclase in Duchenne red blood cells, 
and a reduced epinephrine stimulation of the enzyme. These 
2+ 
and our findings on Ca -ATPase suggest that the alterations 
in the membrane of Duchenne erythrocytes are caused by an 
epinephrine receptor, the conformation of which is identical 
to a normal receptor loaded with its effector. This 
stimulated a-adrenergic state can explain the diminished 
osmotic stability of Duchenne erythrocytes, and also the 
increased rigidity reported in the literature. This 
conformational change presumably induces augmented affinity 
of certain parts of the membrane for ca2+. This may explain 
the increased sensitivity of Duchenne red cells towards ca2+, 
and the impaired membrane protein phosphorylation reported 
by others. 
The hypothesis of a conformational change of the 
a-adrenergic receptor explains many erythrocyte membrane 
alterations in Duchenne muscular dystrophy. This change may 
play a role in the pathogenesis of the disease. 
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SAMENV A TTING 
Het onderwerp van deze studie is het vinden van 
karakteristieke biochernische veranderingen bij personen, 
die het gen van Duchenne dystrofie of myotonische dystrofie 
dragen. Hopenlijk zullen deze onderzoekingen uiteindelijk 
een bijdrage leveren aan het begrijpen van de primaire 
oorzaak van spierdystrofie bij de mens. 
Kortgeleden kwamen gegevens beschikbaar 1 die de hypo-
these ondersteunen, dat spierdystrofie veroorzaakt wordt 
door een algerneen voorkornend mernbraandefekt. Niet alleen de 
spiermembranen van de spiercellen zijn dus aangetast, maar 
ook die van andere soorten cellen. Wij hebben erytrociet-
mernbranen onderzocht van patienten, die lijden aan Duchenne 
spierdystrofie of congenitale myotonische spierdystrofie. 
Lipiden (Hoofdstuk II) 
Ieder van de acht fosfolipideklassen in erytrociet-
membranen van dystrofische patienten hebben normale concen-
traties van de belangrijkste vetzuren. Andere onderzoekers 
vonden onveranderde concentraties van de verschillende fosfo-
lipiden in geisoleerde erytrocietmembranen van patienten. 
Uit deze feiten concluderen we, dat er geen afwijkingen 
bestaan in de belangrijkste lipiden van de erytrocieten van 
patienten met een van de twee vormen van spierdystrofie. De 
onveranderde vloeibaarheid van de lipiden, gemeten met 
behulp van fluorescentie polarizatie (zie 3.2.1.), stemt 
met deze conclusie overeen. 
We vonden wel verschillen in beperkt voorkomende lipide-
componenten van geisoleerde membranen. Palrnitoliezuur in 
neutrale lipidefrakties van de patienten is verminderd. 
Bij Duchenne-patienten is het gehalte in de diglyceriden af-
genomen met 66% en bij myotonische patienten met 86%. In deze 
laatste patientengroep is palmitoliezuur in triglyceriden 
verrninderd met 75%. Di t hoeft niet per se op een ahJijking in 
het membraan te duiden. 
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De vetzuursamenstelling van fosfolipiden in bleed-
plasma is normaal bij spierdystrofie. 
Osmotische stabiliteit (Hoofdstuk III) 
Gewassen erytrocieten van dystrofische patienten 
hebben een verminderde osmotische stabiliteit. Een abner-
male eigenschap van rode bloedcellen van patienten met myo-
tonische dystrofie werd waargenomen na behandeling met fos-
folipase. Deze cellen blijken, evenals onbehandelde cellen, 
stabieler te zijn in isotone dan in hypotone oplossingen. 
Dit in tegenstelling tot de met fosfolipase behandelde ery-
trocieten van controles en Duchenne-patienten. Deze hemoly-
seren meer in isotone oplossingen dan in 0,5% met fosfaat 
gebufferde NaCl-oplossingen. Het door fosfolipase veroor-
2+ + 
zaakte proces wordt door Ca , Na en fosfaat gestimuleerd. 
De aard van het afwijkende osmotische gedrag van de myo-
tonische erytrocieten zou kunnen zijn, dat de acetylcholine 
receptor enjof het Na+-ion kanaal in deze cellen niet door 
fosfolipase wordt vernietigd en bij controles wel. 
Membraan-gebonden enzymen (Hoofdstuk IV) 
Andere aanwijzingen voor een membraandefekt kunnen ver-
anderingen zijn in de kinetische eigenschappen van membraan-
gebonden enzymen. 
Aktivering van lang-keten vetzuren in de erytrociet-
membranen is alleen bij congenitale rnyotonische dystrofie 
verhoogd. De aktivering in leukocieten is onveranderd. De 
aktivering van palmitaat, palmitoleaat en linoleaat in ery-
trocieten is even snel. Leukocieten aktiveren palrnitaat 
sneller dan de beide andere vetzuren. 
Carnitine palmitoyltransferase is in myotonische ery-
trocieten niet veel verhoogd. De affiniteit voor palrnitoyl-
CoA is bij patienten en controles gelijk. 
De aktiviteiten van (Na+ + K+)-ATPase en K+-gestimu-
leerde p-nitrofenylfosfatase, beide betrokken bij de 
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+ + Na -K -pomp, zijn niet verschillend bij dystrofie. Ook 
gevoeligheid voor ouabaine is ongewijzigd. 
De aktiviteiten van ca2+-ATPase en ca2+-gestirnuleerde 
p-nitrofenylfosfatase zijn verdubbeld voor beide vormen van 
spierdystrofie. De interaktie van ca2+-ATPase van Duchenne 
rnernbranen met MgATP en ca2+ is identiek aan die bij contro-
les, maar de aktivering van de ca2+-ATPase door Na+ ver-
schilt. ca 2+-ATPase in Duchenne erytrocieten heeft twee 
aktiveringsplaatsen voor Na+, terwijl controle cellen 
slechts een plaats bezitten met lage affiniteit. De plaats 
met hoge affiniteit leidt tot extra enzymaktiviteit in 
Duchenne erytrocieten bij Na+-concentraties lager dan 34 mM. 
Bij de fysiologische intracellulaire Na+-concentratie van 
10 mM is de aktiviteit van ca2+-ATPase bijna verdubbeld ten 
opzichte van controles. Bij controle membranen wordt een 
tweede plaats voor Na+-aktivering vrijgemaakt door ethanol 
of epinefrine. De Na+-aktivering in controle membranen in 
aanwezigheid van ethanol is dezelfde als in Duchenne rnem-
branen zonder ethanol. Epinefrine stimuleert de aktiviteit 
bij afnemende Na+-concentraties zelfs nog meer dan ethanol. 
Hypothese 
Andere onderzoekers hebben een verhoogde basale akti-
viteit beschreven van adenylcyclase in Duchenne erytrocieten, 
en een verminderde epinefrine stimulatie van het enzym. Deze 
2+ 
en onze resultaten met Ca -ATPase doen veronderstellen, dat 
de veranderingen in de membranen van Duchenne erytrocieten 
veroorzaakt worden door een epinefrine receptor, waarvan de 
struktuur identiek is aan een normale receptor opgeladen met 
zijn effektor. Deze gestimuleerde B-adrenergische staat kan 
de verrninderde osmotische stabiliteit van de Duchenne erytro-
cieten verklaren, evenals de toegenomen starheid, die de 
literatuur vermeldt. De struktuurverandering veroorzaakt 
waarschijnlijk verhoogde affiniteit van bepaalde rnernbraan-
groepen voor ca 2+. Dit verklaart rnogelijk de verhoogde ge-
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voeligheid van Duchenne erytrocieten voor ca 2+ en de door 
anderen beschreven veranderde fosforylering van rnembraan-
eiwitten. 
De hypothese van een verandering in struktuur van de 
S-adrenergische receptor verklaart veel afwijkingen in 
rnembraaneigenschappen van erytrocieten bij Duchenne spier-
dystrofie; die een rol zouden kunnen spelen bij het ontstaan 
van de ziekte. 
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Summary 
Ten lipid fractions, both neutral and phospholipids, were isolated from 
erythrocytes of patients with Duchenne and congenital myotonic dystrophy. 
These fractions were: phosphatidylethanolamine, phosphatidylcholine, phos-
phatidylserine, sphingomyelin, lysophosphatidylcholine, phosphatidic acid, 
glycosphingolipids, triglycerides, diglycerides and one unknown. The fatty acid 
compositions were compared with control values. The major deviation was a 
decreased level of palmitoleic acid (16 : 1w7) in three neutral lipid fractions. It 
was lowered from 9.1 to 1.3% in diglycerides and from 10.6 to 2.6% in tri-
glycerides in myotonic dystrophy. In Duchenne muscular dystrophy this 
percentage was decreased from 9.1 to 4.0 in diglycerides. 
From blood plasma were isolated phosphatidylcholine, lysophosphatidyl-
choline, sphingomyelin and phosphatidylethanolamine. The myristic acid 
(14: 0) content was raised in lysophosphatidylcholine (from 4.4 to 8.6%) and 
in sphingomyelin (from 3.3 to 5.0%) in myotonic dystrophy. In the latter phos-
pholipid the stearic acid level was decreased from 18.6 to 12.8%. In phos-
phatidylcholine from plasma in myotonic dystrophy the level of eicosatrienoic 
acid (20 : 3w6) was lowered from 3.1 to 2.0%. Plasma fractions from 
Duchenne dystrophy showed no deviation. 
The results do not constitute an explanation for the various biochemical 
abnormalities found in dystrophic erythrocytes. Neither do they point to a 
defect in a major pathway in lipid metabolism. However, an aberration in the 
de novo synthesis of lipids in immature red blood cells cannot be excluded. 
Introduction 
One of the most clear phenomena found in Duchenne muscular dystrophy is 
the drastically elevated activity of creatine phosphokinase in serum. It seems 
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likely that a muscle membrane defect leads to leakage of compounds originally 
localized in the cytosol of the fibers. This hypothesis has been confirmed by 
abnormal characteristics of erythrocyte membranes. Erythrocytes from 
Duchenne patients have a lower mechanical resistance [1,2], an altered mem-
brane conformation [ 3], a higher potassium influx [ 4] and show a changed 
electrophoretic mobility [5]. Furthermore, many membrane bound enzymes 
possess kinetic properties different from control values; among them acetyl-
cholinesterase, adenylate cyclase, (Na ... + K ... )ATPase, protein kinase (for review, 
see Rowland [6]). The fatty acids of the membrane lipids have been analysed; 
the relative content of palmitoleic acid (16 : 1w7) was decreased in Duchenne 
patients and carriers [7}. In another study [8] this fatty acid level was found 
normal in the three major phospholipid fractions, but other acids had abnormal 
levels in sphingomyelin and phosphatidylethanolamine. Among them stearic 
(18 : 0), linoleic (18 : 2w6), arachidonic (20 : 4w6) and nervonic (24 : 1w9) 
acid. 
The fatty acid composition of memlelrane lipids plays an important role in 
the physical state of the membrane, which can influence metabolic processes. 
The minor phospholipids such as phosphatidylserine and phosphatidylinositol 
might be of great importance for special enzymes and transport processes [ 9]. 
We have studied the fatty acid pattern in six different phospholipid and four 
neutral lipid fractions from erythrocyte membranes in two types of muscle 
dystrophy, namely Duchenne dystrophy and myotonic dystrophy. These forms 
are genetically different. The first is X-chromosomal, recessive, the latter auto-
somal dominant. 
The fatty acids of four phospholipids isolated from plasma have also been 
determined. Some of these compounds are exchangeable with erythrocyte 
lipids. Therefore, they may have influenced the composition of them. More-
over, serum lipid abnormalities are indicative of the involvement of other 
organs. 
Abnormal fatty acid composition can either be used as a diagnostic tool or 
may be a clue to the metabolic origin of muscle dystrophy. 
Materials and methods 
1. Preparation of erythrocyte membranes 
Peripheral blood was taken from overnight fasted patients suffering from 
Duchenne dystrophy or the congenital form of myotonic dystrophy, or male 
controls not suffering from a neuromuscular or hematological disorder. The age 
of all donors varied between 4 and 18 years (mean 9 years). 10-25 ml blood 
was collected in a siliconized glass cylinder with 1 ml67 mM EDTA (Na salt) in 
0.8% NaCl, pH 7 .4, per 25 ml blood. Red and white blood cells were separated 
according to the method of Wyss et al. [10] by addition of 50 ml 3% Dextran 
moL wt. approx. 250 000) in isotonic NaCl per 25 ml blood. The erythrocytes 
were sedimented after standing 45 min at room temperature. The pellet was 
washed two times in 1 volume 172 mM Tris-HCl, pH 7 .6, at 0-4"C. The cells 
were lysed with 6 volumes 11 mM Tris-HCl, pH 7 .6, for 10 min in an ice-bath. 
The suspension was centrifuged for 35 min at 37 000 X gmax at 0-4°C. The 
pellet was was4ed until the pink colour disappeared (2-4 times) [11]. The 
membranes were stored at -70"C in the hypotonic Tris-HCl buffer at a protein 
concentration of about 2 mg per ml. 
2. Preparation of the plasma 
The upper phase of the dextran-blood mix (see above) was centrifuged for 
10 min at 600 X gmax and after that for 10 min at 10 000 X gmax at 0-4"C in 
order to remove leukocytes and thrombocytes, respectively. The remaining 
supernatant, which contains the serum lipoproteins, was stored at -20"C. 
3. Extraction, purification and analysis of the lipids 
About 2 ml of the membranes or plasma were treated with half that volume 
of dry n-butanol at room temperature during 15 min. After centrifugation (10 
min, 9000 X gmaxl the organic phase was pipetted into a tube. The water phase 
and protein layer were extracted another 3 times with 1 ml of butanol, 
saturated with water. The combined organic phases were washed 3 times with 
the same volume of water, saturated with butanol [12]. The butanol phase was 
dried with a stream of nitrogen at 45°C, the residue taken up in chloroform/ 
methanol (1 : 1, v/v) and stored at -20°C under nitrogen atmosphere. 
For the separation of the different phospholipid classes the system of 
Siakotos and Rouser [13] was applied: Silicagel 60 plates (Merck, G.F.R.), 
20 X 20 em, thickness 0.25 mm with the developing system for the first dimen-
sion chloroform/methanol/aqueous ammonia (280 g/1) (13 : 7 : 1, v/v) and for 
the second dimension chloroform/acetone/methanol/acetic acid/water (10 : 4 : 
2: 2 : 1, vjv). Between the two runs the plates were dried in a vacuum desicca-
tor for 50 min. 
The neutral lipid classes were separated on the same type of plate with the 
developing system toluene/ethyl acetate/diethyl ether/acetic acid (SO : 10 : 
10: 0.2, vjv). 
Lipid spots became visible under ultraviolet light after spraying with concen-
trated ammonia and 2.7-dichlorofluorescein (20 mg per 100 ml ethanol) [14]. 
The spots were scraped off and the lipids eluted by chloroform/methanol 
(1 : 2, vjv). The solution was dried under nitrogen at 45°C and hydrolysed and 
methylated with boron trifluoride (14% in methanol; Sigma) at 100"C, in 
accordance with Morrison and Smith [15], as was the extraction procedure 
for the methyl esters with pentane. The methyl esters of the fatty acids were 
analysed with a gas chromatograph (type F & M 402, Hewlett-Packard), 
equipped with an ECNSS-S column (10% on Gaschrom P, 100-120 mesh, 
Applied Science; length 6ft, inner diameter 3 mm) and a flame ionization 
detector. Nitrogen was used as carrier gas (flow rate 20 ml/min); temperature 
was 155°C. Area of the peaks was measured by an electronic integrator 
(Hewlett-Packard 3370 B). Retention times were compared with standard 
esters (Supelco) and mixtures of known composition (kindly supplied by Dr. 
U.M.T. Houtsmuller, Unilever Research, Vlaardingen, The Netherlands). 
Results 
Fig. 1 shows the separation of phospholipids from erythrocyte membranes. 
The pattern agrees with that of Siakotos and Rouser [131 and Marggraf {16]. 
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Fig, 1. Separation on TLC·plates of erythrocyte phospholiPids, using the 2.-<iimensional system of SiakO· 
tos and Rouser [13]. 1, phosphatidylethanolamine {PE); 2, phosphatidylcholine {PC); 3, phosphatidYl· 
sezine (PS); 4, sphingomyelin (SPH); 5, lysophosphatidylcholine {LPC); 6, glycosphingolipids; 7, phos· 
phatidic acid {PA); 8, unknown. NL, neutral lipids; S, start. 
In contrast to these workers, we found the lysophosphatidylcholine spot just 
beneath the sphingomyelin spot, and not to the right of it. The same pattern 
was obtained with plasma. Spot 6 may contain two types of glycospingolipid, 
because sometimes there were visible two partly separated spots. These spots 
were resorcinol·positive [14], pointing to gangliosides. Spot 8 was not detect· 
able every time. It probably does not contain phosphorus, but may contain 
traces of complex sugar·lipids. 
One of the lipids present in low concentrations in erythrocytes is phospha-
tidylinositol. We were not able to detect this phospholipid, but it is plausible that 
its location is in the environment ofphosphatidylserine or sphingomyelin [15]. 
A few times we have scraped off these spots and, after elution, developed them 
two dimensionally on thin-layer chromatographic plates according to Peter and 
Wolf [17]. Nevertheless, phosphatidylinositol was never detected by the 
periodic acid·Schiff method [14]. The reason for this may be the low con· 
centration of phosphatidylinositol or an incomplete extraction of the cell mem· 
branes. However, the extraction used has been proven to be useful for different 
kinds of phospholipid [12]. 
The separation pattern of plasma phospholipids was totally comparable with 
Fig. 1. Four lipids were always detectable, namely phosphatidylethanolamine, 
phosphatidylcholine, sphingomyelin and lysophosphatidylcholine. 
The di· and triglyceride fractions from erythrocytes were not visible on the 
plates when developed as described under Materials and methods. The amount 
of neutral lipids, except cholesterol, is very low in these cells [18]. We have 
scraped off areas with Rr-values corresponding to standard di- and triglycerides, 
which may have been contaminated with some free fatty acids and cholesterol 
esters. 
The fatty acid profiles of the various lipids are given in Tables I-VII. The 
fatty acids are coded as follows: (number of carbon atoms) : (number of 
double C-C bonds) w (number of carbon atoms until the first double bond, 
starting from the methyl end). 
Table I shows the fatty acids in the negatively charged phosphatidylethanol-
amine and -serine from erythrocytes. Both lipids are partly present in the plas-
malogen form, in which one ester bond is replaced by a vinyl ether bond [14]. 
During methylation dimethylacetals (DMA) are formed instead of methyl esters 
of fatty acids. The quantities of the dimethylacetals are included in the figures 
of 16 0 and 18 : 0. There was no difference between the 3 groups with 
respect to these compounds. In phosphatidylethanolamine the mean for 16 : 0 
DMA was 3.2%, for 18 0 DMA 7.1%. In phosphatidylserine only a few tenths 
of a percent were present as acetals. Kunze eta!. [8] did not analyse the serine 
compound, but found a two-fold increase in dimethylacetals (16 0 DMA + 
18 · 0 DMA?) in phosphatidylethanolamine in Duchenne patients. However, 
they found a normal content of plasmalogens in this fraction. We did not find 
TABLE I 
FATTY ACID COMPOSITION OF PHOSPHATIDYLETHANOLAMINE AND PHOSPHATIDYLSERINE 
FROM ERYTHROCYTE MEMBRANES 
All data expressed as percentage (mean ± S.E.M.). Numbers in parentheses: number of samples analyzed. 
n.d., not detectable. 
Acid Ph osp ha tidy !ethan oiamin e 
:>1Yotonic Duchenne 
dystrophy (4) dystrophy (5) 
14 : 0 0.6 " 0.1 0.9 ± 0.4 
15 : 0.3 :': 0.1 0.5 ± 0.2 
H ,o l 7.9 ± 0.8 § 18.4 ± 2.0 5 
16 : 1w7 1.2 ± 0.3 2.0 ± 0.5 
18 : 0 18.8 ± 1.3 § 18.5 ± 1.4 5 
18 : 1w9 18.3 i 1.8 18.7 ± 1.0 
18 : 2w6 6.6 t 0.6 6.8 ± 0.9 
20 : 2w9 0.4 :': 0.1 0.5 ± 0.2 
20: 3w6 0.8 ± 0.1 0.8 ± 0.1 
20 : 4w6 17.6 
' 
1.< 18.2±2.0 
22 : 0 trace trace 
" 
:4w6 6.; ': 0.8 5.6 ± 1.1 
22 : 5w3 3.4 ± 0.4 2.; t 0.7 
22 : 6w3 4.2 ± 0.7 2.8 t 0.7 
Others 3.1 1.5 
* Difference significant in t·test, P , 0.05. 
±Y Difference sitmificant in 1-test, P , 0.02. 
*~~Difference significant in l·test, P , 0.01. 
±*~:Difference significant in 1-tcst, P '- 0.002. 
~ Including the dimethylacetals (DMA). 
Phosphatidylserine 
Control (7) Myotonic Duchenne Control (6) 
dystrophy (4) dystrophy (5) 
1.0 ± 0.2 1.0 !". 0.2 1.5±0.4 1.3 ± 0.2 
0.5 ± 0.1 0.4 ± 0.1 0.3 ± 0.1 0.4 ± 0.1 
18.2 
' 
0.5 § 4.0 ± 0.2 § -~~* 5.1 
' 
L1 6.7 
' 
0.6 
1.6 
' 
OA 1.0 ± 0.1 2.0 ± 0.6 1.9 
' 
0.5 
18.0 
' 
1.0 5 42.4 :': 0.6 § 40.2 t ,., § 39.4 ± 1.3 
18.3 ± 0.3 8.4:':0.4* 9.1 ± 1.1 10.3 ± 0.6 
6.3 t 0.3 2.3 . 1.2 2.7 
' 
1.3 2.1 ± 0.2 
0.3 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.4 t 0.1 
0.8 ± 0.1 1.4 ± 0.2 1.6 ± 0.4 3.0 t 1.2 
19.5 t 0.6 21.4 ± 0.3 ~ 20.4 ± 1.1 18.4" 1.0 
0.2 ± 0.1 0.4 ± 0.2 0.2 ± 0.1 0.3 ± 0.1 
5.8 " 0.6 3.4 ± 0.5 3.2 ± 0.2 2.7 ± 0.2 
2.9 ± 0.2 3.0 ± 0.3 2.2 ± 0.3 2.3 ± 0.3 
3.9 ± 0.4 6.6 ± 1.0 5.0 ± 0.8 5.7 ± 0.7 
2.; 3.8 6.0 5.1 
§ 
113 
114 
a lower arachidonic acid (20 : 4w6) leveL In phosphatidylserine from myotonic 
patients we found a decrease in palmitic acid (16 : 0). 
Table II gives the results for the major choline-containing phospholipids, 
namely phosphatidylcholine and sphingomyelin. !\'o important abnormality 
was found, in contrast to the findings of Kunze [8] who reported sphingo-
myelin from dystrophic patients as having too much stearic acid (18 : 0) and 
too little linoleic (18: 2w6), nervonic (24: 1w9) and palmitic (16: 0) acid. 
Table III contains the fatty acid pattern of lysophosphatidylcholine and 
phosphatidic acid, and Table IV the composition of the glycosphingolipid frac-
tion and of spot 8, an unidentified lipid. The fatty acid profiles of the last four 
compounds have never been reported in muscle dystrophies. The only differ-
ence from normal was a lower content of 22 : 0 in lysophosphatidylcholine 
from Duchenne erythrocytes. Control values for these lipids are scarce in litera-
ture, although higher levels of palmitic acid (16 : 0) have been reported in lyso-
phosphatidylcholine than we found [18]. Suitable values for the other three 
lipids are not available. 
The most astonishing deviations were found in the di- and triglycerides 
(Table V). The palmitoleic acid (16 : 1w7) content was drastically lowered, 
both in Duchenne and myotonic dystrophy. This supports to some extent the 
findings of Howland and Iyer [7], who reported less palmitoleic acid in total 
lipid extract. 
The results for the blood plasma phospholipids are given in Tables VI and 
VII. Duchenne phospholipids do not show any aberration. In myotonic 
dystrophy the content of myristic acid (14 : 0) is raised in sphingomyelin and 
lysophosphatidylcholine. Very significant is the decrease in eicosatrienoic acid 
TABLE II 
FATTY ACID COMPOSITION Or PHOSPHATIDYLCHOLINE AND SPHINGOMYELIN FROM 
ERYTHROCYTE MEl>.'IBRANES 
Legends: see Table I. 
Acid Phosphatid y lch oline 
14 : 0 
15 : 0 
16 : 0 
16: lw7 
18 ; 0 
18: 1w9 
18: 2w6 
20 : 2w9 
20 : 3w6 
20 : 4w6 
22 : 0 
22 :4w6 
" 
'0 
" 
: lw9 
, : 6w3 
Others 
Myotonic 
dystrophy (4) 
L1 ± 0.4 
0.5 ± 0.1 
33.3 ± 0.8 
1.3 t 0.7 
12.8 t 0.6 
18.2t0.6 
22.13 t 0.5 * 
0.8 ± 0.3 
1.3 ± 0.3 
4.0 t 0.4 
0.3 ± 0.1 
0.4 t 0.2 
trace 
n.d. 
0.7 ± 0.2 
2.6 
Duchenne 
dystrophy (6) 
L1 ± 0.2 
0.5 t 0.1 
31.2 ± 0.7 
1.9 ± 0.4 
15.5 ± 1.0 
1&.3 t 0.6 
19.1 t 1.3 
0.6 ± 0.2 
1.5 ± 0.2 
4.e t 0.7 
0.3 ± 0.1 
0.4 ± 0.1 
trace 
n.d. 
0.7 ± 0.2 
3.1 
Control (6) 
1.2 t 0.2 
L1 ± 0.5 
32.6 ± 0.4 
1.5±0.4 
14.0 t 0.7 
19.9 ± 0.3 
20.3 ± 0.4 
0.3 ± 0.2 
1.5 ± 0.1 
4.0 ± 0.2 
0.3 ± 0.1 
0.2 ± 0.1 
trace 
n.d. 
0.9 ± 0.2 
2.1 
Sphingomyelin 
Myotonic Duchenne Control (5) 
dystrophy (4) dystroPhY (5) 
L1 !: 0.3 L1 :: 0.4 1.4 ± 0.3 
0.5 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 
25.7 ± 0.9 24.0 ± '-' 25.fl ± 0.9 
1.3 ± 0.7 1.5 ± 0.4 1.9 ± 0.4 
9.8 ± 1.0 16.3 ± 3.1 10.1 : 1.0 
4.2 ± o.e 7.1 
' 
1.4 e.1 t 0.6 
0.8 !: 0.1 2.3 ± 0.7 1.0 ± 0.2 
0.7±0.3H OA ± 0.1 0.2 ± 0.1 
n.d. n.d. n.d. 
1.5 t 0.5 2.0 !: 0.5 1.2 ~ 0.3 
8.7 ± 0.6 7.7 ± 0.6 8.3 ± 0.8 
n.d. n.d. n.d. 
15.2t0.5 11.8-tl.7 13.5 ~ 1.2 
21.6 ± 1.2 17.2 ± 2.4 19.5 ± 1.1 
1.1 ± 0.2 0.9 : 0.3 1.5 t 0.5 
7.8 7.2 8.9 
TABLE Ill 
FATTY ACID COMPOSITION OF LYSOPHOSPHATIDYLCHOLINE AND PHOSPHATIDIC ACID 
FROM ERYTHROCYTE MEMBRANES 
Legends: see Table I. 
Acid LYSO p hosphatid yl choline Phosphatidic acid 
Myotonic Duchenne Control (6) Myotonic Duchenne Control {4) 
dystrophy (4) dystrophy {6) dystrophy (4) dystrophy (5) 
14 : 0 4.6 ±0.4 5.3 ± 0.6 5.7 ± 0.6 3.2 ± 0.4 4.0 t 0.7 3.6 ± 0.8 
15 : 0 2.0 ± 0.2 1.6 t 0.1 1.8 ± 0.2 3.9 ± 2.1 1.4 ± 0.2 0.8 ± 0.4 
16 : 0 24.2 ± 3.7 21.1 ± 1.0 23.7 ± 2.6 21.0 ± 1.3 21.8 ± 1.5 23.0 ± 2.3 
16 : 1w7 5.0 ± 0.9 3.6 ± 0.8 3.7 ~ 1.2 4.3 ± 1.4 4.3 ± 0.7 4.4 ± 0.7 
18 : 0 32.4 ~ ,.6 36.0 ~ 3.4 ~ 25.1 :': 7.5 24.8 ± 1.9 26.3 ± 2.3 21.9 ±4.4 
18 : 1w9 12.2 :': 1.0 13.8 ± 1.4 16.0 ± ,.1 18.1 ± 1.7 18.8 ± 2.5 21.9 ± 3.7 
18 ! 'w6 1.8 ± 0.2 
'·' 
± 0.7 
'·1 :': 0.2 7.1 ± 1.1 6.2 ± 1.3 6.2 ± 1.2 
" 
:2w9 2.6 ± 1.1 2.2 ± 0.4 2.3 ± 0.4 3.1 ± 0.8 3.3 ± 1.5 1.7 ± 0.5 
20 : 4w6 0.4 ± 0.1 0.4 ± 0.1 0.3 ± 0.1 2.1 ± 0.9 1.7 ± 0.7 2.5 ± 0.4 
:l2; 0 3.9±0.4 2.0 :': 0.4 " 5.0 ± 1.0 2.5 ± 0.7 1.8 ± 0.8 1.5 ± 0.5 
" 
: 4w6 1.6 ± 0.3 . 0.1 :': 0.1 0.3 ± 0.2 3.7 ± 1.8 1.0 ± 0.4 0.4 ± 0.3 
" 
,o 2.1 ± 0.7 1.0 ± 0.7 2.0 ± 1.1 n.d. n.d. n.d. 
24 : 1w9 0.9 ± 0.3 0.6 :': 0.5 1.6 ± 1.4 n.d. n.d. n.d. 
Others 6.7 9.9 10.4 
'·' 
9.4 12.1 
(:.:0 3w6) in phosphatidylcholine. The dimethylacetal contents included in 
the figures of 16 0 and 18 : 0 of phosphatidylethanolamine were not signifi-
cantly different between the 3 groups. The values were (on an average) 1.9% 
for 16 0 DMA and 3.9% for 18 : 0 DMA. Wakamatsu et al. [19] measured a 
decreased level of palmitoleic acid and more stearic acid in the total phospho-
lipid fraction of myotonic plasma. Phillips and Dodge [20] reported fatty acid 
TABLE IV 
FATTY ACID COMPOSITIOl'.' OF SPOT 8 (SEE FIG. 1 AND TEXT) AND GLYCOSPHINGOLIPIDS 
FROM ERYTHROCYTE ME~IBRANES 
Legends: see Table I. 
Acid Spot 8 Glycosphingolipids 
Myotonic Duchenne Control (3) Myotonic Duchenne Contxol (5) 
dystrophy {2) dystrophy (4) dystrophy (4) dystrophy {4) 
14 ,Q 8.6 
' 
2.3 ~ 5.1 ::0,4 4.9 ± 0.1 4.8 :t 2.4 3.6 ± 0.5 3.9 ± 0.2 
15 : 0 1.3 ± 0.5 1.9 ~ 0.3 ,., ± 0.4 1.8 ~ 0.2 1.4 :t 0.3 1.5 ± 0.3 
16 ,o 16.3 ± 1.0 "21.9 ± 3.0 19.9 ± 1.3 16.3 ± 1.6 15,2 ± 1.9 17.7 ~ 0.4 
16 ' lw7 3.2 ± 1.0 7.4 ± 1.0 6.7 ± 1.5 4.9±0.7 3.6 ~ 0.7 6.1 ± 1.1 
18 : 0 20.9 
' '·' 
213.5 ± 3.0 35.0 ± 2.6 18.4 ± 2.3 22.9 ± 2.7 20.4 :t 4.5 
18 : 1w9 11.4 ± 0.2 15.8 ± 1.1 16.8 ± 1.9 12.6 ± 2.7 11.2 ± 0.7 15.5 ± 2.4 
1!;1 : 2w6 ~.~: 0.4 3.1 ± LO 3.4 ! 0.6 1.6 ± 0.4 2.6:!: 0.4 2.4±0.7 
20 : 2w9 2.3 ± 1.1 1.9 ± 0.6 1.0 ± 0.2 1.6 ± 0.7 2.2±0.7 1.4 ± 0.2 
20 : 4w6 0.1 :': 0.1 0.2 ± 0.1 0.2 ± 0.1 n.d. trace n.d. 
22 : 0 1.2:: 0,7 1.7 ± 0.2 1.7 ± 0.5 7.9 ± 0.5 7.4±1.4 8.3 ± 2.1 
" 
:4w6 0.8 ± 0.4 0.8 ± 0.2 1.1 ± 0.5 n.d. n.d. n.d. 
" 
,o n.d. n.d. n.d. 10.4 ± 1.1 9.1 
' 
,.9 6.7 ± 1.5 
24: lw9 n.d. n,d, l".d. 8.6 ± 1.1 7.8 ± ,.6 5.2 ± 1.8 
Others 32.6 11.7 7.3 11.1 12.9 10.9 
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TABLE V 
FATTY ACID COMPOSITION OF TRIGLYCERIDES AND DIGLYCERIDES FROM ERYTHROCYTE 
MEMBRANES 
Legends: see Table I. 
Acid 
14 : 0 
15 : 0 
16 ; 0 
" 
: 1w7 
" 
'0 
18 : 1w9 
18 :2w6 
19 : 0 
18 : 3w6 
" 
:2w9 
20 : 3w6 
22 '0 
Others 
Triglycerides 
Myotonic 
dystrophy (4) 
6.2 ± 1.5 
1.7 ± 0.2 
17.0±1.2 
2.6 
' 
0.3 " 
11.4 ± 1.6 
9.0 ± 3.6 
2.3 ± 0.2 
6.0 ± 2.2 * 
2.3 t 0.5 
7.6±1.6 
7.9 ± 1.5 
10.2 ± 1.6 
15.8 
Duchenne Control (5) 
dystrophy (5) 
5.6 t LO 3.7 ± 1.6 
2.5 ± 0.2 1.5 ± 0.3 
20.4 ± 2.9 20.0 ± 1.6 
8.2 ± 1.3 10.6 ± 2.3 
9.0 ± 1.0 9.7 ± 0.8 
10.5 ± o.7 12.7 ± 0.9 
1.4 ± 0.2 1.7 ± 0.4 
2.1 ± 1.3 1.2 ± 0.6 
2.2±0.7 3.0 ~ 1.5 
12.2 ± 2.4 8.8 ± 2.0 
3.6 ± 1.5 5.5 ± 2.0 
10.1 ± 3.5 9.6 ± 1.3 
12,2 21.6 
Diglycerides 
Myotonic Duchenne Control (4) 
dystrophy (4) dystrophy (5) 
5.0 = 1.6 4.4 ± 1.4 5.3 ± 0.9 
5.7 ± 3.8 1.8 ± 0.3 3.0 ± 0.6 
16.9 ± 2.1 15.8 ± 0.8 20.3 ± 2.7 
1.3 ± 0.5 **~ 4.0 :±-. 0.7 9.1 ± 2.5 
12.8 ± 1.8 10.3 ± 0.9 9.2 ± 0.9 
9.2 ± 4.4 6.5 ± 1.4 10.3 ± 2.4 
1.5 ± 0.5 1.2 ± 0.2 1.0 ± 0.2 
<.7 ± 3.7 3.0 ± 1.1 3.8 ± 2.7 
1.2 ± 0.5 2.8 ± 1.2 2.8 ± 1.0 
7.9±1.9 14.0 ± 2.5 9.9 ± 2.2 
10.4 ± 2.4 5.4±1.7 3.6 ± 1.3 
15.6 ± 2.2 13.9 ± 2.5 9.1 
' 
1.2 
7.8 16.9 12.6 
values for phospholipid fractions in controls. Our phosphatidylcholine profile 
agrees well with their values, the other three profiles less well for some fatty 
acids. 
It may be observed that the standard deviations in myotonic material are 
rather small, those in Duchenne dystrophy are higher than in controls. The 
significance is unclear, but it may point to a difference in homogeneity 
between the groups. 
TABLE VI 
FATTY ACID COMPOSITION OF PHOSPHATIDYLCHOLINE AND LYSOPHOSPHATIDYLCHOLINE 
FROM BLOOD PLASMA 
Legends: see Table I. 
Acid Ph osP ha tidy !choline 
14 : 0 
15: 0 
16 : 0 
16: 1w7 
18 : 0 
18: 1w9 
18: 2w6 
20 : 2w9 
20 : 3w6 
20: 4w6 
22: 0 
22 : 6w3 
Others 
Myotonic 
dystrophy (4) 
2.1 ± 0.7 
0.6 ± 0.1 
28.0 ± 0.8 
2.2 ± 0,7 
13.3 ± 0.3 
13.9 ± 0.3 
23.2 ± 1.7 
0.7 t 0.1 
2,0 ± 0.2 ***~ 
6.6 ± 0,4 
0.2 ± 0.1 
2.0 ± 0.6 
5.2 
Duchenne 
dystrophy (4) 
1.9 ~ 0.6 
0.5 ± 0.1 
28.3 ± 0.9 
2.4 ± 0.8 
13.4 t 0.5 
14.8 ± 0.1 
20.5 ± 1.3 
0.7 t 0.4 
3.0 ± 0.6 
8.0 ± 0.6 
0.2 ± 0.1 
2.1 ± 0.2 
4.2 
Control (6) 
1.0 ± 0.2 
0.4 ± 0.1 
26.9 ± 0.4 
1.6±0.7 
15.3 t 0.5 
14.1 ± 0.5 
23.7 ± 0.8 
0.5 ± 0.2 
3.1 ± 0.2 
7.6 ± 0.5 
0.2 ± 0.1 
2.2 ± 0.3 
3.4 
Ly so ph ospha ti dylch o!ine 
Myotonic Duchenne Control (6) 
dystrophy (3) dystrophy (5) 
8.6 ± 1.5 ,. 5.8 ± 1.5 4.4 ±0.4 
1.5 ± 0.7 2.2 ± 0.5 1.9 ± 0.5 
30.8 ± 0.5 28.0 ± 1.9 27.6 ±2.4 
5.7 t 1.9 4.8 ± 1.0 6.1 ± 1.5 
13.5 ~ 0.9 16.9 ± 2.9 23.8 ± 3.7 
14.6 ± 1.4 17.6 t 4.6 17.8 ± 0.9 
6.0 ~ 1.4 6.4 ± 0.4 7.0 t 0.8 
1.4 ~ 0.5 2.2 ± 0.6 1.5±0.4 
0.4 ~ 0.1 0.4 ± 0.1 0.4 
' 
0.1 
0.5 t 0.2 0.5 ~ 0.2 0.7 ± 0.5 
1.9 ., 0.8 1.7 ± 0.2 1.5 ± 0.6 
n.d. n.d. n.d. 
15.1 13.5 ;.a 
TABLE Vll 
FATTY ACID COMPOSJTIO~ OF SPHJNGOMYELI~ AND PHOSPHATIDYLETHANOLAMINE FROM 
BLOOD PLASMA 
Legends: sec Table l. 
Acid 
14 : 0 
15 : 0 
16 : 0 
16: lw7 
18 : 0 
18: 1w9 
18: 2w6 
20 : 2w9 
20 : 4w6 
22 : 0 
24 : 0 
24: 1w9 
22 : 6w3 
Others 
Sphingomyelin 
Myotonic 
dntrophy (4) 
5.0 = 0.4 ~* 
2.7 = 0.9 
26.9 :: 1.3 
3.3 t 2.0 
12.8 = 1.3 ' 
u 
' 
2A 
2.8 " 0.8 
0.3 ~ 0.1 
1.6 ± 0.6 
10.2 " 2.5 
2.4 ! 0.8 
5.3 
' 
1.5 
1.2±0.7 
18.4 
Discussion 
Duchenne Control (6) 
dystrophy (5) 
3.5 t 0.5 3.3 ± 0.4 
1.5::0.4 1.1 ± 0.2 
24.8 ~ 2.8 24.4 ± 0.6 
4.6 ~ 1.0 3.5 ± 0.5 
15.6 ~ 2.1 18.6 t 2.3 
12.3 ± 2.3 5.5 ± 0.8 
2.6 ± 0.3 3.5 ± 0.4 
0.8 ± 0.2 0.9 ± 0.4 
2.4 ± 0.6 2.6 ± 0.4 
8.0 ± 0.6 o.s ± 0.8 
3.3 ± 0.5 5.0 ± 0.9 
6.1 ± 0.9 6.5 ± 2.0 
0.3 ± 0.1 0.2 ± 0.1 
14.2 12.5 
Phosphatidylethanolamine 
Myotonic Duchenne Control (4) 
dYstrophy (4) dystrophy (5) 
6.7 ± 1.5 u 
' 
1.6 4.6 t 1.0 
1.6 t 0.5 1.7 ± 0.5 1.8 ~ 0.3 
22.7 ± 2.2 § 24.3 ~ 3.1 
* 
17.2 ~ 2.6 
7.2±0.9 .., ±_ 1.3 4.4 ± 2.0 
17.9 " 2.5 5 18.8 ;I; 4.2 § 25.9 ' 3.5 
14.0 ± 1.4 14.1 ± 4.7 15.5 ± 1.0 
6.1 t 0.7 u ± 0.7 6.1 
' 
1.8 
2.5 ± 0.8 1.5 ± 0.2 2.2 ± 0.5 
6.5 ± 0.7 2.4 ;I; 1.0 5.6 
' 
1.0 
1.1 :': 0.2 2.5 ± 1.0 1.6 ± 0.7 
n.d. n.d. n.d. 
n.d. n.d. n.d. 
2.3 ± 0.2 1.9 ± 0.9 1.6 ~ 0.5 
11.4 16.9 11.5 
Although the clinical syndromes in Duchenne dystrophy are very different 
from those in myotonic dystrophy, in both diseases the plasma membrane may 
be impaired. Rowland [6] has summarized many indications for this hypothesis, 
coming from both muscle and erythrocyte membrane data. Recently, a few 
other reports have been published, which point to the possibility of a general 
membrane defect. Mokri et al. [21] demonstrated lesions in muscle plasma 
membranes in an early stage of the Duchenne disease. Furthermore, the mem-
brane of Duchenne erythrocytes responds abnormally to high cellular calcium 
concentrations [22]. Interestingly in this context, Roses et al. [23] found that 
phenytoin normalizes the increased membrane fluidity in myotonic erythro-
cytes. Phenytoin stimulates calcium binding to phospholipids [ 24]. This drug 
also lowers the increased phospholipase A activity in both myotonic and 
Duchenne red blood cells [ 25]. Whether this effect is due to increased calcium 
affinity of the membrane lipids, is not clear; phospholipase A is stimulated by 
calcium [26]. 
It seems likely to ascribe many of the aberrations to a defect in the architec-
ture of the cell membrane of various tissues, among them the red blood cells. 
Structural proteins or lipids, or both, may be affected in a different manner in 
the various types of muscular dystrophy. Apart from the abnormal phos-
phorylation of membrane proteins, there has existed hitherto no clear indica-
tion of impairment of erythrocyte structural proteins (see also Roses [27]). 
With respect to erythrocyte lipids in muscle disease some papers have been 
published. Andiman et al. [28} and Roses and coworkers [29] found the same 
phospholipid and ganglioside content for myotonic and control cells without 
§ 
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giving details. Thomas and Harper [30] found no deviation in neutral and phos-
pholipid classes in dystrophia myotonica. Kunze et al. [ 8], too, reported no 
change in this disease but found that sphingomyelin content in Duchenne 
erythrocytes was increased. This was also found by Kalofoutis [ 31]. The latter 
study shows lowered lecithin and raised lysolecithin and cardiolipin levels. The 
fatty acid pattern of the total lipid extract from Duchenne erythrocytes has 
been analysed by Howland and Iyer [7]. They found four times less palmitoleic 
acid (16 : 1), ascribing this partly to a lower triglyceride content. Kunze and 
coworkers [8] have reported the fatty acid composition of the three phos-
pholipids, with the highest concentration in red blood cel!s. They have detected 
changes in phosphatidylethanolamine and sphingomyelin. However, their fatty 
acid pattern of control sphingomyelin differed greatly from literature values 
(for example [18]). Furthermore, they do not distinguish between autosomal 
and X-recessive progressive muscle dystrophy and found no palmitoleic acid in 
any group. 
Therefore we studied the fatty acid composition of isolated neutral and 
phospholipids in erythrocytes from both Duchenne patients and another well-
defined group, namely patients suffering from the congenital form of myotonic 
dystrophy. 
In Duchenne erythrocytes was found only a raised content of 18 : 0 and less 
22 : 0 in lysophosphatidylcholine and less 16 : 1 in diglycerides. In myotonic 
cells various significant differences exist, the most striking ones being the five-
fold increased level of 22 : 4w6 in lysophosphatidylcholine and the 19 : 0 level 
in triglycerides, less 16 : 0 in phosphatidylserine and the drastically lowered 
content in di- and triglycerides of palmitoleic acid (16 1). 
Therefore it is clear that we were not able to reproduce the findings of 
Kunze et al. [8]. Especially, their fatty acid pattern of sphingomyelin both in 
controls and in dystrophic patients is quite different from our results. The con-
trol values we found agree well with those in the literature [ 18 J. 
The decreased level of palmitoleic acid in two neutral lipid fractions from 
both groups of patients is of interest. This fatty acid was mentioned by How-
land and lyer [ 7] to be decreased to a great extent in total lipid extract from 
Duchenne patients and carriers. In some other types of neuromuscular disorder 
increased or normal levels were measured. The decreased level we found in 
diglycerides cannot explain their findings, because this fraction covers only 
traces in erythrocytes [ 18]. Combination of decreased di- and triglyceride con-
tents with lower palmitoleic acid concentrations in both fractions could 
account for their results. However, they did not report a lowered diglyceride 
content. When a calculation is based on the lipid levels in control cells [ 18] and 
our fatty acid compositions, we find for palmitoleic acid roughly only 2.5% in 
total lipids, which is in good agreement with other figures [18], but two times 
lower than those of Howland and lyer. There is hardly any knowledge about 
the metabolism of palmitoleic acid so that further conclusions had to be 
omitted. 
To obtain insight into possible involvement of other tissues in lipid metab-
olism and to analyse its consequence for the erythrocyte fatty acid pattern, we 
have studied the fatty acid composition of four phospholipids present in the 
lipoproteins of plasma. The only abnormalities found were an increased level of 
14 : 0, both in sphingomyelin and lysosphosphatidylcholine, less 18 : 0 in 
sphingomyelin and less 20 : 3w6 in phosphatidylcholine, all in myotonic 
plasma. The origin of these aberrations is unclear, with no indication of a 
special metabolic path way or organ which could be involved. In Duchenne 
plasma fractions no deviation was found. To our knowledge only one report 
has been published which shows fatty acid composition of dystrophic serum 
[19]. More stearic and less palmitoleic acid in total phospholipids were found. 
A lower percentage of palmitoleic acid in all lipid fractions, measured by these 
authors, was observed. 
From these studies we cannot exclude a membrane lipid deviation present 
only in the early stages of the dystrophic red blood cell lifesp2.Il. From diet, 
incorporation and cell-plasma exchange studies [32] we have to conclude that 
deviations due to de novo lipid synthesis in bone marrow or circulating reticu-
locytes may have been normalized in mature blood cells. The extent to which 
fatty acid patterns originally present and possibly abnormal, have disappeared 
by these mechanisms cannot be established. Anyhow, we have not found any 
phospholipid type possessing more deviations than others. 
Di- and triglycerides can be synthesized de novo by reticulocytes [33], 
!llthough most of these fractions found in erythrocytes may have been derived 
from contamination with serum lipoproteins [18]. Therefore abnormalities in 
these lipids can hardly be interpeted. Recently, attention has been paid to 
diglycerides, which may be involved in hormone and calcium action [34]. 
Together vvith the described effects of phenytoin, an important metabolic 
starting-point for research in the field of muscle dystrophy may exist here. 
We have to conclude that the various deviations found ir.. both dystrophic 
groups cannot simply be explained by influences of the fatty acids in erythro-
cyte lipids. It may be suggested that it is not only the bulk of the phospho-
lipids which regulates cell metabolism. The compounds constituting the micro-
environment of enzymes or ion channels are of great importance [ 35,17]. The 
influence of fatty acids on this has scarcely been reported [9], but Bloj and 
coworkers have clearly demonstrated a correlation between the double bond 
index of membrane lipids and changes in allosteric transitions of (Na+ + K+)-
ATPase and acetylcholinesterase in rat erythrocytes [36]. Nevertheless, it is 
dii'ficult to connect the many metabolic differences with a deviation in one 
micro-environment. 
Obviously, if there exists a lipid abnormality in muscle dystrophies, it is not 
manifested in the phospholipid fatty acid patterns of erythrocytes, but aberra-
tions in lipid metabolism cannot be excluded from this study. 
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Note added in proof: (Received July 28th, 1978) 
After the acceptance of this paper two studies have been published in which 
are reported the lipid content and fatty acid composition of some phospholip-
ids in erythrocytes from Duchenne patients ( 3 7 ,38]. Both papers give further 
evidence in support of our conclusion that the phospholipids in Duchenne 
muscular- dystrophy are unaltered. The levels of other membrane components 
of red blood cells from these patients were also recently found by Godin et al. 
[ 39] to be normal. 
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SUMMARY 
The stability of washed erythrocytes from patients with muscular 
dystrophy was determined in hypotonic phosphate buffered sodium chlo-
ride. Control cells were more stable than cells from Duchenne and 
myotonic patients. 
After pretreatment of the cells with phospholipase from pancreas, 
2+ 
snake venom or bee venom in the presence of 14 mM Ca the order of 
osmotic stability in the 3 groups was not changed. In isotonic phos-
phate buffered NaCl, however, the erythrocytes of the myotonic patients 
were much more stable than the cells of the Duchenne and the control 
group. 
The lytic process was further studied in control cells with pan-
creatic phospholipase. 21+3 (SEM) % of the cells were lysed. This pro-
cess was (partly) prevented by omitting the phospholipase, by replace-
ment of Na+ by K+ or Li+, by lowering the ca2+-concentration, by omit-
ting phosphate, by ouabain, by glucose, by sucrose and by tetrodotoxin, 
+ ~ 3+ 
a Na -transport inhibitor. Blocking of the Ca -transport by La or 
mersalyl greatly stimulated the lytic process. 
INTRODUCTION 
Since Matheson and Howland [1] reported an enhanced percentage of 
echinocytes in blood of Duchenne patients and carriers, several studies 
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have been published about morphology of patient erythrocytes. Although 
the results were often controversial [2 and its references], it seems 
legitimate to conclude from these studies that erythrocytes of Duchen-
ne patients have an increased chance to be transformed in vitro to ab-
normally shaped cells [3,4], which perhaps also holds for cells of 
myotonic muscular dystrophic patients [s]. However, the survival of 
dystrophic red blood cells is normal [6]. The same study reports a 
normal resistance of Duchenne erythrocytes to hypotonic solutions, in 
contrast to three other publications, reporting a decreased osmotic 
stability [7,8,9]. 
We were interested in the osmotic stability because it may offer 
a chance to check the hypothesis, which postulates a general membrane 
defect in human muscular dystrophy [10]. Interactions between membrane 
proteins and phospholipids can be modified by treatment of cells by 
phospholipases. These enzymes might affect patient erythrocytes dif-
ferent from control cells, if the mozaic of membrane components would 
be altered. It is likely that this then might be reflected by a change 
in osmotic resistance. 
In the present study we have measured the osmotic stability of 
erythrocytes, both before and after treatment by various phospholipa-
ses, of patients suffering from either congenital myotonic muscular 
dystrophy or Duchenne muscular dystrophy. The phospholipases used 
differ in activity when the compression state of the membrane lipid 
layer is different [11]. Therefore the study of the effects of various 
phospholipases on different erythrocyte sources may reveal possible 
variations in interaction between membrane components of red blood 
cells from patients. 
MATERIALS AND METHODS 
Blood samples were taken by venapuncture from boys, aged between 
3 and 19 years after an overnight fast period. Patients suffered from 
myotonic muscular dystrophy (congenital form) or from Duchenne muscu-
lar dystrophy; controls did not suffer from any neuromuscular or hema-
tological disease. Erythrocytes were purified as described before [12]. 
The washed cells were suspended in 172 mM Tris-HCl, pH 7.6, to yield a 
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hematocrit of about 50%. Part of the suspension was diluted with 
0.90% (w/v) NaCl, 10 mM phosphate (Na-salt), pH 7.3, to a hematocrit 
of 4.5%. When pretreatment with added phospholipase was carried out, 
the dilution medium contained only 0.90% (w/v) NaCl. 
The pretreatment step of erythrocytes by various phospholipases 
(EC 3.1.1.4) was carried out as follows [13]: to 1 ml medium, con-
taining 0.90% (w/v) NaCl, 25 mM Cac12 and 0.6 mM MgC1 2 , either 8 ~g 
phospholipase A (Crotalus terr.terr.; Boehringer), 0.3 mg phospho-
lipase A (bee venom; Calbiochem) or 0. 7 mg phospholipase (porcine pan-
creas; Boehringer) was added. 50 ~1 phospholipase mixture was then 
added to 50 ~l erythrocyte suspension and incubated for 45 min at 
37°C under shaking. Thereafter, 1 ml of one of the solutions, used 
in the lysis step, was added. Hemolysis was determined as described 
below. 
The lysis step was performed according to Beutler [14]. To 50 wl of 
the untreated erythrocyte suspension or to 100 ~1 of the phospholipase 
treated erythrocyte suspension, 1 ml of isotonic or hypotonic phosphate 
buffered saline was added. After 30 min at 37°C hemolysis was measu-
red at 540 nm in th~ supernatant. 100% hemolysis is defined as the 
extinction of the cells incubated with water, the blank contains iso-
tonic saline. 
ATP was measured with the luciferin-luciferase assay [Is]. 2,3-
Diphosphoglycerate was measured with the method of Krimsky [16]. 
RESULTS 
The osmotic stability of erythrocytes from Duchenne and congeni-
tal myotonic muscular dystophy patients in hypotonic solutions is 
shown in Fig. 1. Both patient groups are more fragile than controls. 
This can be expressed by the NaCl concentration at which half the 
amount of the erythrocytes is lysed. The most accurate way to calcu-
late this is to transform the sigmoid curves to straight logistic 
curves [17], from which the 
calculated. This yields for 
half maximal lytic concentration can be 
w 
controls 0.341~0.006% ( /v) NaCl, for 
Duchennes 0.372~0.008 and for myotonics 0.392~0.007 (mean~ SEM). The 
value for Duchenne dystrophy patients is significantly different from 
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Fig. I. Lysis of erythrocytes from patients with myotonic dystrophy (congenital form) and with 
Duchenne muscular dystrophy, and from controls. 
Fig. 2. Lysis of erythrocytes, treated with pancreatic phospholipase, from patients with myotonic 
muscular dystrophy (congenital form) and with Duchenne muscular dystrophy, and from controls. 
Fig. 3. Lysis of erythrocytes, treated with snake venom phospholipase (Crotalus terr.terr.), from 
patients '-''ith myotonic muscular dystrophy (congenital form) and with Duchenne muscular dystrophy, 
and from controls. 
Fig. 4. Lysis of erythrocytes, treated with bee venom phospholipase, from patients with myotonic 
muscular dystrophy (congenital form) and "'ith Duchenne muscular dystrophy, and from controls. 
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that of controls with p<0.02 (Student's t-test), the value for myotonia 
with p<O.OOJ. The difference between Duchenne and myotonic values is 
not significant (p>O.l). 
Hemolysis patterns of phospholipase treated erythrocytes are shown 
in Figs. 2, 3 and 4 for pancreatic phospholipase, snake venom phospho-
lipase and ~ee venom phospholipase, respectively. The $-shaped curves 
of untreated cells have been turned into biphasic curves after attack 
by any of the phospholipases used. At tonicities of 0.45% saline or 
less the curves resemble that of untreated cells. Red blood cells of 
myotonic patients are more fragile at 0.35 and 0.40% saline than con-
trol cells. Statistical significance followed from the Wilcoxon's 
signed rank test [see 18]. Transformation of the biphasic curves to 
logistic curves does not result in straight lines. Although the avera-
ge hemolysis at 0.35 and 0.40% NaCl is higher for Duchenne than for 
control cells, the differences of the individual points are not signi-
ficant according to the Wilcoxon test. We can say that all three 
groups of cells have become more fragile by about the same degree after 
phospholipase treatment. This is the case for all the phospholipases 
tested. 
It was surprising to find that treated cells of Duchenne patients 
and controls lyse to a greater extent in isotonic than in 0.5-0.6% 
NaCl, while cells from patients with myotonic muscular dystrophy do not 
(see Figs. 2, 3 and 4). We have tried to identify the cause of this 
difference by determining a number of factors which may be responsible 
for the high hemolysis of treated cells from controls. As the differ-
ence seems rather independent of the type of phospholipase used, pan-
creatic phospholipase has been used through the following experiments 
(Table I). Erythrocytes treated with this enzyme in the standard manner 
(see Materials and Methods) are lysed to 21~3%. This percentage has 
been taken as 100% reference to express the influence of the various 
incubation conditions upon hemolysis. From Table I it can be seen that 
omission of the enzyme in the pretreatment step results in half the 
amount of lysis detected in the presence of the lipase. Furthermore, 
lowering of the Ca2+-concentration from 14 to 6 mM results in almost 
complete suppression of the hemolysis, while replacement of Na+ by 
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TABLE I 
ntE IKFLLTNCE OF VARIOUS COl\DITIO:'-JS 0~ THE RATE OF HEMOLYSIS OF ERYTHROCYTES FROM CONTROLS, 
PRETREATED ',HTH PMCREAS PHOSPHOLIPASE. 
Hemolysis in the changed medium is expressed as percentage (mean:!:_ SEM) of the hemolysis after 
standard pretreatment with pancreas phospholipase in the same series of expe:r:iments in order to 
determine the relative influences. Hemolysis under standard conditions is 21~3%. 
(P) alteration in the pretreatment step (see Haterials and Nethods); in the lysis step the 
compound concentration is 11-fold lower. 
(L) alteration in the lysis step (absent during pretreatment step). 
(P+L): compound concentration equal in pretreatment and lysis step. 
number of experiments. 
Change in incubation conditions 
standard method 
no pancreas phospholipase (P) 
17.0 instead of 14 m.l1 ca2+ (P) 
8.5 (P) 
(9) 6.0 
10 0 no pancreas phospholipase (P) 
. 5 
rnM EGTA (L) 
10 ~1 EGTA (L) 
0.1 rnM LaC1 3 (P+L) 
50 wH mersalyl (P) 
choline chloride inste-ad of 90% NaCl (L) 
KCl (L) 
LiCl (L) 
Tris-HCl IU 
+ 25 nM tetrodotoxin (P+L) 
3.7 instead of 5 rnM phosphate (L) 
I .8 
Tris-HCl 
(L) 
(L) 
(L) 
pretreatmenc medium instead of KaCl-phosphate (L) 
I ].JM carbamyl choline (P+L) 
20 m.l1 phenylrnethylsulfonyl fluoride (P) 
10 rnM glucose (P) 
10 1!1.':\ ribose (P) 
10 I!l.'t sucrose (P) 
mM ouabain (P) 
(9) 
Relative hemolysis 
I 00 
sz::J 
119 
32 
16 
9•3 
0; 1 
330:!:_70 
266;422 
4•3 
8•3 
HI 
6; 17 
34.":.3 
49 
10 
,., 
33:!:_23 
31:;.22 
47+14 
22~8 
6 ;28 
49:;.15 
' 
' 
(n~l8) 
(n~l3) 
(n~6) 
(n~J) 
(nm3) 
(nm9) 
(n~4) 
(n~6) 
(nmS) 
(nmJ) 
(n,.J) 
(nm3) 
(n-3) 
(nm9) 
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other monovalent cations like K+ and Li+ results in less than 15% of 
the original lysis. Omission of phosphate results in hardly detectable 
. 3+ hemolysLs. La and 1 b h . . . f 2+ mersaly , ot LllhLbltors o the Ca -efflux, 
stimulate hemolysis. Tetrodotoxin, which inhibits Na+-uptake, and the 
protease inhibitor phenylmethylsulfonyl fluoride suppress lysis,as does 
carbamyl ch~line, a cholinergic agent. The sugars glucose, ribose and 
sucrose depress the rate of lysis to 47%, 22% and 17%, respectively. 
DISCUSSION 
Increased [7-9,19] and unchanged [6] fragility of Duchenne ery-
throcytes in the presence of plasma has been reported. Our results with 
washed red cells suggest that the erythrocyte itself had a lower resis-
tance to osmotic shock, both in Duchenne and congenital myotonic 
dystrophy. 
The aim of the phospholipase treatment was to obtain information 
about the phospholipid architecture of the membrane. Pure bee venom 
phospholipase causes breakdown of 20% of phospholipids of intact ery-
throcytes [13]. Purified pancreatic and snake venom (Crotalus) phospho-
lipase do not hydrolyse these phospholipids, due to the inability of 
these enzymes to hydrolyse phospholipids at surface pressures above 
23 dynes/em [11]. From Figs. 1-4 it is clear that bee venom phospho-
lipase induces the highest extent of lysis. The order of stability 
between patient and control groups remains the same at 0-0.5% NaCl, and 
is not dependent on the kind of phospholipase used. We conclude that 
the phospholipid packing in patient red cells is not much altered. 
At 0.90 and 0.65% NaCl, pretreated cells from myotonic patients 
are significantly more stable than cells from controls and Duchenne 
patients. This lability of control erythrocytes was further investi-
gated (Table I). Incubation in pretreatment medium without lipases 
results in 11% lysis, being 52% of the value found under standard con-
ditions in the 
or lowering of 
presence of pancreatic phospholipase. Addition of EGTA, 
2+ Ca from 14 to 6 mM in the presence (or absence) of 
phospholipase strongly reduces the rate of lysis. A role for ca2+ in 
the promotion of lysis 
3+ 
effect of La and mersalyl, 
is further supported by the lysis stimulating 
being inhibitors of ca2+-extrusion, and 
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2+ 
stimulators of the passive Ca -uptake ~ee 20,21]. Hemolysis is higher 
3+. . . 
when La 1s present durtng the pretreatment and the lysts step, com-
pared with its presence during one of these steps. These findings 
h . 2+ . . h 45 suggest t e 1mportance of extracellular Ca Expertments w1t CaC1 2 
l l . b f l . d 45 2+ l l . do not revea a corre at1on etween extent o ys1s an Ca - eve 1n 
the non-lysed cells. Cellular radioactivity disappears by washing with 
EGTA. 
Also Na+ promotes lysis. When it is replaced by monovalent cations 
with a smaller or larger radius, lysis decreases to less than 15%. 
Tetrodotoxin, a selective suppressor of the Na+-uptake [zz], reduces 
lysis to 34%. 
Decrease of phosphate below the standard level of 5.5 mM results 
in decreased lysis. No lysis occurs in the pretreatment medium (con-
taining no phosphate) . 
2+ + the Ca -, Na - and phosphate-Which process is responsable for 
dependent lysis? It has been reported 2+ + that Ca and Na are involved in 
the response of red cells to cholinergic agents [23]. In our study 
carbamyl choline reduced hemolysis. The rate of lysis is optimal 
between pH 7.6 and 7.8 (with or without pancreas lipase). Maybe an 
2+ + 
enzymatic process stimulated by Ca , Na and phosphate is involved. A 
serine protease inhibitor, which does not inhibit Ca2+-stimulated ery-
throcyte protease [24], inhibits lysis in our experiments. 
Energy depletion of red cells, causing high ca2+ -permeability [zs], 
has to be considered as probable cause of hemolysis. However, both 
metabolizable and non-metabolizable sugars (sucrose) strongly reduce 
lysis. Ouabain has the same effect. Probably this is not due to inhibi-
tion of the 
K+-level of 
+ + Na -K -pump, since this pump cannot function at exogenous 
0.5 mM [26], which was measured in the incubation medium by 
flame photometry. Moreover, we were not able to detect a correlation 
between levels of ATP or 2,3-diphosphoglycerate in the remaining non-
lysed cells and the degree of lysis. 
2+ + In conclusion we can say that a combination of Ca , Na and 
phosphate causes lysis of phospholipase treated erythrocytes from 
controls and Duchenne patients under isotonic conditions. This process, 
likely not due to lack of energy, is much less active in red cells from 
patients with congenital myotonic dystrophy. 
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DYSTROPHY; (Na+ + K+ )-ATPase, Ca2+ -ATPase, K+- and Ca2+ -p-Nitrophenylphosphatase 
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SUMMARY 
Four enzyme activities were studied in erythrocyte membranes from 
patients with Duchenne 
(Na+ + K+)-stimulated, 
and congenital 
2+ Mg -dependent 
myotonic muscular dystrophy. 
adenosinetriphosphatase, measu-
red in two different media, showed normal activity and ouabain inhibi-
tion, as did K+-stimulated p-nitrophenylphosphatase. The specific 
activity of Ca2+-stimulated p-nitrophenylphosphatase was twice normal 
2+ . 2+ in Duchenne membranes. Ca -st~mulated, Mg -dependent adenosinetri-
phosphatase was augmented in membranes from both Duchenne and congeni-
tal myotonic muscular dystrophic patients. The cause of the increased 
activities may be the necessity for compensating an alteration in the 
calcium metabolism in the dystrophic erythrocytes. 
l k . . h Z+ . l Severa ~net~c parameters of t e two Ca -st~mu ated enzyme 
activities were studied in Duchenne and control membranes. Most were 
not changed, with the exception of the Na+-stimulation of ca2+-ATPase. 
In Duchenne membranes two affinity sites were 
mal activating concentrations of 58+4 and 4+1 
present 
+ 
rnM Na . 
Hith half maxi-
In control mem-
branes only one affinity site was found with Ka + 26+9 mM Na . 
INTRODUCTION 
There is increasing evidence that a general membrane defect is 
the primary cause of human muscular dystrophy (Rowland 1976). Not only 
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the membranes of muscle, but also those of other tissues may have alter-
ed properties. In the last decade, many data have been published on ery-
throcyte membranes. Much attention has been paid to the membrane-bound 
+ + . 2+ + + (Na +K )-st~mulated, Mg -dependent adenosinetriphosphatase ((Na + K )-
ATPase; EC 3.6.1.3) and the effect of ouabain on it. In Duchenne ery-
throcytes, ouabain has been reported to stimulate the ATPase activity 
(Brown et al. 1967; Peter et al. 1969; Araki and Mawatari 1971; 
Niebr6j-Dobosz 1976; Pearson 1978). Others reported ouabain inhibition, 
although to a slight degree (Mawatari et al. 1976; Siddiqui and Penning-
ton 1977), while normal inhibition has also been described (Klassen and 
Blostein 1969; Hodson and Pleasure 1977; Souweine et al. 1978). Instead 
of determining the influence of ouabain on the rate of ATP hydrolysis, 
the measurement of its effect on the hydrolysis of p-nitrophenylphospha-
te may be studied. The 
ty (K+-PNPPase), which 
dephosphorylation step 
2+ . 1 Ca -stLmu ated, 
K+ -stimulated component of this hydrolytic activi-
is sensitive to ouabain, probably reflects the 
of (Na+ + K+)-ATPase (Banting 1970). 
2+ . . ( 2+ Mg -dependent adenosLnetrLphosphatase Ca -
ATPase; EC 3.6.1.3) is the enzymatic activity corresponding to the 
active Ca2+-extrusion from the (red blood) cell (Schatzmann 1975). One 
group has reported an increased activity of this enzyme in Duchenne ery-
throcytes (Hodson 
tics identical to 
phenyl phosphatase 
and Pleasure 1977). An enzyme with some characteris-
h C 2+ . h 2+ . 1 . t ose of a -ATPase LS t e Ca -st~mu ated p-nLtro-
2+ (Ca -PNPPase). It is also membrane-bound and it has 
been suggested (Rega et al. 1973) that both enzyme activities are cata-
lyzed by the same molecular system. 
In this study the K+-stimulated and the ca2+-stimulated PNPPase 
activities have been measured in erythrocytes of patients suffering 
from congenital myotonic and Duchenne muscular dystrophy. These enzymes 
. h ( + +) 2+ . are compared wlt Na + K -ATPase and Ca -ATPase, respectLvely. 
Deviations from control values may indicate changes in membrane archi-
tecture and may reflect differences in capacity to pump Na+, K+ and 
ca
2+-ions. 
MATERIALS AND METHODS 
Blood donors were Duchenne patients and male myotonic muscular 
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dystrophy patients (congenitally manifest type). Controls were boys 
without neuromuscular or hematological disease. Their age varied 
between 2.5 and 19.5 years. All children were fasted overnight. Ery-
throcyte membranes were isolated immediately after venapuncture 
according to the procedure described previously (Ruitenbeek 1978). Mem-
branes were stored at -70°C and assayed from 1 day to I~ years later 
(the length of the storage period had no detectable influence on the 
properties of the enzymes studied). Protein was determined according to 
Lowry et al. (1951). 
K+-PNPPase activity was determined in a medium (modification of 
procedure of Garrahan et al. 1969 and of Lamers et al. 1978) containing 
100 mM Tris-HCl, pH 7.5 (37°C), 0.25 mM ATP, 1 mM disodium ethylenedi-
amine tetraacetic acid (EDTA), 40 mM KCl, 5 mM MgC1 2 , 4.5 mM NaCl and 
10 mM p-nitrophenylphosphate (Tris-salt). The blanks contained Tris-HCl 
instead of KCl. If present, the ouabain concentration was 0.1 mM. Incu-
bation was carried out at 37°C during 50 min in a volume of 1.1 ml with 
0.1-0.4 mg protein. Reactions were stopped with 0.1 ml 40% (w/v) tri-
chloroacetic 
nm (E 13. 1 
8.5. 
acid (TCA). The p-nitrophenol formed was measured at 412 
-1 -] 
mM em ) after neutralization of the supernatant to pH 
(Na+ + K+)-ATPase was assayed in two different media. The first 
one (minor modification of Mawatari et al. 1976) with optimal Na+ and 
+ 0 [32 J K contains: 20 mM Tris-HCl, pH 7.4 (37 C), 3 mM y- P -ATP (labeled 
ATP: Amersham, England; 70 mCi/mol; Tris-salt prepared from the di-
sodium salt (Boehringer, G.F.R.) according to Garrahan et al. 1969), 13 
mM KCl, 4 mM MgC1 2 , 80 mM NaCl. From the blanks Na+ and K+ were omitted. 
Ouabain (Merck, G.F.R.) was tested at 0.1 mM. Membranes (about 0.1 mg 
protein per test) were pretreated with 0.04% (w/v) deoxycholate during 
10 min at 21°C (this sometimes increased the activity). After incuba-
tion at 37°C (3,0 min) 20 111 20% (w/v) TCA was added to the incubation 
mix (200 ~1), followed by 20 ~l ammonium molybdate (30% (w/v) in 5 M 
H2so4), 10 ~1 5 mM K2HP04 and 1.2 ml isobutanol. After rapid mixing and 
centrifugation the radioactivity of 1 ml of the organic phase was 
+ 
counted. The (Na 
ce in 
sence 
the amount 
of Na+ and 
+ K+)-ATPase activity was calculated as the differen-
of [32P]-phosphate liberated in the presence and ab-
+ K . 
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The second medium contained low Na+ and K+ as described by Brown 
et al. (1967; see also Niebr6j-Dobosz 1976 and Mawatari et al. 1976). 
The procedure followed was similar as described for the optimal Na+ 
and K+ medium. 
Ca2+-PNPPase was measured in the following mixture (see Rega et 
al. 1973): 40 mM Tris-HCl, pH 7.8 (37°C), 1 mM Na2-ATP (Boehringer, 
G.F.R.), 0.3 mM CaC1 2, 100 mM KCl, 5 mM MgC1 2 , IO mM Na-p-nitrophenyl-
phosphate, about 0.2 mg 
neutralized EDTA before 
protein, which was washed I time with 0.6 mM 
2+ 
use, to remove traces of Ca . In the blanks 
CaC1 2 was replaced by 0.5 mM Na2-ethyleneglycolbis (beta-aminoethyl-
ether)-N,N'-tetraacetic acid (EGTA). The reaction (50 min at 37°C) 
was stopped by adding 0.1 ml 40% TCA to the incubation medium of 1 ml. 
The amount of p-nitrophenol was measured as described under K+-PNPPase. 
ca2+-ATPase activity was determined in a medium (see Wolf 1972) 
with 40 mM Tris-maleic acid, pH 7.2 (37°C), 1.32 mM y-[32P]-ATP 
(labeled ATP: Amersham, England; 0.5 Ci/mol; Tris-salt prepared from 
the disodium salt (Boehringer, G.F.R.; Garrahan et al. 1969), I .68 mM 
CaC1 2 , 1 
G.F .R.). 
mM EDTA, 2.03 mM MgCl 2 , 70 roM 
Under these conditions MgATP, 
NaCl, 0.5 mM ouabain (Merck, 
2+ 2+ free Ca , and free Mg -
concentrations were calculated (Wolf 1973; Sillen and Martell 1964) to 
be 0.97, 0.60 and 1.00 mM, respectively. In some experiments 0.26 mM 
ATP and 1.23 mM MgClz was used, yielding 0.18 mM MgATP. Membranes were 
pretreated as for Ca2+-PNPPase. In an incubation volume of 0.2 ml 
about 0. l mg protein was used. Blanks did not contain CaC1 2 . Incuba-
tions (20 min at 37°C) were stopped and analysed as described for 
+ + (Na + K )-ATPase. 
RESULTS 
Table shows the K+-PNPPase and (Na+ + K+)-ATPase activities of 
the 3 groups of erythrocyte membranes. Both enzymes had normal activi-
ties in the two dystrophic groups. Furthermore the influence of 
ouabain was also normal. Both enzymes were inhibited for 63-100%. In 
no individual case stimulation by ouabain was found. The K+-PNPPase 
activity (y in nmoles PNP formed/min) seems to be positively correla-
ted with the age (x in years; y = 0.0867 x + 0.184 with r = 0.94) of 
136 
the control children. This correlation was hardly visible in the 
Duchenne membranes nor for (Na+ + K+)-ATPase in control membranes. One 
+ 
would expect to find age-dependency for the ATPase, because K -PNPPase 
reflects the dephoshorylating, rate-limiting step of (Na+ + K+)-ATPase 
(Banting 1970). The mean activity of K+-PNPPase of the two dystrophic 
groups was not significantly different from control activity with or 
without regard to the effect of age. 
TABLE I 
. . . 
ACTIVITIES OF K -PNPPase AND {Ka + K )-ATPase Ac'lD THE OUABAIN lelFLUENCE D! ERYTHROCYTE 
MEHBRANES OF DUCHENNE, MYOTO~IC HUSCULAR DYSTROPHY AND COl\TROL BOYS 
Activities in nm<>les/min/mg pr<>tein are expressed as mean:':_ SEM; the ouabain influence as 
percentage of the activity in the absence of ouabain. 
Enzyme Duchennes Myotonic:s Controls 
activity ouabain activity ouabain activity ouabain 
inhibition inhibiti<>n inhibition 
K -PNPPase 1.15:<:_0.!4 87• 3Z 0.91+0.13 95+3Z !.03+0. 17 86• 
" {n~6) (n~J) (n~7} 
(I\ a . . K+)-ATPase, 
io low 
. ,, ,• 3.5 •O 63+22); n.d. n.d. 3.4 +!.I 74+12); 
(n~4) (n~S) 
in high N• 
. 
. ,. 4.6 •0 74+ 5! n.d. n.d • 4. 1 •O 100+31% 
(n~4) (n~S) 
n.d. not determined. 
In Table 2 some properties of Ca2+-PNPPase are summarized. Duchen-
ne membranes possessed a higher specific activity at 10 mM and at 
infinite PNPP concentration than control membranes. Although the ave-
rage activity of myotonic membranes was increased, the difference was 
not significant. Apart from the activity, other kinetic parameters of 
Ca2+-PNPPase of Duchenne cells had the same values as control cells. 
The affinity for p-nitrophenylphosphate was similar, while this com-
pound exerted an identically positive allosteric effect on the erythro-
cyte membrane enzyme from both groups (see also Fig. 1), resulting in 
a Hill coefficient of + 1 .8. The sensitivity to ca2+-ions and the 
optimal pH were also the same. 
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TABLE 2 
PROPERTIES OF CaZ+ -PNPPase OF ERYTHROCYTE MEMBRA.'IES FROM DUCHENNE AND CONGENITAL MYOTONIC 
MUSCULAR DYSTROPHIC PATIENTS 
Activities (mean+ SEM) are expressed in nmoles/min/mg protein. KO.Sa represents the con-
centration of Cai+ resulting in half-maximal stimulation by Ca 2+ 
Activity at 10 mM PNPP 
' m"' 
KO.S for PNPP (mM) 
Hill coefficient for PNPP 
2• K0 Sa for Ca ()lM) 
pH-optimum 
Duc.hennes 
4.4+0.6 (n:9)a 
9.2 ;9. 5 
6.2; 7.5 
+1.7;+1.9 
I 2 
7.8 
3Significantly different from control value: P<O.OI. 
nmoles min·~ mg·1 
' 
Myotonics 
6+0 6 (n:4) 
Controls 
2.1+0.5 (nwiO) 
2.8 ;3 .8 
5. 7 ;6. 9 
+I .5 ;+I. 7 
10 
7.8 
---.r---
~0 mM PNPP 
Fig. I. Activity of Ca2+-PI\'PPase as function of the concentration of p-nitrophenylphosphate in 
erythrocyte membranes from a control (0-0) and a Duchenne patient C•-•>. From this curve and 
an identical one, the Km values and Hill coefficients were calculated (see Table 2). 
Table 3 contains kinetic characteristics of ca2+-ATPase of dystro-
phic and control membranes. Its velocity has been determined at 0.18 
and 0.97 mM MgATP. At both substrate concentrations, the membrane pre-
parations of Duchenne and myotonic dystrophic patients were more active 
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TABLE 3 
PROPERTIES OF c}+ -ATPase IN ERYTHROCYTE MEMBRANES FROM PATIENTS WITH DUCHENNE AJI.'D 
CONGENITAL MYOTONIC MUSCt;LAR DYSTROPHY 
Activities (mean _:1:. SE~l) are expressed in nmoles/min/mg protein. See text for explanation 
of the data. Ka is the concentration of activator at which half-maximal stimulation is 
reached. 
Activity at 0.18 mM MgATF 
Activity at 0.97 mM MgATF 
Vmax 
K for MgATP (mM) 
m 2• 
Ka for Ca (mM) 
Hill codficient for ca2+ 
Hill coefficient for 
stimulator protein 
Ka for :-la+ (low affinity 
site) (mM) 
Ka for Na+ (high affinity 
si tel (lfu'1) 
aSignificantly different 
bSignificantly different 
"significantly different 
"Duchennes 
4.0 +0 
5. 6 +0 
6. I 
0. l 0 
(n=ll)a 
(n=ll)b 
0.11+001 (n=4) 
+0.8 
58 +9 
(n=4) 
from control value: P<0.02. 
from control value: P<O .0 I. 
from control value: P<0.002. 
Myotonics 
4.9+0.6 (n,6)" 
5.9+0 (n=6)a 
6.2 
0.05 
Controls 
2.3 +0 .6 (n=8) 
2. 9 •O (n=S) 
3.1 
0.06 
0.08+0.03 (n"'4) 
+0 .8 •O (n=4) 
+0 .8 
26 _:+:9 (n=4) 
absent 
in hydrolysing MgATP than control membranes. Calculation of the Vmax' 
using the average activities at the two mentioned concentrations, 
revealed values of 6.1 and 6.2 nmoles phosphate/min/mg protein for 
Duchenne and myotonic membranes, respectively, which is twofold 
higher than the control value of 3.1. The same calculation gives KID-
values of 0.10 and 0.05 mM for membranes of Duchenne and myotonic 
dystrophy patients, respectively, and a control value of 0.06 mM 
MgATP. These calculations are only allowed when the Lineweaver-Burk 
plots are straight, which was so in the 3 groups. The activation by 
2+ 
Ca of the enzyme from Duchenne patients was found to be the same 
as for control enzyme which results in a normal value for the activa-
tion constant KO.Sa and for the Hill coefficient: 0.11 mM and 0.8, 
respectively. Application of a soluble protein, which stimulates the 
2+ Ca -ATPase activity (Gopinath and Vincenzi 1977; isolated from bovine 
brain according to Cheung 1971), resulted in the same Hill coefficient 
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of both types of enzymes for this protein. The values, measured at 
~ . ~ 1 mM MgATP, were + 0.8 both at 50 and 500 WM Ca • At f~xed Ca -
2+ 
concentration the protein stimulates Ca -ATPase from Duchenne and 
2+ 
control membranes by the same factor, namely 7.8-fold at 50 wM Ca , 
and 1.8-fold at 500 wM ca 2+. The ratio in specific activity between 
patient and control membranes was therefore not influenced by the 
protein. In the presence of saturating amounts of stimulator 
protein the same velocity was obtained at 50 and 500 wM Ca2+ in 
each preparation. The blank values were not increased by the protein, 
which points to the absence of calcium in the membrane preparations. 
Apart from the increased activity, only one other kinetic para-
2+ 
meter of the Ca -ATPase of Duchenne red blood cells was found to be 
abnormal. It is the Na+-dependency, as shown in Fig. 2. Control enzyme 
g~ves a straight line in a Lineweaver-Burk plot, while Duchenne enzyme 
shows + a biphasic curve, the point of intersecting being 34~2 mM Na . 
~eK 
a 
+ . . for Na -~ons of the control enzyme ~s 26+9 mM, that for Duchen-
ne membranes 58+9 and 4+1 mM, above and under 34 mM Na+, respectively. 
DISCUSSION 
Many reports have been published on (Na+ + K+)-ATPase in ery-
throcyte membranes from Duchenne patients. The results are highly 
variable with regard to ouabain influence on enzyme activity, some 
workers finding remarkable stimulation by this glycoside (Brown et al. 
1967; Peter et al. 1969; Araki and Mawatari 1971; Niebr6j-Dobosz 1976; 
Pearson 1978). The present study describes the ouabain influence on 
+ . . K -PNPPase actlV~ty, both in Duchenne and myotonic muscular dystrophy. 
Ouabain inhibits the phosphatase activity in all individual cases, as 
is the case for the (Na+ + K+)-ATPase activity measured under diffe-
rent assay conditions. It seems likely that the isolation procedure 
for erythrocyte membranes is more important for the ouabain influence 
than the assay medium (see also Niebr6j-Dobosz 1976); for example, 
serum contamination may play a role. In this study ouabain had the 
same effect on K+-PNPPase as on (Na+ + K+)-ATPase in membranes of 
both groups of dystrophy, so it would be interesting to determine its 
effect 
(Na+ + 
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+ 
on K -PNPPase in those cases in which ouabain stimulates 
K+)-ATPase. 
erythrocyte cytoplasm~ because addition of the protein stimulated both 
control and Duchenne ATPase by the same factor. 
A second kinetic parameter of the ca2+-ATPase from Duchenne cell 
membranes appears to be altered. The enzyme has a two-phase dependen-
cy on Na+-ions (see Fig. 2). It is probable that in these dystrophic 
cells an extra enzymatic activity is present at Na+-concentrations 
below 34 mM. This activity may have a physiological significance as 
the sodium concentration in erythrocytes is about 9 mM (Natelson and 
Natelson 1978). Preliminary experiments suggest the presence of the 
Na+-effect also in Duchenne carriers, an interesting point for further 
research. 
One study has been published on ca2+-ATPase in Duchenne muscle 
dystrophy. Hodson and Pleasure (1977) reported a higher activity as 
was found in this study and an increased affinity for MgATP, which 
disagrees with the results 
0.83 mM, however, was very 
in Table 3. Their K value for controls of 
m 
high in comparison with other reports 
(Schatzmann 1975) of values of 0.04-0.05 mM. The K values of Table 3 
m 
are of the same order of magnitude as reported data. 
2+ The high activity of Ca -ATPase may form a mechanism, necessary 
to compensate for changes in calcium metabolism in dystrophic red 
blood cells.Plishker et al. (1978) reported normal calcium levels in 
erythrocytes of patients suffering from (non-congenital) myotonic 
muscular dystrophy, which were able to extrude ca 2+ at a higher rate. 
The study of Dise et al. (1977) suggests a normal level also in Duchen-
2+ 
ne erythrocytes, but demonstrated that a high Ca -level had a greater 
influence on stability and K+-permeability of Duchenne erythrocytes 
than of control cells. An increased ca2+-stimulated K+-efflux was 
described previously (Appel and Roses 1976) for Duchenne cells. All 
these effects may 
. h Z+ 1 . Wlt Ca p ay1ng 
point to an abnormality of the erythrocyte metabolism 
a causative or intermediary role. If the same defect 
is present in dystrophic muscle, its function may be impaired to a 
great extent, in view of the key role of calcium in muscle contraction, 
relaxation and metabolism. In this context it is of interest that 
Bodensteiner and Engel (1978) reported calcium accumulation in Duchenne 
muscle fibres. 
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Fig. 2. Reciprocal plot of the ca2+-ATPase activity against Na+-concentration. At lower Na+-
concentrations NaCl was replaced by choline chloride. Erythrocyte membranes from Duchenne 
patients (11-S) and from control (0-0). Curves are the mean of 4 control and 4 Duchenne mem-
b~·ane activities. The relationship is shown between the calculated velocity at infinite Ka+, 
Vmax' divided by the measured velocity, against the reciprocal ~a+-concentration in~-!_ 
Another membrane-bound enzyme activity, of which determination in 
2+ human muscular dystrophic erythrocytes has not been reported, is Ca -
PNFPase. Table 2 shows that it is twofold increased in Duchenne 
dystrophy, while other kinetic parameters are unchanged. These results 
2+ + 
are comparable with the data of Ca -ATPase measurements at 70 mM Na 
(see Table 3), although this enzyme also has a significantly augmented 
2+ 
activity in myotonic dystrophy. The kinetic characteristics of Ca 
ATPase in red blood cell membranes from Duchenne patients have been 
further analysed in order to find differences which may be useful for 
diagnosis of the carrier status in this disease. Enzyme from patients 
d 1 . ' . h M d Z+ . h emonstrates norma ~nteract~on WLt gATP an Ca -Lons. T e Ka-
values for ca2+ of 80 and 110 ~Mare higher than reported for the K 
m 
(see Schatzmann 1975), but in agreement with studies in which the 
ATPase activity was measured at 80 mM Na+ (Schatzrnann and Rossi 1971). 
The interaction between the enzyme and a calcium-dependent regulator 
protein which stimulates ca2+-ATPase, probably by enhancing the 
affinity of the enzyme to bind Ca2+ (Gopinath and Vincenzi 1977) was 
also normal for patient's membranes. This protein has been found to 
stimulate the transport of Ca2+-ions from erythrocytes (Macintyre 
and Green 1978). It seems unlikely that the cause of the higher activi-
ty could be contamination of the membranes with stimulator protein from 
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SUMMARY 
Two membrane-bound enzymes, concerned in repair of erythrocyte 
membranes, have been investigated in patients with muscular dystrophy. 
The activation of long-chain fatty acids is normal in erythrocytes 
from Duchenne patients, but increases twofold in cells from myotonic 
dystrophy patients (congenital form). This alteration is not present 
in leucocytes. 
In all leucocytes tested palmitate was the preferred substrate 
while palmitoleate and linoleate were activated at a lower rate. In 
the erythrocytes the 3 fatty acids were activated at the same rate. 
Carnitine palmitoyltransferase was not significantly altered in 
erythrocytes of both groups of patients. 
INTRODUCTION 
Erythrocyte membranes can easily be purified. These preparations 
are useful for measurements of general membrane properties, and have 
been used as a model in attempts to determine the primary biochemical 
defect in human muscular dystrophy. Both in the Duchenne and myotonic 
forms of muscular dystrophy indications of abnormalities in cell mem-
branes have been found (Rowland 1976). In addition to muscle membra-
nes (Mokri and Engel 1975; Rowland 1976; Schotland et al. 1977), ery-
throcyte membranes also possess altered morphological (Matheson and 
14 7 
Howland 1974), physical (Percy and Miller 1975; Bosmann et al. 1976; 
Butterfield 1977) and biochemical (Appel and Roses 1976; Iyer et al. 
1976; Dise et al. 1977; Plishker et al. 1978) characteristics. 
In this study we have tested long-chain acyl-CoA synthetase and 
carnitine palmitoyltransferase. These enzymes are not only bound to 
membrane, but also play a role in the synthesis of membrane lipids. A 
change in these enzymes could cause the lowered content of palmit-
oleic acid in erythrocyte membrane lipids from Duchenne patients and 
carriers found by Howland and Iyer (1977), We have found the same re-
duction in red cell di- and triglycerides from dystrophic patients 
(Ruitenbeek 1978). Abnormal membrane architecture may be reflected 
in altered enzyme properties. 
MATERIALS AND METHODS 
Patients were suffering from either Duchenne dystrophy or the 
congenital form of myotonic muscular dystrophy. Controls were boys 
without any neuromuscular or hematological disorder. All individuals 
were aged between 2 and 19 years and did not use any medication. Peri-
pheral blood was taken after overnight fast. The isolation procedure 
of the erythrocyte membranes has been described before (Ruitenbeek 
1978). 
Leucocytes were isolated from the upper phase of the dextran-
blood mixture according to Wyss et al. (1971). For lysis of the conta-
minating erythrocytes 50 mM NaCl was used instead of NaF. The cells, 
isolated at 0°C, were homogenized with a Potter-Elvehjem homogenizer 
in 0.25 M sucrose, 1 mM EDTA, 10 mM tricine-KOH (pH 7.4). Preparations 
were stored at -70°C. 
Acyl-CoA synthetase (EC 6.2.1 .3) was measured according to 
Farstad et al. (1967) as modified by Van Tal and Hlllsmann (1969) at 
37°C during 30 min. The reaction volume was 0.25 ml, and contained 
0.1-0.6 mg protein. 
Carnitine palmitoyltransferase (EC 2.3.1.21) was determined by 
method II of Van Tal and Hlllsmann (1969) with modifications resulting 
in the following final concentrations: 2 mM ATP, 1 mM L-[3H]carnitine 
(0.2 Ci/mole), 0.5 mM dithiothreitol, 0.5 mM EDTA, 1 mM KCN, 2.5 mM 
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MgC1 2 , 0.25 mM palmitate, 36 ~M bovine serum albumin, I .6 or 8.0 ~ 
palmitoyl-CoA, 5 mM phosphoenolpyruvate, 80 mM Tris-HCl (pH 7.4), 0.4 
U adenylate kinase (EC 2.7.4.3) and 0.4 U pyruvate kinase 
(EC 2.7.!.40). 
Succinate dehydrogenase (EC 1.3.99.1) was assayed by the method 
of Pennington as described by Meijer et al. (1977). 
Protein was determined according to Lowry et al. (1951). 
RESULTS 
The rate of activation of 0.5 mM palmitate, linoleate or palmit-
oleate in the presence of 70 ~M bovine serum albumin by erythrocyte 
membranes is given in Table 1. The membranes of patients with congeni-
tal myotonic muscular dystrophy show a twofold increase in the rate 
of activation of the 3 fatty acids tested, while membranes of Duchenne 
patients do not, The range in myotonic cells is 0.42-0.73 nmoles acyl-
GoA formed/mg protein/min, that in control cells 0.09-0.51. In all the 
membranes tested, the rate of activation is the same for the 3 fatty 
acids tested. 
TABLE l 
ACYL-CoA SYNTHETASE ACTIVITIES OF ERYTHROCYTE MEMBRANES 
The activities are given in runoles acyl-CoA formed/min/mg protein:;:_ the standard error of the 
mean. The significance of the difference is given between patients and controls (Student's 
t-test). 
Controls 
Duchenne dystrophy 
Myotonic dystrophy 
N.S. =not significant. 
Fatty acid 
Palmitate 
0.26:;:_0.04 
(n,9) 
0.25:t:0.04 
(n"' !0; N .S 
0.55:;:_0.05 
(n~5; P<O.OOl) 
Palmitoleate 
0.25+0.05 
(n=6) 
0.27+0.06 
(n~6; N.S.) 
0.56:;:_0.05 
(n~5; P<0.005) 
Linoleate 
0.28+0.04 
(n=9) 
0.29+0.04 
(n~lO; N.S.) 
0.55!_0.04 
(n"'S; P<0.002) 
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TABLE 2 
ACYL-CoA SYNTHETASE ACTIVITIES IN LEUCOCYTE HOMOGENATES 
Activities are in nmoles acyl-CoA formed/min/mg protein:!:_ the standard error of the mean. 
The significance of the difference is given between the rate of palmitoleate or linoleate 
activation and that of palmitate. There was no significant difference between the rates 
with palmitoleate and linoleate. 
Fatty acid 
Palmitate Palmitoleate Linoleate 
Controh (n=4) I .04+0.11 0.66:_0.05 0.55_:!:0.04 
(p<0.02) (P<0.01) 
Duchenne dystrophy (n=4) 1.02+0.08 0.64_:0.06 0.58+0.04 
(p<0.01) (P<O.OOS) 
Myotonic dystrophy (n=4) 1. 12+0. 16 0.79:_0.10 0.67+0.07 
(p<O. 2) (P<O.OS) 
TABLE 3 
CARNITINE PALMITOYLTR.ANSFERASE ACTIVITIES IN ERYTilROCYTE MEMBRANES 
Activities are given in runoles palmitoylcarnitine. formed/min/mg protein :_ the standard error 
of the mean. BetYeen Duchenne and myotonic patients there was a significant difference with 
P<O.Ol at 8 llM palmitoyl-CoA and P<0.05 at 1.6 IJM palmitoyl-CoA. 
Palmi toyl-CoA ()1M) 
1.6 8.0 
Controls (n=lO) 0.064+0.008 0.13:_0.02 
Duchenne dystrophy (n=9) 0 .054+0. 005 0 .11:_0.01 
Myotonic dystrophy (n=6) 0.083+0.015 0.17+0.04 
Table 2 shows the activity of acyl-GoA synthetase in homogenates 
of leucocytes. There is no difference between fatty acid activation in 
cells from patients and controls. The pattern of activation of the 3 
fatty acids was different from that of erythrocytes. The 3 groups of 
preparations show a significantly greater velocity in palmitate activa-
tion than in palmitoleate and linoleate activation, the latter being 
50-70% of the activity with palmitate of 1.0+0.1 nmoles acyl-GoA formed/ 
mg protein/min. 
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Table 3 shows the carnitine palmitoyltransferase activity in ery-
throcyte membranes of patients and controls at 1.6 and 8.0 ~M palmi-
toyl-CoA. Respectively 0.064~0.008 and0.13~0.02 nmoles palmitoylcarni-
tine were formed/mg protein/min in controls. At both substrate concen-
trations no abnormality could be detected~ either in membranes from 
Duchenne or in those of congenital myotonic muscular dystrophic 
patients. But when the patient groups are compared the enzyme is signi-
ficantly more active in myotonic than in Duchenne patients. 
DISCUSSION 
In order to maintain the stability of the cell, renewal of its 
membranes, and thus phospholipid synthesis, is necessary. Mature ery-
throcytes are unable to synthesize phospholipids de novo, but they can 
acylate lysophospholipids (Van Deenen and De Gier 1974). The substrate 
for this acylation is long chain acyl-CoA, synthesized by acyl-CoA 
synthetase. Oliveira and Vaughan (1964) reported the presence of the 
synthetase in erythrocytes by demonstrating incorporation of fatty 
acids into phospholipids. We have measured the activity of the enzyme 
in erythrocyte membranes of patients suffering from two types of muscu-
lar dystrophy. In congenital myotonic muscular dystrophy the fatty acid 
activating capacity is increased, independently of the fatty acid. This 
may point to the necessity of more intensive renewal of the membranes 
in this disease. Kunze et al. (1973) have measured the incorporation of 
palmitate and linoleate into various lipid fractions in intact erythro-
cytes from Duchenne and control subjects. They found a somewhat higher 
level of incorporation of the fatty acids in dystrophic erythrocytes. 
In both groups they measured less linoleate than palmitate incorporation, 
in contrast to other studies (Oliveira and Vaughan 1964; Waku and Lands 
1968), reporting that linoleate was more rapidly incorporated in intact 
erythrocytes and isolated membranes from controls than palmitate. 
We did not find a slower rate of palmitoleate activation compared 
with palmitate and linoleate activation. This implies that the low con-
tent of palmitoleic acid in red blood cell lipids from Duchenne and myo-
tonic muscular dystrophic patients (Howland and Iyer 1977; Ruitenbeek 
1978) is not due to relative impairment of the activation of this fatty 
acid. 
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The fatty acid activation pattern in homogenates of leucocytes is 
different from that in erythrocytes. In the congenital form of myo-
tonic muscular dystrophy the activation in leucocytes is not augmented 
as is the case in erythrocytes (Table 2). The velocity with 
palmitoleate and linoleate is 50-70% of that with palmitate. This dis-
tinction may be explained by the different intracellular localization 
of acyl-CoA synthetase in erythrocytes and leucocytes. In the latter 
cells the enzyme is mainly localized in the mitochondria (Scholte 
1974). The activity observed in erythrocyte membranes (Table I) cannot 
be attributed to contamination with mitochondria, since succinate 
dehydrogenase (EC 1.3.99.1) was hardly detectable. So, it is likely 
that the synthetase activity in erythrocytes is localized in the 
plasma membranes. This membrane may have undergone a fusion at the end 
of the reticulocyte stage with mitochondrial and/or reticular membrane 
components. Acyl-GoA synthetase is confined to mitochondria and endo-
plasmic reticulum in the investigated tissues (Groot et al. 1976). A 
difference in intracellular localization may imply a different micro-
environment for the acyl-CoA synthetase, affecting acyl-specificity. 
Carnitine palmitoyltransferase activity in erythrocyte membranes 
was found by Wittels and Hochstein (1967). They assumed it to be 
involved in the transport of activated fatty acids, as it is in mito-
chondria (Bremer 1962; Fritz and Yue 1963). In this context it is of 
interest to know that acylation of lysophospholipids largely takes 
place at the inner side of the erythrocyte membrane (Renooij et al. 
1974). Recently, Scholte et al. (1979) found that erythrocyte membra-
nes, in contrast to mitochondria, only contain carnitine palmitoyl-
transferase I. This enzyme also catalyzes the reverse reaction, e.g. 
the formation of acyl-CoA from acylcarnitine, and may also be 
involved in acyl-delivery for erythrocyte membrane repair. 
The transferase, like acyl-CoA synthetase, is membrane-bound, and 
could have a different activity if membrane architecture is changed in 
disease. It is likely to have its origin in mitochondria from reticulo-
cytes, of which membranes may have undergone fusion with the plasma 
membrane during maturation. We found that carnitine palmitoyltrans-
ferase does not have a significantly higher activity in patients with 
myotonic dystrophy, in contrast to acyl-CoA synthetase. The enzyme was 
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tested at 1.6 and 8 vM palmitoyl-CoA. Calculation of Michaelis 
constant yields 2.5-2.8 vM palmitoyl-CoA for the 3 groups, which 
suggests an unaltered affinity for palmitoyl-CoA, which is of the same 
order of magnitude as in adult human erythrocytes and other cells 
(Scholte et al. 1979). 
The increased acyl-CoA synthetase activity in the mature erythro-
cyte membrane in congenital myotonic muscular dystrophy may reflect 
a need for intensified membrane production or repair at an unknown 
stage of erythroid development. The anomaly is absent in Duchenne 
dystrophy. Carnitine palmitoyltransferase activity is normal in ery-
throcytes in both groups of muscular dystrophy. 
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